CME Outfitters, LLC Podcasts https://www.cmeoutfitters.com/ Continuing Education for Physicians, Doctors and Medical Professionals Wed, 14 Nov 2018 22:27:28 +0000 en-US © 2018 CME Outfitters Continuing Education for Physicians, Doctors and Medical Professionals CME Outfitters episodic CME Outfitters tmeyers@cmeoutfitters.com Continuing Education for Physicians, Doctors and Medical Professionals Continuing Education for Physicians, Doctors and Medical Professionals CME Outfitters, LLC tmeyers@cmeoutfitters.com clean No http://www.cmeoutfitters.com/wp-content/uploads/2015/11/CMEO_PodcastArt.jpg.jpeg CME Outfitters, LLC Podcasts https://www.cmeoutfitters.com/ Getting to the Heart of the Underdiagnosis and Undertreatment of Non-valvular Atrial Fibrillation: Integrating Optimal Screening, Team-Based Care and Digital Health Tools in Primary Care Settings https://www.cmeoutfitters.com/getting-to-the-heart-of-the-underdiagnosis-non-valvular-atrial/ Fri, 02 Nov 2018 20:07:46 +0000 Alex Perez https://www.cmeoutfitters.com/?p=10448 full

Getting to the Heart of the Underdiagnosis and Undertreatment of Non-valvular Atrial Fibrillation: Integrating Optimal Screening, Team-Based Care and Digital Health Tools in Primary Care Settings

CMEO Live and On Demand

Premiere Date: Thursday, September 27, 2018This activity offers CE credit for:

  1. Physicians (CME)
  2. Nurses (CNE)
  3. Pharmacists (ACPE)
  4. ABIM
  5. Other

All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™

Credit Expiration Date: Friday, September 27, 2019

Get FREE E-Consultations and Digital Health Coaching

We at CME Outfitters have partnered with AristaMD to offer FREE eConsults to the first 100 clinicians who sign up, and with Pack Health to offer 3-month digital health coaching programs to patients.

Free 1-on-1 Digital Health Coaching for Your Patients

Enroll your patients in this fully funded digital health coaching program. Over the course of 3 months, Pack Health Advisors provide behavior change support by:

• Creating personalized action plans to change health behaviors

• Providing tangible accountability tools (e.g. medication charts, health budgets, and day trackers)

• Referring to local resources (e.g. transportation resources)

• Arranging for services (e.g. mail-order pharmacy)

• Securing discounts/cost savings (e.g. medication assistance programs)

Pair your patients with a non-clinical health advisors to provide them with the support they need between visits. Simply visit https://www.packhealth.com/AFCMEO/ and click “Get Started”

Free e-Consultations with a Specialist

Be one of the first 100 clinicians to sign-up and receive 1 month of free e-consultations with a specialist. E-consults can replace >70% of routine referrals and can improve patient outcomes.

It’s easy to claim your FREE AristaMD eConsults:

• Step 1: Access the sign-up form here.

• Step 2: AristaMD will set up your 1-month account within 24 hours and send information on how to use the eConsult platform for your patients.

Faculty

Christopher P. Cannon, MD Christopher P. Cannon, MD (Moderator)
Director, Education, Cardiovascular Medicine Innovation
Cardiovascular Division, Brigham and Women?s Hospital
Professor of Medicine, Harvard Medical School
Boston, MA
Deepak L. Bhatt, MD, MPH, , FACC, FAHA, FSCAI, FESC Deepak L. Bhatt, MD, MPH, , FACC, FAHA, FSCAI, FESC
Executive Director of Interventional Cardiovascular Programs
Brigham and Women’s Hospital Heart & Vascular Center
Professor of Medicine, Harvard Medical School
Boston, MA
Elaine M. Hylek, MD, MPH Elaine M. Hylek, MD, MPH
Director, Thrombosis and Anticoagulation Service
Boston Medical Center
Professor of Medicine
Boston University School of Medicine
Boston, MA

Statement of Need

With the increasing age of the U.S. population, the “perceived” incidence of atrial fibrillation (AF) – the most common arrhythmia in clinical practice and a leading cause of morbidity and mortality – is increasing. However, patients may not notice symptoms that warrant care-seeking, which leads to physicians not having an index of suspicion relative to those at high risk for AF. Because AF is a major risk factor for thromboembolic disease and can lead to an increased risk for stroke, increased screening and use of anticoagulation treatment can help high-risk patients avoid these events.

However, as 20% or more of patients who have an AF-related stroke are not diagnosed until the time of stroke or shortly thereafter, screening and appropriate use of anticoagulants are suboptimal, and clinicians face challenges in understanding the tools available and strategies for implementing opportunistic and systematic screening in order to detect non-valvular atrial fibrillation (NVAF).

Given these challenges, expert faculty in this live, interactive CME Outfitters webcast address the impact of undiagnosed NVAF, the benefit and use of screening tools for early detection, appropriate implementation of oral anticoagulant therapy, and the use of digital health technologies to foster shared decision-making and collaborative care.

Learning Objectives

At the end of this CE activity, participants should be able to:

  • Examine the significance of identifying patients at high risk for NVAF in the primary care setting who might benefit from anticoagulant therapy.
  • Increase the rate of detection of NVAF by implementing both opportunistic and systematic screening in primary care settings to reduce the risk of stroke and death.
  • Implement guideline-directed therapy for the appropriate use of oral anticoagulants in patients with NVAF to mitigate the risk of stroke.

The following learning objectives pertain only to those requesting CNE or CPE credit:

  • Explain the significance of identifying patients at high risk for NVAF in the primary care setting who might benefit from anticoagulant therapy.
  • Describe how NVAF screening in the primary care setting can reduce the risk of stroke and death.
  • Identify guideline-directed therapy for the appropriate use of oral anticoagulants in patients with NVAF that will mitigate the risk of stroke.

Financial Support

Supported by an educational grant from the Bristol-Myers Squibb and Pfizer Alliance.

Target Audience

Primary care physicians, cardiologists, physician assistants, nurse practitioners, nurses, and pharmacists who treat patients with non-vascular atrial fibrillation.

Credit Information

CME Credit (Physicians):
CME Outfitters, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CME Outfitters, LLC, designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CNE Credit (Nurses):
Provider approved by the California Board of Registered Nursing, Provider Number CEP 15510, for 1.5 contact hours.

Note to Nurse Practitioners and Clinical Nurse Specialists: the content of this activity pertains to pharmacology. Earn up to 1.5 contact hours of pharmacotherapeutic contact hours.

Note to Nurse Practitioners: Nurse Practitioners can apply for AMA PRA Category 1 Credit™through the American Academy of Nurse Practitioners (AANP). AANP will accept AMA PRA Category 1 Credit™ from organizations accredited by the Accreditation Council for Continuing Medical Education. Nurse practitioners can also apply for credit through their state boards.

CPE Credit (Pharmacists):
ACPECME Outfitters, LLC, is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. 1.5 contact hours (0.15 CEUs) Universal Activity Number:
Live: 0376-0000-18-022-L01-P
Enduring: 0376-0000-18-022-H01-P

Type: Knowledge-based

ABIM/MOC Credit:
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Learning Formats
Live activity
Enduring material

MIPS Improvement Activity: This activity counts towards MIPS Improvement Activity requirements under the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.

Note to Physician Assistants: AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the Accreditation Council for Continuing Medical Education.

Post-tests, credit request forms, and activity evaluations must be completed online at www.cmeoutfitters.com/TST28429 (requires free account activation), and participants can print their certificate or statement of credit immediately (75% pass rate required). This website supports all browsers except Internet Explorer for Mac. For complete technical requirements and privacy policy, visit www.neurosciencecme.com/technical.asp.

Disclosure Declaration

It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

Dr. Cannon reports that he receives research grants from Amgen Inc.; Boehringer-Ingelheim (BI); Bristol-Myers Squibb Company (BMS); Daiichi Sankyo; Janssen Pharmaceuticals, Inc.; Merck & Co., Inc. He is a consultant for Alnylam Pharmaceuticals, Inc.; Amarin Corporation; Amgen Inc.; Boehringer-Ingelheim (BI); Bristol-Myers Squibb Company (BMS); Eisai Inc.; Janssen Pharmaceuticals, Inc.; Kowa Pharmaceuticals America, Inc.; Merck & Co., Inc.; Pfizer Inc.; Regeneron Pharmaceuticals, Inc.; sanofi-aventis U.S. LLC.

Dr. Bhatt reports that he receives research grants from Abbott; Amarin Corporation; Amgen Inc.; Astra Zeneca; Bayer Corporation; Boehringer Ingelheim; Bristol-Myers Squibb Company; Chiesi USA, Inc.; Eisai Inc.; Ethicon USA, LLC; Forest Laboratories; Idorsia Pharmaceuticals Ltd; Ironwood Pharmaceuticals, Inc.; Ischemix; Lilly USA; Medtronic; PhaseBio Pharmaceuticals, Inc.; Pfizer Inc.; Regeneron; Roche; sanofi-aventis U.S. LLC; Synaptic; and The Medicines Company.

Dr. Hylek reports that she received a research grant from Janssen Pharmaceuticals, Inc. Speakers sympoisa for Boehringer Ingelheim; Bristol-Myers Squibb Company; Medtronic; Pfizer Inc. She is consultant for Bristol-Myers Squibb Company; Janssen Pharmaceuticals, Inc.; Medtronic

Dr. Helfand (peer reviewer) has no disclosures to report.

Ms. Ochoa (peer reviewer) has no disclosures to report.

Kashemi D. Rorie, PHD (planning committee) has no disclosures to report.

Sharon Tordoff (planning committee) has no disclosures to report.

Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report.

Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.

Questions about this activity? Call us at 877.CME.PROS(877.263.7767).

This document was last modified on: 11/02/2018 16:07:13

TV-097-092718-90

]]>

Getting to the Heart of the Underdiagnosis and Undertreatment of Non-valvular Atrial Fibrillation: Integrating Optimal Screening, Team-Based Care and Digital Health Tools in Primary Care Settings

CMEO Live and On Demand

Premiere Date: Thursday, September 27, 2018This activity offers CE credit for:

  1. Physicians (CME)
  2. Nurses (CNE)
  3. Pharmacists (ACPE)
  4. ABIM
  5. Other

All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™

Credit Expiration Date: Friday, September 27, 2019

Get FREE E-Consultations and Digital Health Coaching

We at CME Outfitters have partnered with AristaMD to offer FREE eConsults to the first 100 clinicians who sign up, and with Pack Health to offer 3-month digital health coaching programs to patients.

Free 1-on-1 Digital Health Coaching for Your Patients

Enroll your patients in this fully funded digital health coaching program. Over the course of 3 months, Pack Health Advisors provide behavior change support by:

• Creating personalized action plans to change health behaviors

• Providing tangible accountability tools (e.g. medication charts, health budgets, and day trackers)

• Referring to local resources (e.g. transportation resources)

• Arranging for services (e.g. mail-order pharmacy)

• Securing discounts/cost savings (e.g. medication assistance programs)

Pair your patients with a non-clinical health advisors to provide them with the support they need between visits. Simply visit https://www.packhealth.com/AFCMEO/ and click “Get Started”

Free e-Consultations with a Specialist

Be one of the first 100 clinicians to sign-up and receive 1 month of free e-consultations with a specialist. E-consults can replace >70% of routine referrals and can improve patient outcomes.

It’s easy to claim your FREE AristaMD eConsults:

• Step 1: Access the sign-up form here.

• Step 2: AristaMD will set up your 1-month account within 24 hours and send information on how to use the eConsult platform for your patients.

Faculty

Christopher P. Cannon, MD Christopher P. Cannon, MD (Moderator)
Director, Education, Cardiovascular Medicine Innovation
Cardiovascular Division, Brigham and Women?s Hospital
Professor of Medicine, Harvard Medical School
Boston, MA
Deepak L. Bhatt, MD, MPH, , FACC, FAHA, FSCAI, FESC Deepak L. Bhatt, MD, MPH, , FACC, FAHA, FSCAI, FESC
Executive Director of Interventional Cardiovascular Programs
Brigham and Women’s Hospital Heart & Vascular Center
Professor of Medicine, Harvard Medical School
]]>

Getting to the Heart of the Underdiagnosis and Undertreatment of Non-valvular Atrial Fibrillation: Integrating Optimal Screening, Team-Based Care and Digital Health Tools in Primary Care Settings

CMEO Live and On Demand

Premiere Date: Thursday, September 27, 2018This activity offers CE credit for:

  1. Physicians (CME)
  2. Nurses (CNE)
  3. Pharmacists (ACPE)
  4. ABIM
  5. Other

All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™

Credit Expiration Date: Friday, September 27, 2019

Get FREE E-Consultations and Digital Health Coaching

We at CME Outfitters have partnered with AristaMD to offer FREE eConsults to the first 100 clinicians who sign up, and with Pack Health to offer 3-month digital health coaching programs to patients.

Free 1-on-1 Digital Health Coaching for Your Patients

Enroll your patients in this fully funded digital health coaching program. Over the course of 3 months, Pack Health Advisors provide behavior change support by:

• Creating personalized action plans to change health behaviors

• Providing tangible accountability tools (e.g. medication charts, health budgets, and day trackers)

• Referring to local resources (e.g. transportation resources)

• Arranging for services (e.g. mail-order pharmacy)

• Securing discounts/cost savings (e.g. medication assistance programs)

Pair your patients with a non-clinical health advisors to provide them with the support they need between visits. Simply visit https://www.packhealth.com/AFCMEO/ and click “Get Started”

Free e-Consultations with a Specialist

Be one of the first 100 clinicians to sign-up and receive 1 month of free e-consultations with a specialist. E-consults can replace >70% of routine referrals and can improve patient outcomes.

It’s easy to claim your FREE AristaMD eConsults:

• Step 1: Access the sign-up form here.

• Step 2: AristaMD will set up your 1-month account within 24 hours and send information on how to use the eConsult platform for your patients.

Faculty

Christopher P. Cannon, MD Christopher P. Cannon, MD (Moderator)
Director, Education, Cardiovascular Medicine Innovation
Cardiovascular Division, Brigham and Women?s Hospital
Professor of Medicine, Harvard Medical School
Boston, MA
Deepak L. Bhatt, MD, MPH, , FACC, FAHA, FSCAI, FESC Deepak L. Bhatt, MD, MPH, , FACC, FAHA, FSCAI, FESC
Executive Director of Interventional Cardiovascular Programs
Brigham and Women’s Hospital Heart & Vascular Center
Professor of Medicine, Harvard Medical School
]]> clean No no no 1:25:29 Alex Perez Opioid Use Disorder in Special Populations: Making Recovery a Goal https://www.cmeoutfitters.com/opioid-use-disorder-in-special-populations/ Fri, 02 Nov 2018 20:01:59 +0000 Alex Perez https://www.cmeoutfitters.com/?p=10445 full

Opioid Use Disorder in Special Populations: Making Recovery a Goal

CMEO Live and On Demand

Premiere Date: Wednesday, October 10, 2018This activity offers CE credit for:

  1. Physicians (CME)
  2. Nurses (CNE)
  3. Social Workers (NASW)
  4. Certified Case Managers (CCMC)
  5. Pharmacists (ACPE)
  6. ABIM
  7. Other

All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™

Credit Expiration Date: Thursday, October 10, 2019

Faculty

Mark S. Gold, MD Mark S. Gold, MD (Moderator)
ASAM’s Annual Lifetime Achievement John P. McGovern Award & Prize winner
Adjunct Professor of Psychiatry
Washington University School of Medicine
St. Louis, MO
17th University of Florida Distinguished Alumni Professor
Gainesville, FL
James H. Berry, DO James H. Berry, DO
Associate Professor and Vice Chair
Director of Addictions
Department of Behavioral Medicine and Psychiatry
Department of Neurosciences
West Virginia University School of Medicine
Morgantown, WV
Brian Fuehrlein, MD, PhD Brian Fuehrlein, MD, PhD
Assistant Professor of Psychiatry
Yale University School of Medicine
Director, Psychiatric Emergency Room
VA Connecticut Healthcare System
New Haven, CT
Thomas R. Kosten, MD Thomas R. Kosten, MD
JH Waggoner Chair and Professor of Psychiatry, Neuroscience, Pharmacology, Immunology & Pathology
Director, Division of Addiction Psychiatry
Baylor College of Medicine
Houston, TX
Tobias Wasser, MD Tobias Wasser, MD
Chief Medical Officer, Whiting Forensic Hospital
Middletown, CT
Assistant Professor of Psychiatry, Yale University School of Medicine
Associate Director, Yale Fellowship in Public Psychiatry
New Haven, CT

Statement of Need

The opioid epidemic is ravaging many parts of the United States, resulting in drug overdose deaths emerging as the leading cause of injury death. The 2015 statistics from Health and Human Services on human and economic costs were staggering, reporting that 12.5 million people misused prescription opioids that year, resulting in $78.5 billion in economic costs. Yet the National Institute on Alcohol Abuse and Alcoholism (NIAA)’s National Epidemiological Survey on Alcohol Abuse and Related Conditions-III showed that only about 5% of people with OUD received treatment in the past year, and only 17% ever received help such as medication and behavioral counseling.

Two populations in particular warrant attention of healthcare providers: incarcerated individuals and veterans. Approximately half of state and federal prisoners meet criteria for substance use disorder, and the number of veterans addicted to opioids rose 55% between 2010 and 2015.

This CME Outfitters Live and On Demand initiative features expert faculty working to improve recognition of the risk of relapse or death among special populations with OUD and providing information about novel programs and how to integrate them into clinical practice with patients with OUD.

Learning Objectives

At the end of this CE activity, participants should be able to:

  • Recognize the risk of relapse or death among incarcerated individuals with untreated OUD upon release.
  • Apply data for MAT among special populations (veterans in the VA system, incarcerated individuals) to decision-making for individuals with OUD.
  • Heighten awareness of novel programs in the community to treat patients with OUD and integrate one best practice tip into clinical practice.

The following learning objectives pertain only to those requesting CNE or CPE credit:

  • Recognize the risk of relapse or death among incarcerated individuals with untreated OUD upon release.
  • Summarize data for MAT among special populations (veterans in the VA system, incarcerated individuals) to decision-making for individuals with OUD.
  • Heighten awareness of novel programs in the community to treat patients with OUD and integrate one best practice tip into clinical practice.

Financial Support

Supported by educational grants from Alkermes, Inc. and Indivior Inc.

Target Audience

Physicians, physician assistants, nurse practitioners, nurses, and pharmacists who treat patients with opioid use disorder.

Credit Information

CME Credit (Physicians):
CME Outfitters, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CME Outfitters, LLC, designates this enduring activity for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CNE Credit (Nurses):
Provider approved by the California Board of Registered Nursing, Provider Number CEP 15510, for 1.5 contact hours.

Note to Nurse Practitioners and Clinical Nurse Specialists: the content of this activity pertains to pharmacology. Earn up to 1.5 contact hours of pharmacotherapeutic contact hours.

Note to Nurse Practitioners: Nurse Practitioners can apply for AMA PRA Category 1 Credit™through the American Academy of Nurse Practitioners (AANP). AANP will accept AMA PRA Category 1 Credit™ from organizations accredited by the Accreditation Council for Continuing Medical Education. Nurse practitioners can also apply for credit through their state boards.

NASW Credit (Social Workers):
This program is Approved by the National Association of Social Workers (Approval # 886407722-6865 for 1 continuing education contact hours

CCMC Credit (Certified Case Managers):
This program has been approved for 1.5 hours by the Commission for Case Manager Certification (CCMC).

CPE Credit (Pharmacists):
ACPECME Outfitters, LLC, is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. 1.5 contact hours (0.15 CEUs) Universal Activity Number:
Live: 0376-0000-18-023-L01-P
Enduring: 0376-0000-18-023-H01-P

Type: Knowledge-based

ABIM/MOC Credit:
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Learning Formats
Live activity
Enduring material

MIPS Improvement Activity: This activity counts towards MIPS Improvement Activity requirements under the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.

Note to Physician Assistants: AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 CreditTM from organizations accredited by the Accreditation Council for Continuing Medical Education.

Post-tests, credit request forms, and activity evaluations must be completed online at www.cmeoutfitters.com/TST28426 (requires free account activation), and participants can print their certificate or statement of credit immediately (75% pass rate required). This website supports all browsers except Internet Explorer for Mac. For complete technical requirements and privacy policy, visit www.neurosciencecme.com/technical.asp.

Disclosure Declaration

It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

Dr. Gold has no disclosures to report.

Dr. Berry has no disclosures to report

Dr. Fuehrlein has no disclosures to report

Dr. Kosten reports that he is a consultant for Alkermes; Amygdala Neurosciences, Inc.; Braeburn Pharmaceuticals, Inc.; GuidePoint Global, LLC; Indivior Inc.; MedaCorp; Novartis Pharmaceuticals Corporation; Promentis Pharmaceuticals, Inc.; US WorldMeds, LLC.

Dr. Wasser has no disclosures to report

Dr. Helfand (peer reviewer) has no disclosures to report.

Ms. Ochoa (peer reviewer) has no disclosures to report.

Jan Perez (planning committee) has no disclosures to report.

Sharon Tordoff (planning committee) has no disclosures to report.

Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report.

Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.

Questions about this activity? Call us at 877.CME.PROS(877.263.7767).

This document was last modified on: 11/02/2018 16:00:38

TV-098-101018-90

]]>

Opioid Use Disorder in Special Populations: Making Recovery a Goal

CMEO Live and On Demand

Premiere Date: Wednesday, October 10, 2018This activity offers CE credit for:

  1. Physicians (CME)
  2. Nurses (CNE)
  3. Social Workers (NASW)
  4. Certified Case Managers (CCMC)
  5. Pharmacists (ACPE)
  6. ABIM
  7. Other

All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™

Credit Expiration Date: Thursday, October 10, 2019

Faculty

Mark S. Gold, MD Mark S. Gold, MD (Moderator)
ASAM’s Annual Lifetime Achievement John P. McGovern Award & Prize winner
Adjunct Professor of Psychiatry
Washington University School of Medicine
St. Louis, MO
17th University of Florida Distinguished Alumni Professor
Gainesville, FL
James H. Berry, DO James H. Berry, DO
Associate Professor and Vice Chair
Director of Addictions
Department of Behavioral Medicine and Psychiatry
Department of Neurosciences
West Virginia University School of Medicine
Morgantown, WV
Brian Fuehrlein, MD, PhD Brian Fuehrlein, MD, PhD
Assistant Professor of Psychiatry
Yale University School of Medicine
Director, Psychiatric Emergency Room
VA Connecticut Healthcare System
New Haven, CT
Thomas R. Kosten, MD Thomas R. Kosten, MD
JH Waggoner Chair and Professor of Psychiatry, Neuroscience, Pharmacology, Immunology & Pathology
Director, Division of Addiction Psychiatry
Baylor College of Medicine
Houston, TX
Tobias Wasser, MD

Opioid Use Disorder in Special Populations: Making Recovery a Goal

CMEO Live and On Demand

Premiere Date: Wednesday, October 10, 2018This activity offers CE credit for:

  1. Physicians (CME)
  2. Nurses (CNE)
  3. Social Workers (NASW)
  4. Certified Case Managers (CCMC)
  5. Pharmacists (ACPE)
  6. ABIM
  7. Other

All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™

Credit Expiration Date: Thursday, October 10, 2019

Faculty

Mark S. Gold, MD Mark S. Gold, MD (Moderator)
ASAM’s Annual Lifetime Achievement John P. McGovern Award & Prize winner
Adjunct Professor of Psychiatry
Washington University School of Medicine
St. Louis, MO
17th University of Florida Distinguished Alumni Professor
Gainesville, FL
James H. Berry, DO James H. Berry, DO
Associate Professor and Vice Chair
Director of Addictions
Department of Behavioral Medicine and Psychiatry
Department of Neurosciences
West Virginia University School of Medicine
Morgantown, WV
Brian Fuehrlein, MD, PhD Brian Fuehrlein, MD, PhD
Assistant Professor of Psychiatry
Yale University School of Medicine
Director, Psychiatric Emergency Room
VA Connecticut Healthcare System
New Haven, CT
Thomas R. Kosten, MD Thomas R. Kosten, MD
JH Waggoner Chair and Professor of Psychiatry, Neuroscience, Pharmacology, Immunology & Pathology
Director, Division of Addiction Psychiatry
Baylor College of Medicine
Houston, TX
Tobias Wasser, MD clean No no no 1:24:42 Alex Perez From Pathways to PROs: Translating the Latest Evidence for Current and Emerging JAK Inhibitors to Clinical Practice https://www.cmeoutfitters.com/from-pathways-to-pros/ Fri, 02 Nov 2018 19:51:15 +0000 Alex Perez https://www.cmeoutfitters.com/?p=10440 full From Pathways to PROs: Translating the Latest Evidence for Current and Emerging JAK Inhibitors to Clinical Practice

CMEO Webcast

Premiere Date: Tuesday, October 23, 2018This activity offers CE credit for:

  1. Physicians (CME)
  2. Nurses (CNE)
  3. Pharmacists (ACPE)
  4. ABIM
  5. Other

All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™

Credit Expiration Date: Tuesday, October 23, 2018
Note: Credit Is No Longer Available

Faculty

Stanley B. Cohen, MD Stanley B. Cohen, MD
Clinical Professor, Department of Internal Medicine
University of Texas Southwestern Medical School
Co-Director, Division of Rheumatology
Presbyterian Hospital, Dallas
Co-Medical Director
Metroplex Clinical Research Center
Dallas, TX
Past President of the American College of Rheumatology
Atlanta, GA
Leonard H. Calabrese, DO Leonard H. Calabrese, DO
Professor of Medicine
Vice Chair, Department of Rheumatic & Immunologic Disease
Cleveland Clinic Lerner College of Medicine
of Case Western Reserve University
R.J. Fasenmyer Chair of Clinical Immunology
Cleveland Clinic Foundation
Cleveland, OH

Statement of Need

Current therapeutic approaches for RA rely on disease-modifying antirheumatic drugs (DMARDs) as well as on biologic therapeutics that target tumor necrosis factor (TNF), interleukin-6 (IL-6), and T cell activation or that eliminate CD20+ B cells. These treatments have limitations, such as waning efficacy over time, side effects, and dosing inconvenience. Clinicians need to be aware of what other treatment options exist or are emerging. Further, rheumatology clinicians often face challenges in translating clinical evidence and data to real-world practice, and assessing the role of patient-reported outcomes (PROs) is pertinent when determining the value of new therapeutics for RA.

This CME Outfitters symposium, featuring expert faculty discussion and learner interactivity, will address gaps related to emerging discoveries of inflammatory targets, clinical trial data, and the role of patient-reported outcomes (PROs) in practice, with resources posted to the Rheumatology Digital Hub after the symposium.

Learning Objectives

At the end of this CE activity, participants should be able to:

  • Translate basic clinical immunology to current evidence for the pathophysiology and MOA for current and emerging JAK inhibitors.
  • Evaluate clinical trial data for emerging small molecule/intracellular signaling targets in the management of patients with rheumatoid arthritis.
  • Assess the role of patient-reported outcomes (PROs) as measures for the value of new therapeutics for RA, in addition to safety and efficacy data.

The following learning objectives pertain only to those requesting CNE or CPE credit:

  • Translate basic clinical immunology to current evidence for the pathophysiology and MOA for current and emerging JAK inhibitors.
  • Evaluate clinical trial data for emerging small molecule/intracellular signaling targets in the management of patients with rheumatoid arthritis (RA).
  • Assess the role of patient-reported outcomes (PROs) as measures for the value of new therapeutics for RA, in addition to safety and efficacy data.

Financial Support

Supported by an educational grant from Gilead Sciences, Inc.

Target Audience

Rheumatologists, physicians, nurse practitioners, physician assistants, nurses, and pharmacists who treat patients with rheumatoid arthritis.

Credit Information

CME Credit (Physicians):
CME Outfitters, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CME Outfitters, LLC, designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CNE Credit (Nurses):
Note to Nurse Practitioners: Nurse practitioners can apply for AMA PRA Category 1 CreditTMthrough the American Academy of Nurse Practitioners (AANP). AANP will accept AMA PRA Category 1 CreditTM from organizations accredited by the Accreditation Council for Continuing Medical Education. Nurse practitioners can also apply for credit through their state boards.

CPE Credit (Pharmacists):
ACPECME Outfitters, LLC, is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. 1.5 contact hours (0.15 CEUs) Universal Activity Number:
Live: 0376-0000-18-020-L01-P
Enduring: 0376-0000-18-020-H01-P

Type: knowledge-based

ABIM MOC Credit:
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Learning Formats:
Live activity
Enduring Material

MIPS Improvement Activity: This activity counts towards MIPS Improvement Activity requirements under the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.

Note to Physician Assistants: AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the Accreditation Council for Continuing Medical Education.

Post-tests, credit request forms, and activity evaluations must be completed during the live activity participants will receive their certificate by email in 2-3 weeks, (75% pass rate required).
This website supports all browsers except Internet Explorer for Mac. For complete technical requirements and privacy policy, visit www.neurosciencecme.com/technical.asp.

Disclosure Declaration

It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

Dr. Cohen reports that he is a clinical investigator and/or research consultant for AbbVie Inc.; AstraZeneca; Biogen Idec Inc.; Bristol-Myers Squibb Company; Genentech, Inc.; Janssen Pharmaceuticals, Inc.; Eli Lilly and Company; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Merck & Co., Inc.; F. Hoffmann-La Roche Ltd.

Dr. Calabrese reports that he is a consultant for AbbVie Inc.; Centocor Biopharmaceutical; Crescendo Bioscience, Inc.; GlaxoSmithKline; Horizon Pharma; Janssen Pharmaceuticals, Inc.; Pfizer Inc.; Regeneron Pharmaceuticals, Inc.; UCB, Inc.

Kate Nelson, PHD (planning committee) has no disclosures to report.

Sharon Tordoff(planning committee) has no disclosures to report.

Jan Perez (planning committee) has no disclosures to report.

Jeffrey Helfand, DO, MS (peer reviewer) has no disclosures to report.

Mae Ochoa, RPh (peer reviewer) has no disclosures to report.

Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report.

Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.

Questions about this activity? Call us at 877.CME.PROS(877.263.7767).

This document was last modified on: 11/02/2018 15:49:34

MM-085LS-102318-47

]]> From Pathways to PROs: Translating the Latest Evidence for Current and Emerging JAK Inhibitors to Clinical Practice

CMEO Webcast

Premiere Date: Tuesday, October 23, 2018This activity offers CE credit for:

  1. Physicians (CME)
  2. Nurses (CNE)
  3. Pharmacists (ACPE)
  4. ABIM
  5. Other

All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™

Credit Expiration Date: Tuesday, October 23, 2018
Note: Credit Is No Longer Available

Faculty

Stanley B. Cohen, MD Stanley B. Cohen, MD
Clinical Professor, Department of Internal Medicine
University of Texas Southwestern Medical School
Co-Director, Division of Rheumatology
Presbyterian Hospital, Dallas
Co-Medical Director
Metroplex Clinical Research Center
Dallas, TX
Past President of the American College of Rheumatology
Atlanta, GA
Leonard H. Calabrese, DO Leonard H. Calabrese, DO
Professor of Medicine
Vice Chair, Department of Rheumatic & Immunologic Disease
Cleveland Clinic Lerner College of Medicine
of Case Western Reserve University
R.J. Fasenmyer Chair of Clinical Immunology
Cleveland Clinic Foundation
Cleveland, OH

Statement of Need

Current therapeutic approaches for RA rely on disease-modifying antirheumatic drugs (DMARDs) as well as on biologic therapeutics that target tumor necrosis factor (TNF), interleukin-6 (IL-6), and T cell activation or that eliminate CD20+ B cells. These treatments have limitations, such as waning efficacy over time, side effects, and dosing inconvenience. Clinicians need to be aware of what other treatment options exist or are emerging. Further, rheumatology clinicians often face challenges in translating clinical evidence and data to real-world practice, and assessing the role of patient-reported outcomes (PROs) is pertinent when determining the value of new therapeutics for RA.

This CME Outfitters symposium, featuring expert faculty discussion and learner interactivity, will address gaps related to emerging discoveries of inflammatory targets, clinical trial data, and the role of patient-reported outcomes (PROs) in practice, with resources posted to the Rheumatology Digital Hub after the symposium.

Learning Objectives

At the end of this CE activity, participants should be able to:

  • Translate basic clinical immunology to current evidence for the pathophysiology and MOA for current and emerging JAK inhibitors.
  • Evaluate clinical trial data for emerging small molecule/intracellular signaling targets in the management of patients with rheumatoid arthritis.
  • Assess the role of patient-reported outcomes (PROs) as measures for the value of new therapeutics for R]]> From Pathways to PROs: Translating the Latest Evidence for Current and Emerging JAK Inhibitors to Clinical Practice

    CMEO Webcast

    Premiere Date: Tuesday, October 23, 2018This activity offers CE credit for:

    1. Physicians (CME)
    2. Nurses (CNE)
    3. Pharmacists (ACPE)
    4. ABIM
    5. Other

    All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™

    Credit Expiration Date: Tuesday, October 23, 2018
    Note: Credit Is No Longer Available

    Faculty

    Stanley B. Cohen, MD Stanley B. Cohen, MD
    Clinical Professor, Department of Internal Medicine
    University of Texas Southwestern Medical School
    Co-Director, Division of Rheumatology
    Presbyterian Hospital, Dallas
    Co-Medical Director
    Metroplex Clinical Research Center
    Dallas, TX
    Past President of the American College of Rheumatology
    Atlanta, GA
    Leonard H. Calabrese, DO Leonard H. Calabrese, DO
    Professor of Medicine
    Vice Chair, Department of Rheumatic & Immunologic Disease
    Cleveland Clinic Lerner College of Medicine
    of Case Western Reserve University
    R.J. Fasenmyer Chair of Clinical Immunology
    Cleveland Clinic Foundation
    Cleveland, OH

    Statement of Need

    Current therapeutic approaches for RA rely on disease-modifying antirheumatic drugs (DMARDs) as well as on biologic therapeutics that target tumor necrosis factor (TNF), interleukin-6 (IL-6), and T cell activation or that eliminate CD20+ B cells. These treatments have limitations, such as waning efficacy over time, side effects, and dosing inconvenience. Clinicians need to be aware of what other treatment options exist or are emerging. Further, rheumatology clinicians often face challenges in translating clinical evidence and data to real-world practice, and assessing the role of patient-reported outcomes (PROs) is pertinent when determining the value of new therapeutics for RA.

    This CME Outfitters symposium, featuring expert faculty discussion and learner interactivity, will address gaps related to emerging discoveries of inflammatory targets, clinical trial data, and the role of patient-reported outcomes (PROs) in practice, with resources posted to the Rheumatology Digital Hub after the symposium.

    Learning Objectives

    At the end of this CE activity, participants should be able to:

    • Translate basic clinical immunology to current evidence for the pathophysiology and MOA for current and emerging JAK inhibitors.
    • Evaluate clinical trial data for emerging small molecule/intracellular signaling targets in the management of patients with rheumatoid arthritis.
    • Assess the role of patient-reported outcomes (PROs) as measures for the value of new therapeutics for R]]> clean No no no 1:17:48 Alex Perez The PROMIS® of Improved Bone Health in Older Adults https://www.cmeoutfitters.com/the-promis-of-improved-bone-health-in-older-adults/ Fri, 02 Nov 2018 19:45:29 +0000 Alex Perez https://www.cmeoutfitters.com/?p=10436 full The PROMIS® of Improved Bone Health in Older Adults

      CMEO Medical Meeting

      Symposium Date: Sunday, September 30, 2018
      on September 30, 2018 at The Palais des congrès de Montréal
      Montreal, QuebecThis activity offers CE credit for:

      1. Physicians (CME)
      2. Nurses (CNE)
      3. Pharmacists (ACPE)
      4. ABIM
      5. Other

      All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™

      Credit Expiration Date: Monday, September 30, 2019

      Faculty

      Joseph M. Lane, MD (Chair) Joseph M. Lane, MD (Chair)
      Professor, Orthopaedic Surgery
      Assistant Dean, Medical Students (HSS)
      Weill Cornell Medical College
      Chief, Metabolic Bone Disease Service
      Hospital for Special Surgery
      New York, NY
      Richard S. Bockman, MD, PhD Richard S. Bockman, MD, PhD
      Chief, Endocrine Service
      Attending Physician
      Senior Scientist
      Hospital for Special Surgery
      Professor of Medicine, Endocrine Division
      Weill Cornell Medical College
      New York, NY
      Kirsten Grueter, RN Kirsten Grueter, RN
      Fracture Liaison Nurse
      Office of Joseph Lane, MD
      Hospital for Special Surgery
      New York, NY
      Emily M. Stein, MD, MS Emily M. Stein, MD, MS
      Associate Attending Physician
      Associate Research Scientist
      Internal Medicine, Endocrinology, Metabolic Bone
      Hospital for Special Surgery
      Associate Professor of Medicine
      Weill Cornell Medical College
      New York, NY

      Statement of Need

      A bone-healthy lifestyle includes a diet that is rich in vitamins and nutrients, regular exercise, and avoidance of smoking and excessive alcohol intake. This, along with essential nutrients calcium and vitamin D, contribute to optimal bone health. Inadequate dietary intake of calcium and vitamin D for long periods of time can cause osteopenia, which can lead to osteoporosis as well as placing individuals at risk for falls and fractures. Fragility fractures due to osteoporosis have far-reaching consequences and pose a burden to sufferers, their family, and the economy. Additionally, osteoporosis is most often associated with women, but one in three osteoporotic fractures occurs in men and the consequences tend to be more severe than in when. Clinicians need to evaluate their male patients for osteoporosis.

      While vitamin D and calcium supplementation are broadly recommended to treat and prevent osteoporosis, there are contrasting viewpoints regarding their efficacy and safety. Deep understanding of this research is necessary to contextualize this data for individual patients that may not be achieving adequate intake via diet.

      This CME Outfitters live symposium features expert faculty and an interactive, case-based program that will teach the importance of utilizing validated PROMIS® (Patient-Reported Outcomes Measurement Information System) measures to assess treatment progress and monitor disease. Join us for this symposium and heighten your awareness of the need of evaluation and treatment of osteoporosis beyond women to include men.

      Learning Objectives

      At the end of this CE activity, participants should be able to:

      • Recognize the prevalence and impact of osteoporosis in older men and initiate an assessment of bone health.
      • Assess the safety and efficacy data for calcium and vitamin D supplementation in reducing fracture risk.
      • Implement PROs into clinical workflow to measure change in function and quality of life in patients with osteoporosis.

      The following learning objectives pertain only to those requesting CNE or CPE credit:

      • Recognize the prevalence and impact of osteoporosis in older men and initiate an assessment of bone health.
      • Assess the safety and efficacy data for calcium and vitamin D supplementation in reducing fracture risk.
      • Explain how PROs may be implemented into clinical workflow to measure change in function and quality of life in patients with osteoporosis.

      Financial Support

      Supported by an educational grant from Pfizer Inc.

      Target Audience

      Endocrinologists, orthopedists, primary care physicians, nurse practitioners, physician assistants, nurses, and pharmacists who treat patients with osteoporosis.

      Credit Information

      CME Credit (Physicians):
      CME Outfitters, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

      CME Outfitters, LLC, designates this live activity for a maximum of 1.25 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

      CNE Credit (Nurses):
      Provider approved by the California Board of Registered Nursing, Provider Number CEP 15510, for 1.25 contact hours

      Note to Nurse Practitioners: Nurse practitioners can apply for AMA PRA Category 1 Credit(s)TMthrough the American Academy of Nurse Practitioners (AANP). AANP will accept AMA PRA Category 1 Credit(s)TM from organizations accredited by the Accreditation Council for Continuing Medical Education. Nurse practitioners can also apply for credit through their state boards.

      CPE Credit (Pharmacists):
      ACPECME Outfitters, LLC, is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. 1.25 contact hours (0.125 CEUs) Universal Activity Number: Live: 0376-0000-18-019-L01-P Enduring: 0376-0000-18-019-H01-P Type: knowledge-based practice-based

      Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.25 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

      Learning Formats: Live activity Enduring Material

      MIPS Improvement Activity: This activity counts towards MIPS Improvement Activity requirements under the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.

      Note to Physician Assistants: AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit(s)TM from organizations accredited by the Accreditation Council for Continuing Medical Education.

      Post-tests, credit request forms, and activity evaluations must be completed online at www.cmeoutfitters.com/TST28404 (requires free account activation), and participants can print their certificate or statement of credit immediately (75% pass rate required). This website supports all browsers except Internet Explorer for Mac. For complete technical requirements and privacy policy, visit www.neurosciencecme.com/technical.asp

      Disclosure Declaration

      It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

      Dr. Lane reports that he receives grants from National Institutes of Health (NIH) – subcontract with Helen Hayes Hospital. He receives research support from Novartis Pharmaceuticals Corporation – clinical trial hip fracture study. He is a consultant for ON Foundation; CollPlant Inc.

      Dr. Bockman has no disclosures to report.

      Ms. Grueter has no disclosures to report.

      Dr. Stein reports that she receives research grants from Novartis Pharmaceuticals Corporation.

      Dr. Helfand (peer reviewer) has no disclosures to report.

      Ms. Ochoa (peer reviewer) has no disclosures to report.

      Kashemi D. Rorie, PhD (planning committee) has no disclosures to report.

      Sharon Tordoff(planning committee) has no disclosures to report.

      Jan Perez (planning committee) has no disclosures to report.

      Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report.

      Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty has been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.

      Questions about this activity? Call us at 877.CME.PROS(877.263.7767).

      This document was last modified on: 11/02/2018 15:46:38

      MM-084-093018-02

      ]]>
      The PROMIS® of Improved Bone Health in Older Adults

      CMEO Medical Meeting

      Symposium Date: Sunday, September 30, 2018
      on September 30, 2018 at The Palais des congrès de Montréal
      Montreal, QuebecThis activity offers CE credit for:

      1. Physicians (CME)
      2. Nurses (CNE)
      3. Pharmacists (ACPE)
      4. ABIM
      5. Other

      All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™

      Credit Expiration Date: Monday, September 30, 2019

      Faculty

      Joseph M. Lane, MD (Chair) Joseph M. Lane, MD (Chair)
      Professor, Orthopaedic Surgery
      Assistant Dean, Medical Students (HSS)
      Weill Cornell Medical College
      Chief, Metabolic Bone Disease Service
      Hospital for Special Surgery
      New York, NY
      Richard S. Bockman, MD, PhD Richard S. Bockman, MD, PhD
      Chief, Endocrine Service
      Attending Physician
      Senior Scientist
      Hospital for Special Surgery
      Professor of Medicine, Endocrine Division
      Weill Cornell Medical College
      New York, NY
      Kirsten Grueter, RN Kirsten Grueter, RN
      Fracture Liaison Nurse
      Office of Joseph Lane, MD
      Hospital for Special Surgery
      New York, NY
      Emily M. Stein, MD, MS Emily M. Stein, MD, MS
      Associate Attending Physician
      Associate Research Scientist
      Internal Medicine, Endocrinology, Metabolic Bone
      Hospital for Special Surgery
      Associate Professor of Medicine
      Weill Cornell Medical College
      New York, NY

      Statement of Need

      A bone-healthy lifestyle includes a diet that is rich in vitamins and nutrients, regular exercise, and avoidance of smoking and excessive alcohol intake. This, along with essential nutrients calcium and vitamin D, contribute to optimal bone health. Inadequate dietary intake of calcium and vitamin D for long periods of time can cause osteopenia, which can lead to osteoporosis as well as placing individuals at risk for falls and fractures. Fragility fra]]> The PROMIS® of Improved Bone Health in Older Adults

      CMEO Medical Meeting

      Symposium Date: Sunday, September 30, 2018
      on September 30, 2018 at The Palais des congrès de Montréal
      Montreal, QuebecThis activity offers CE credit for:

      1. Physicians (CME)
      2. Nurses (CNE)
      3. Pharmacists (ACPE)
      4. ABIM
      5. Other

      All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™

      Credit Expiration Date: Monday, September 30, 2019

      Faculty

      Joseph M. Lane, MD (Chair) Joseph M. Lane, MD (Chair)
      Professor, Orthopaedic Surgery
      Assistant Dean, Medical Students (HSS)
      Weill Cornell Medical College
      Chief, Metabolic Bone Disease Service
      Hospital for Special Surgery
      New York, NY
      Richard S. Bockman, MD, PhD Richard S. Bockman, MD, PhD
      Chief, Endocrine Service
      Attending Physician
      Senior Scientist
      Hospital for Special Surgery
      Professor of Medicine, Endocrine Division
      Weill Cornell Medical College
      New York, NY
      Kirsten Grueter, RN Kirsten Grueter, RN
      Fracture Liaison Nurse
      Office of Joseph Lane, MD
      Hospital for Special Surgery
      New York, NY
      Emily M. Stein, MD, MS Emily M. Stein, MD, MS
      Associate Attending Physician
      Associate Research Scientist
      Internal Medicine, Endocrinology, Metabolic Bone
      Hospital for Special Surgery
      Associate Professor of Medicine
      Weill Cornell Medical College
      New York, NY

      Statement of Need

      A bone-healthy lifestyle includes a diet that is rich in vitamins and nutrients, regular exercise, and avoidance of smoking and excessive alcohol intake. This, along with essential nutrients calcium and vitamin D, contribute to optimal bone health. Inadequate dietary intake of calcium and vitamin D for long periods of time can cause osteopenia, which can lead to osteoporosis as well as placing individuals at risk for falls and fractures. Fragility fra]]> clean No no no 1:11:02 Alex Perez Precision Medicine in Ankylosing Spondylitis: Fine-tuning Diagnosis and Treatment https://www.cmeoutfitters.com/podcast/mmv079pc/ Fri, 19 Oct 2018 16:38:06 +0000 Alex Perez https://www.cmeoutfitters.com/?post_type=podcast&p=10364 full

      Premiere Date: Sunday, May 20, 2018

      This activity offers CE credit for:

      1. Physicians (CME)
      2. Nurses (CNE)
      3. Pharmacists (ACPE)
      4. ABIM (ABIM)
      5. Other

      All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™

      Credit Expiration Date: Monday, May 20, 2019

      Faculty

      Allan Gibofsky, MD, JD, MACR, FACP, FCLM Allan Gibofsky, MD, JD, MACR, FACP, FCLM
      Professor of Medicine, Healthcare Policy and Research
      Weill Medical College of Cornell University
      Attending Rheumatologist
      Hospital for Special Surgery
      New York, NY
      Joerg Ermann, MD Joerg Ermann, MD
      Instructor in Medicine
      Brigham and Women’s Hospital
      Harvard Medical School
      Boston, MA

      Statement of Need

      Ankylosing spondylitis (AS) is a chronic, inflammatory arthritis that affects the axial skeleton. Due to an aging population, declining number of rheumatologists, and limited access to care, care for patients with AS is suboptimal and it is critically important that primary care can optimally recognize and manage these patients. AS is challenging to diagnose and has a 5-10 year delay in diagnosis, the longest diagnostic delay among rheumatic diseases. Studies have shown that patients with shorter disease duration have better response to treatment. A diagnostic delay may cause patients to miss the chance of early appropriate treatment and consequently have poorer prognosis, increased disability, limitation of spinal and hip movements, pain, poor quality of life, and poor functional status.

      This CME Outfitters recorded symposium features expert faculty and aims to improve confidence in practitioners that will lead to improved screening, evaluation, and early treatment of individuals with AS.

      Learning Objectives

      At the end of this CE activity, participants should be able to:

      • Recognize key clinical features of ankylosing spondylitis (AS) to aid in timely diagnosis.
      • Incorporate classification criteria and diagnostic tests into clinical practice to support early detection of AS.
      • Implement biologic treatments for AS into clinical practice when appropriate.

      The following learning objectives pertain only to those requesting CNE or CPE credit:

      • Describe key clinical features of ankylosing spondylitis (AS) that aid in timely diagnosis.
      • Identify classification criteria and diagnostic tests that support early detection of AS.
      • Explain appropriate implementation of biologic treatments for AS.

      Financial Support

      Supported by an educational grant from Novartis Pharmaceuticals Corporation.

      Target Audience

      Primary care physicians, internists, physician assistants, nurse practitioners, nurses, and pharmacists who treat patients with ankylosing spondylitis.

      Credit Information

      CME Credit (Physicians):
      CME Outfitters, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

      CME Outfitters, LLC designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

      CNE Credit (Nurses):
      Provider approved by the California Board of Registered Nursing, Provider Number CEP 15510, for 1.5 contact hours

      Note to Nurse Practitioners and Clinical Nurse Specialists: the content of this activity pertains to pharmacology. Earn up to 1.5 contact hours of pharmacotherapeutic contact hours.

      Note to Nurse Practitioners: Nurse practitioners can apply for AMA PRA Category 1 CreditTMthrough the American Academy of Nurse Practitioners (AANP). AANP will accept AMA PRA Category 1 CreditTM from organizations accredited by the Accreditation Council for Continuing Medical Education. Nurse practitioners can also apply for credit through their state boards.

      CPE Credit (Pharmacists):
      ACPECME Outfitters, LLC, is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. 1.5 contact hours (0.15 CEUs) Universal Activity Number:
      Enduring: 0376-0000-18-010-H01-P

      Type: Knowledge-based

      ABIM/MOC Credit:
      Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

      Learning Formats
      Enduring material

      Note to Physician Assistants: AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 CreditTM from organizations accredited by the Accreditation Council for Continuing Medical Education.

      Post-tests, credit request forms, and activity evaluations must be completed online at www.cmeoutfitters.com/TST27393 (requires free account activation), and participants can print their certificate or statement of credit immediately (75% pass rate required). This website supports all browsers except Internet Explorer for Mac. For complete technical requirements and privacy policy, visit www.neurosciencecme.com/technical.asp.

      Disclosure Declaration

      It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

      Dr. Allan Gibofsky disclosed that he is on the Speakers Bureau for AbbVie Inc.; Celgene Corporation; Merck & Co., Inc.; Pfizer Inc. He is a consultant for AbbVie Inc., Celgene Corporation; Merck & Co., Inc.; Pfizer Inc.; Regeneron Pharmaceuticals, Inc.; Samumed, LLC; Sandoz. He is a stock shareholder of AbbVie Inc.; Bristol-Myers Squibb Company; Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Pfizer Inc.; Regeneron Pharmaceuticals, Inc.

      Dr. Joerg Ermann disclosed that he receives grants from Boehringer Ingelheim and Pfizer Inc.

      Sharon Tordoff(planning committee) has no disclosures to report.

      Jan Perez (planning committee) has no disclosures to report.

      Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report.

      Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.

      Questions about this activity? Call us at 877.CME.PROS(877.263.7767).

      ]]>

      Premiere Date: Sunday, May 20, 2018

      This activity offers CE credit for:

      1. Physicians (CME)
      2. Nurses (CNE)
      3. Pharmacists (ACPE)
      4. ABIM (ABIM)
      5. Other

      All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™

      Credit Expiration Date: Monday, May 20, 2019

      Faculty

      Allan Gibofsky, MD, JD, MACR, FACP, FCLM Allan Gibofsky, MD, JD, MACR, FACP, FCLM
      Professor of Medicine, Healthcare Policy and Research
      Weill Medical College of Cornell University
      Attending Rheumatologist
      Hospital for Special Surgery
      New York, NY
      Joerg Ermann, MD Joerg Ermann, MD
      Instructor in Medicine
      Brigham and Women’s Hospital
      Harvard Medical School
      Boston, MA

      Statement of Need

      Ankylosing spondylitis (AS) is a chronic, inflammatory arthritis that affects the axial skeleton. Due to an aging population, declining number of rheumatologists, and limited access to care, care for patients with AS is suboptimal and it is critically important that primary care can optimally recognize and manage these patients. AS is challenging to diagnose and has a 5-10 year delay in diagnosis, the longest diagnostic delay among rheumatic diseases. Studies have shown that patients with shorter disease duration have better response to treatment. A diagnostic delay may cause patients to miss the chance of early appropriate treatment and consequently have poorer prognosis, increased disability, limitation of spinal and hip movements, pain, poor quality of life, and poor functional status.

      This CME Outfitters recorded symposium features expert faculty and aims to improve confidence in practitioners that will lead to improved screening, evaluation, and early treatment of individuals with AS.

      Learning Objectives

      At the end of this CE activity, participants should be able to:

      • Recognize key clinical features of ankylosing spondylitis (AS) to aid in timely diagnosis.
      • Incorporate classification criteria and diagnostic tests into clinical practice to support early detection of AS.
      • Implement biologic treatments for AS into clinical practice when appropriate.

      The following learning objectives pertain only to those requesting CNE or CPE credit:

      • Describe key clinical features of ankylosing spondylitis (AS) that aid in timely diagnosis.
      • Identify classification criteria and diagnostic tests that support early detection of AS.
      • Explain appropriate implementation of biologic treatments for AS.

      Financial Support

      Supported by an educational grant from Novartis Pharmaceuticals Corporation.

      Target Audience

      Primary care physicians, internis]]>

      Premiere Date: Sunday, May 20, 2018

      This activity offers CE credit for:

      1. Physicians (CME)
      2. Nurses (CNE)
      3. Pharmacists (ACPE)
      4. ABIM (ABIM)
      5. Other

      All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™

      Credit Expiration Date: Monday, May 20, 2019

      Faculty

      Allan Gibofsky, MD, JD, MACR, FACP, FCLM Allan Gibofsky, MD, JD, MACR, FACP, FCLM
      Professor of Medicine, Healthcare Policy and Research
      Weill Medical College of Cornell University
      Attending Rheumatologist
      Hospital for Special Surgery
      New York, NY
      Joerg Ermann, MD Joerg Ermann, MD
      Instructor in Medicine
      Brigham and Women’s Hospital
      Harvard Medical School
      Boston, MA

      Statement of Need

      Ankylosing spondylitis (AS) is a chronic, inflammatory arthritis that affects the axial skeleton. Due to an aging population, declining number of rheumatologists, and limited access to care, care for patients with AS is suboptimal and it is critically important that primary care can optimally recognize and manage these patients. AS is challenging to diagnose and has a 5-10 year delay in diagnosis, the longest diagnostic delay among rheumatic diseases. Studies have shown that patients with shorter disease duration have better response to treatment. A diagnostic delay may cause patients to miss the chance of early appropriate treatment and consequently have poorer prognosis, increased disability, limitation of spinal and hip movements, pain, poor quality of life, and poor functional status.

      This CME Outfitters recorded symposium features expert faculty and aims to improve confidence in practitioners that will lead to improved screening, evaluation, and early treatment of individuals with AS.

      Learning Objectives

      At the end of this CE activity, participants should be able to:

      • Recognize key clinical features of ankylosing spondylitis (AS) to aid in timely diagnosis.
      • Incorporate classification criteria and diagnostic tests into clinical practice to support early detection of AS.
      • Implement biologic treatments for AS into clinical practice when appropriate.

      The following learning objectives pertain only to those requesting CNE or CPE credit:

      • Describe key clinical features of ankylosing spondylitis (AS) that aid in timely diagnosis.
      • Identify classification criteria and diagnostic tests that support early detection of AS.
      • Explain appropriate implementation of biologic treatments for AS.

      Financial Support

      Supported by an educational grant from Novartis Pharmaceuticals Corporation.

      Target Audience

      Primary care physicians, internis]]> clean No no no 0:00 Alex Perez Practicing Precision Medicine in Psoriatic Arthritis: Strategies and Digital Health Tools for Managing a Chronic Disease https://www.cmeoutfitters.com/practicing-precision-medicine-in-psoriatic-arthritis-strategies-and-digital-health-tools-for-managing-a-chronic-disease/ Thu, 02 Aug 2018 14:13:01 +0000 Ben Scarborough https://www.cmeoutfitters.com/?p=9898 full CMEO Live and On Demand

      Premiere Date: Thursday, July 12, 2018

      This activity offers CE credit for:

      1. Physicians (CME)
      2. Nurses (CNE)
      3. Pharmacists (ACPE)
      4. ABIM (ABIM)
      5. Other

      All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™

      Credit Expiration Date: Friday, July 12, 2019

      Begin Activity Now

      Faculty

       

      Allan Gibofsky, MD, JD, MACR, FACP, FCLM Allan Gibofsky, MD, JD, MACR, FACP, FCLM
      Professor of Medicine, Healthcare Policy and Research
      Weill Medical College of Cornell University
      Attending Rheumatologist
      Hospital for Special Surgery
      New York, NY

       

      Joel M. Gelfand, MD, MSCE Joel M. Gelfand, MD, MSCE
      Professor of Dermatology
      Professor of Epidemiology
      Vice Chair of Clinical Research and Medical Director, Dermatology Clinical Studies Unit
      Director, Psoriasis and Phototherapy Treatment Center
      University of Pennsylvania Perelman School of Medicine
      Philadelphia, PA

       

      Jennifer G. Kwan-Morley, MD Jennifer G. Kwan-Morley, MD
      Rheumatologist
      Premier Orthopaedics
      Malvern, PA

      Co-provided by

      USF CME Outfitters

      Statement of Need

      Psoriatic arthritis (PsA) is a serious and potentially disabling condition that affects approximately 30% of psoriasis patients. In addition to the physical and functional impairments from joint destruction, PsA also negatively impacts relationships, daily activities, work productivity, and overall quality of life. Several agents have been FDA-approved for the treatment of moderate-to-severe PsA since 2008, and there are still more currently under investigation. Digital health tools provide clinicians with multiple touchpoints and reminders; they can help reinforce SMART goals, provide tips, and link to additional resources. Despite the availability of effective PsA agents, clinicians are often not aware of new and pipeline agents for their patients with moderate-to-severe PsA. Often, clinicians are not implementing newer agents or digital health tools into clinical practice that lead to better patient outcomes.

      In this CME Outfitters Live and On Demand expert faculty will highlight the molecular targets of currently available and emerging biologic treatments for managing PsA, discuss individualized treatment plans, and provide updates on the latest clinical trials focused on the impact of long-term treatment, improving pain, and quality of life.

      Learning Objectives

      At the end of this CE activity, participants should be able to:

      • Identify the molecular targets of currently available and emerging biologic treatments for the management of PsA.
      • Develop individualized treatment plans for patients with PsA that weigh the risks and benefits of newer agents.
      • Evaluate recent clinical trial data regarding the impact of long-term treatment on improving pain and quality of life.

      The following learning objectives pertain only to those requesting CNE or CPE credit:

      • Identify the molecular targets of currently available and emerging biologic treatments for the management of PsA.
      • Describe individualized treatment plans for patients with PsA that weigh the risks and benefits of newer agents.
      • Evaluate recent clinical trial data regarding the impact of long-term treatment on improving pain and quality of life.

      Financial Support

      Supported by educational grants from Celgene Corporation; Janssen Biotech, Inc. administered by Janssen Scientific Affairs, LLC.; and Novartis Pharmaceuticals Corporation

      Target Audience

      Rheumatologists, dermatologists, physicians, physician assistants, nurse practitioners, nurses, and pharmacists who treat patients with psoriatic arthritis

      Credit Information

      CME Credit (Physicians):
      USF Health is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

      USF Health designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with their participation in this activity.

      CNE Credit (Nurses):
      Provider approved by the California Board of Registered Nursing, Provider Number CEP 15510, for 1.5 contact hours

      Note to Nurse Practitioners and Clinical Nurse Specialists: the content of this activity pertains to pharmacology.  Earn up to 1.5 contact hours of pharmacotherapeutic contact hours.

      Note to Nurse Practitioners: Nurse practitioners can apply for AMA PRA Category 1 CreditTMthrough the American Academy of Nurse Practitioners (AANP). AANP will accept AMA PRA Category 1 Credit(s)TM from organizations accredited by the Accreditation Council for Continuing Medical Education. Nurse practitioners can also apply for credit through their state boards.

      CPE Credit (Pharmacists):
      ACPECME Outfitters, LLC, is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. 1.5 contact hours (0.15 CEUs) Universal Activity Number:
      Live: 0376-0000-18-018-L01-P
      Enduring: 0376-0000-18-018-H01-P

      Type: Knowledge-based

      ABIM/MOC Credit:
      Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

      Learning Formats
      Live activity
      Enduring material

      Note to Physician Assistants: AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 CreditTM from organizations accredited by the Accreditation Council for Continuing Medical Education.

      Post-tests, credit request forms, and activity evaluations must be completed online at www.cmeoutfitters.com/TST27399 (requires free account activation), and participants can print their certificate or statement of credit immediately (75% pass rate required). This website supports all browsers except Internet Explorer for Mac. For complete technical requirements and privacy policy, visit www.neurosciencecme.com/technical.asp.

      Disclosure Declaration

      It is the policy of USF Health and CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

      Dr. Gibofsky reports that he is on the Speakers Bureau for AbbVie Inc.; Celgene Corporation; Merck & Co., Inc.; and Pfizer, Inc. He is a consultant for AbbVie Inc.; Celgene Corporation; Merck & Co., Inc; Pfizer Inc.; Samumed, LLC; and Sandoz. He is a stock shareholder of AbbVie Inc.; Bristol-Myers Squibb Company; Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Pfizer Inc..

      Dr. Gelfand reports that he receives research grants (to the Trustees of the University of Pennsylvania) from AbbVie Inc.; Celgene Corporation; Janssen Biologics, Inc.; Novartis Corporation, Pfizer Inc.; Ortho Dermatologics, Inc.; and Sanofi. He is a consultant for Bristol-Myers Squibb Company; Boehringer Ingelheim; GlaxoSmithKline; Janssen Biologics, Inc.; Novartis Corporation; Pfizer Inc.; Regeneron Pharmaceuticals, Inc.; Sanofi; and UCB Data and Safety Monitoring Board (DSMB).

      Dr. Kwan-Morley has no disclosures to report.

      Jeffrey Helfand, DO, MS (peer reviewer) has no disclosures to report.

      Mae Ochoa, RPh (peer reviewer) has no disclosures to report.

      Kate Nelson, PHD (planning committee) has no disclosures to report.

      Sharon Tordoff(planning committee) has no disclosures to report.

      Jan Perez (planning committee) has no disclosures to report.

      Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report.

      Disclosures were obtained from the USF Health staff: No disclosures to report.

      CME Outfitters, LLC, USF Health, and the faculty do not endorse the use of any product outside of the FDA labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use.

      Questions about this activity? Call us at 877.CME.PROS(877.263.7767).

      This document was last modified on: 08/02/2018 10:14:19

      TV-096-071218-90

      ]]> CMEO Live and On Demand

      Premiere Date: Thursday, July 12, 2018

      This activity offers CE credit for:

      1. Physicians (CME)
      2. Nurses (CNE)
      3. Pharmacists (ACPE)
      4. ABIM (ABIM)
      5. Other

      All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™

      Credit Expiration Date: Friday, July 12, 2019

      Begin Activity Now

      Faculty

       

      Allan Gibofsky, MD, JD, MACR, FACP, FCLM Allan Gibofsky, MD, JD, MACR, FACP, FCLM
      Professor of Medicine, Healthcare Policy and Research
      Weill Medical College of Cornell University
      Attending Rheumatologist
      Hospital for Special Surgery
      New York, NY

       

      Joel M. Gelfand, MD, MSCE Joel M. Gelfand, MD, MSCE
      Professor of Dermatology
      Professor of Epidemiology
      Vice Chair of Clinical Research and Medical Director, Dermatology Clinical Studies Unit
      Director, Psoriasis and Phototherapy Treatment Center
      University of Pennsylvania Perelman School of Medicine
      Philadelphia, PA

       

      Jennifer G. Kwan-Morley, MD Jennifer G. Kwan-Morley, MD
      Rheumatologist
      Premier Orthopaedics
      Malvern, PA

      Co-provided by

      USF CME Outfitters

      Statement of Need

      Psoriatic arthritis (PsA) is a serious and potentially disabling condition that affects approximately 30% of psoriasis patients. In addition to the physical and functional impairments from joint destruction, PsA also negatively impacts relationships, daily activities, work productivity, and overall quality of life. Several agents have been FDA-approved for the treatment of moderate-to-severe PsA since 2008, and there are still more currently under investigation. Digital health tools provide clinicians with multiple touchpoints and reminders; they can help reinforce SMART goals, provide tips, and link to additional resources. Despite the availability of effective PsA agents, clinicians are often not aware of new and pipeline agents for their patients with moderate-to-severe PsA. Often, clinicians are not implementing newer agents or digital health tools into clinical practice that lead to better patient outcomes.

      In this CME Outfitters Live and On Demand expert faculty will highlight the molecular targets of currently available and emerging biologic treatments for managing PsA, discuss individualized treatment plans, and provide updates on the latest clinical trials focused on the impact of lon]]> CMEO Live and On Demand

      Premiere Date: Thursday, July 12, 2018

      This activity offers CE credit for:

      1. Physicians (CME)
      2. Nurses (CNE)
      3. Pharmacists (ACPE)
      4. ABIM (ABIM)
      5. Other

      All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™

      Credit Expiration Date: Friday, July 12, 2019

      Begin Activity Now

      Faculty

       

      Allan Gibofsky, MD, JD, MACR, FACP, FCLM Allan Gibofsky, MD, JD, MACR, FACP, FCLM
      Professor of Medicine, Healthcare Policy and Research
      Weill Medical College of Cornell University
      Attending Rheumatologist
      Hospital for Special Surgery
      New York, NY

       

      Joel M. Gelfand, MD, MSCE Joel M. Gelfand, MD, MSCE
      Professor of Dermatology
      Professor of Epidemiology
      Vice Chair of Clinical Research and Medical Director, Dermatology Clinical Studies Unit
      Director, Psoriasis and Phototherapy Treatment Center
      University of Pennsylvania Perelman School of Medicine
      Philadelphia, PA

       

      Jennifer G. Kwan-Morley, MD Jennifer G. Kwan-Morley, MD
      Rheumatologist
      Premier Orthopaedics
      Malvern, PA

      Co-provided by

      USF CME Outfitters

      Statement of Need

      Psoriatic arthritis (PsA) is a serious and potentially disabling condition that affects approximately 30% of psoriasis patients. In addition to the physical and functional impairments from joint destruction, PsA also negatively impacts relationships, daily activities, work productivity, and overall quality of life. Several agents have been FDA-approved for the treatment of moderate-to-severe PsA since 2008, and there are still more currently under investigation. Digital health tools provide clinicians with multiple touchpoints and reminders; they can help reinforce SMART goals, provide tips, and link to additional resources. Despite the availability of effective PsA agents, clinicians are often not aware of new and pipeline agents for their patients with moderate-to-severe PsA. Often, clinicians are not implementing newer agents or digital health tools into clinical practice that lead to better patient outcomes.

      In this CME Outfitters Live and On Demand expert faculty will highlight the molecular targets of currently available and emerging biologic treatments for managing PsA, discuss individualized treatment plans, and provide updates on the latest clinical trials focused on the impact of lon]]> clean No no no 1:26:05 Ben Scarborough Best Practice Approaches to Prior Authorization for Your Patients with IBD: A Three-Part Series for Improving Processes and Success Rates https://www.cmeoutfitters.com/podcast-best-practice-approaches-to-prior-authorization-for-your-patients-with-ibd-a-three-part-series-for-improving-processes-and-success-rates/ Wed, 01 Aug 2018 13:41:34 +0000 Ben Scarborough https://www.cmeoutfitters.com/?p=9881 full CMEO Multimedia Snack

      Premiere Date: Monday, April 30, 2018

      This activity offers CE credit for:

      1. Physicians (CME)
      2. Nurses (CNE)
      3. Pharmacists (ACPE)
      4. Other

      All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™

      Credit Expiration Date: Tuesday, April 30, 2019

      Begin Activity Now

      Faculty

       

      Francis A. Farraye, MD, MSc Francis A. Farraye, MD, MSc
      Clinical Director, Section of Gastroenterology
      Director, Inflammatory Bowel Disease Center
      Boston Medical Center
      Professor of Medicine
      Boston University School of Medicine
      Boston, MA

       

      Michele A. Rubin, APN, CNS, CGRN Michele A. Rubin, APN, CNS, CGRN 
      Associate Director, Inflammatory Bowel Disease Center
      Director, Advanced Practice Nursing
      University of Chicago Medicine
      Chicago, IL

       

      Toni M. Zahorian, PharmD, BCACP Toni M. Zahorian, PharmD, BCACP
      Clinical Pharmacy Specialist – Ambulatory Care
      Center for Digestive Disorders
      Boston Medical Center
      Boston, MA

       

      Statement of Need

      This activity is a combined version of the three-part snack series on prior authorization.

      Much of the national healthcare debate is centered around gaining insurance coverage for more Americans, but individuals with chronic diseases know their issue is not always about having coverage – it is gaining access to treatment within their insurance coverage. Prior authorization (PA) interactions with health insurance companies can be frustrating, taking a heavy toll on clinical workflow, staff time, and patient care. Inefficient PA processes put patients with IBD at risk for poor outcomes from denied access to needed care. Having a plan with proven strategies and resources—for first time submissions and appeal, will ultimately improve outcomes and satisfaction in patients with IBD.

      In this three-part series, faculty will share their best practice approaches for improving PA success rates, including important clinical information that should be routinely gathered and documented in the patient’s EHR to minimize barriers to biologic approval. And when denials happen, they will provide strategies for creating a structured appeal that advocates for the best treatment choice for the patient. Following the successful completion of the series, in addition to credit, CME Outfitters will award a Certificate of Excellence in Prior Authorization.

      Have questions for our faculty? Use the comment box below the presentation. The faculty will be checking in to respond to learners!

      Learning Objectives

      At the end of this CE activity, participants should be able to:

      • Evaluate prior authorization (PA) methods that best fit clinical workflow to reduce disruption, establish clear communication with the payer, and minimize delays.
      • Implement a PA protocol to improve documentation in the EHR and minimize barriers to medication approval.
      • Develop a process for an organized and clinically supported appeal for PAs that are inappropriately declined.

      The following learning objectives pertain only to those requesting CNE or CPE credit:

      • Evaluate prior authorization (PA) methods that best fit clinical workflow to reduce disruption, establish clear communication with the payer, and minimize delays.
      • Describe a PA protocol to improve documentation in the EHR and minimize barriers to medication approval.
      • Describe a process for an organized and clinically supported appeal for PAs that are inappropriately declined.

      Financial Support

      Supported by an educational grant from Takeda Pharmaceuticals USA, Inc.

      Target Audience

      Gastroenterology nurses and other healthcare professionals responsible for the PA process.

      Credit Information

      CME Credit (Physicians):
      CME Outfitters, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. CME Outfitters, LLC, designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

      CNE Credit (Nurses):
      Provider approved by the California Board of Registered Nursing, Provider Number CEP 15510, for 1 contact hours

      CPE Credit (Pharmacists):
      ACPECME Outfitters, LLC, is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. 1 contact hours (0.10 CEUs) Universal Activity Number: 0376-0000-18-016-H01-P Type: knowledge-based practice-based

      Post-tests, credit request forms, and activity evaluation must be completed online at www.cmeoutfitters.com/TST27387 (requires free account activation), and participants can print their certificate or statement of credit immediately (75% pass rate required). this website supports all browsers except Internet Explorer for Mac. For complete technical requirements and privacy policy, visit www.neurosciencecme.com/technical.asp.

      Disclosure Declaration

      It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, sue of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentation.

      Dr. Farraye reports that he is a consultant for Braintree Laboratories Inc.; Celgene Corporation; Ferring Pharmaceuticals; Janssen Pharmaceuticals, Inc.; Merck & Co., Inc; Pfizer Inc.; Protagonist Therapeutics Inc. (DSMB); Takeda Pharmaceuticals U.S.A., Inc. He is a stock shareholder (directly purchased) of Innovation Pharmaceuticals Inc.

      Dr. Rubin reports that she is on the advisory board for Pfizer Inc as spokesperson for results of patient and GI survey only.

      Dr. Zahorian has no disclosures to report.

      Tony Graham, MD (peer reviewer) has no disclosures to report.

      Michelle H. Lavigne, PA-C (peer reviewer) has no disclosures to report.

      Mae Ochoa, Rph (peer reviewer) has no disclosures to report.

      Jan Perez (planning committee) has no disclosures to report.

      Sharon Tordoff (planning committee) has no disclosures to report.

      Disclosures were obtained from the CME Outfitters, LLC staff. No disclosures to report.

      Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.

      Questions about this activity? Call us at 877.CME.PROS(877.263.7767).

      This document was last modified on: 08/01/2018 09:39:25

      SNN-088-043018-20

      ]]> CMEO Multimedia Snack

      Premiere Date: Monday, April 30, 2018

      This activity offers CE credit for:

      1. Physicians (CME)
      2. Nurses (CNE)
      3. Pharmacists (ACPE)
      4. Other

      All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™

      Credit Expiration Date: Tuesday, April 30, 2019

      Begin Activity Now

      Faculty

       

      Francis A. Farraye, MD, MSc Francis A. Farraye, MD, MSc
      Clinical Director, Section of Gastroenterology
      Director, Inflammatory Bowel Disease Center
      Boston Medical Center
      Professor of Medicine
      Boston University School of Medicine
      Boston, MA

       

      Michele A. Rubin, APN, CNS, CGRN Michele A. Rubin, APN, CNS, CGRN 
      Associate Director, Inflammatory Bowel Disease Center
      Director, Advanced Practice Nursing
      University of Chicago Medicine
      Chicago, IL

       

      Toni M. Zahorian, PharmD, BCACP Toni M. Zahorian, PharmD, BCACP
      Clinical Pharmacy Specialist – Ambulatory Care
      Center for Digestive Disorders
      Boston Medical Center
      Boston, MA

       

      Statement of Need

      This activity is a combined version of the three-part snack series on prior authorization.

      Much of the national healthcare debate is centered around gaining insurance coverage for more Americans, but individuals with chronic diseases know their issue is not always about having coverage – it is gaining access to treatment within their insurance coverage. Prior authorization (PA) interactions with health insurance companies can be frustrating, taking a heavy toll on clinical workflow, staff time, and patient care. Inefficient PA processes put patients with IBD at risk for poor outcomes from denied access to needed care. Having a plan with proven strategies and resources—for first time submissions and appeal, will ultimately improve outcomes and satisfaction in patients with IBD.

      In this three-part series, faculty will share their best practice approaches for improving PA success rates, including important clinical information that should be routinely gathered and documented in the patient’s EHR to minimize barriers to biologic approval. And when denials happen, they will provide strategies for creating a structured appeal that advocates for the best treatment choice for the patient. Following the successful completion of the series, in addition to credit, CME Outfitters will award a Certificate of Excellence in Prior Authorization.

      Have questions for our faculty? Use the comment box below the presentation. The faculty will be checking in to respond to learners!

      Learning Objectives

      A]]> CMEO Multimedia Snack

      Premiere Date: Monday, April 30, 2018

      This activity offers CE credit for:

      1. Physicians (CME)
      2. Nurses (CNE)
      3. Pharmacists (ACPE)
      4. Other

      All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™

      Credit Expiration Date: Tuesday, April 30, 2019

      Begin Activity Now

      Faculty

       

      Francis A. Farraye, MD, MSc Francis A. Farraye, MD, MSc
      Clinical Director, Section of Gastroenterology
      Director, Inflammatory Bowel Disease Center
      Boston Medical Center
      Professor of Medicine
      Boston University School of Medicine
      Boston, MA

       

      Michele A. Rubin, APN, CNS, CGRN Michele A. Rubin, APN, CNS, CGRN 
      Associate Director, Inflammatory Bowel Disease Center
      Director, Advanced Practice Nursing
      University of Chicago Medicine
      Chicago, IL

       

      Toni M. Zahorian, PharmD, BCACP Toni M. Zahorian, PharmD, BCACP
      Clinical Pharmacy Specialist – Ambulatory Care
      Center for Digestive Disorders
      Boston Medical Center
      Boston, MA

       

      Statement of Need

      This activity is a combined version of the three-part snack series on prior authorization.

      Much of the national healthcare debate is centered around gaining insurance coverage for more Americans, but individuals with chronic diseases know their issue is not always about having coverage – it is gaining access to treatment within their insurance coverage. Prior authorization (PA) interactions with health insurance companies can be frustrating, taking a heavy toll on clinical workflow, staff time, and patient care. Inefficient PA processes put patients with IBD at risk for poor outcomes from denied access to needed care. Having a plan with proven strategies and resources—for first time submissions and appeal, will ultimately improve outcomes and satisfaction in patients with IBD.

      In this three-part series, faculty will share their best practice approaches for improving PA success rates, including important clinical information that should be routinely gathered and documented in the patient’s EHR to minimize barriers to biologic approval. And when denials happen, they will provide strategies for creating a structured appeal that advocates for the best treatment choice for the patient. Following the successful completion of the series, in addition to credit, CME Outfitters will award a Certificate of Excellence in Prior Authorization.

      Have questions for our faculty? Use the comment box below the presentation. The faculty will be checking in to respond to learners!

      Learning Objectives

      A]]> clean No no no 18:37 Ben Scarborough Optimizing Immunosuppression, Precision Medicine, and Big Data: The Required Path for Innovation in Transplantation https://www.cmeoutfitters.com/optimizing-immunosuppression-precision-medicine-and-big-data-the-required-path-for-innovation-in-transplantation/ Wed, 01 Aug 2018 13:35:30 +0000 Ben Scarborough https://www.cmeoutfitters.com/?p=9875 full CMEO Medical Meeting

      Symposium Date: Monday, June 4, 2018
      On June 4, 2018, Sheraton Hotel, Seattle, WA

      This activity offers CE credit for:

      1. Physicians (CME)
      2. Nurses (CNE)
      3. Pharmacists (ACPE)
      4. ABIM (ABIM)
      5. Other

      All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™

      Credit Expiration Date: Tuesday, June 4, 2019

      Begin Activity Now

      Faculty

       

      Flavio Vincenti, MD Flavio Vincenti, MD
      Professor of Clinical Medicine and Surgery
      Medical Director, Kidney-Pancreas Program
      University of California San Francisco
      San Francisco, CA

       

      Dorry  Segev, MD, PhD Dorry  Segev, MD, PhD
      Marjory K. and Thomas Pozefsky Professor of Surgery and Epidemiology
      Associate Vice Chair, Department of Surgery
      Director, Epidemiology Research Group in Organ Transplantation
      Johns Hopkins University
      Baltimore, MD

       

      Statement of Need

      The optimization of immunosuppression is an important modifiable risk factor that can have a positive impact on long-term outcomes in transplantation. Breakthroughs in transplant procedures and the development of more effective immunosuppressive therapies have improved patient outcomes, with short-term survival rates over 80%. However, by five years post-transplant, up to 25% of patients have returned to dialysis, and 50% of all grafts fail within 10 years. Emerging literature that supports minimization or elimination of CNI therapy while maintaining optimal levels of immunosuppression, may offer new strategies for post-transplant immunosuppression.

      Transplant medicine is moving toward a future of precision medicine that will improve long-term patient outcomes. How success in transplant is defined in 2018 may look much different from what will define success in 2025. Join experts Dr. Vincenti and Dr. Segev as they translate the dynamics of immunosuppression optimization, precision medicine, and the impact of big data on the future of transplant medicine.

      Learning Objectives

      At the end of this CE activity, participants should be able to:

      • Identify modifiable and non-modifiable risk factors for allograft loss in patients receiving a kidney transplant.
      • Integrate strategies to optimize immunosuppression and minimize adverse events in transplant recipients.
      • Explore the impact of big data on precision medicine and the future of transplant medicine.

      The following learning objectives pertain only to those requesting CNE or CPE credit:

      • Differentiate between modifiable and non-modifiable risk factors for allograft loss in patients receiving a kidney transplant.
      • Assess strategies to optimize immunosuppression and minimize adverse events in transplant recipients.
      • Analyze the impact of big data on precision medicine and the future of transplant medicine.

      Financial Support

      Supported by an educational grant from Novartis Pharmaceuticals Corporation.

      Target Audience

      Transplant surgeons, nephrologists, physicians, physician assistants, nurse practitioners, nurses, and pharmacists who treat transplant patients.

      Credit Information

      CME Credit (Physicians):
      CME Outfitters, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

      CME Outfitters, LLC designates this live activity for a maximum of 1.25 AMA PRA Category 1 Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

      CNE Credit (Nurses):
      Provider approved by the California Board of Registered Nursing, Provider Number CEP 15510, for 1.25 contact hours

      Note to Nurse Practitioners and Clinical Nurse Specialists: the content of this activity pertains to pharmacology. Earn up to 1.25 contact hours of pharmacotherapeutic contact hours.

      Note to Nurse Practitioners: Nurse practitioners can apply for AMA PRA Category 1 CreditTMthrough the American Academy of Nurse Practitioners (AANP). AANP will accept AMA PRA Category 1 CreditTM from organizations accredited by the Accreditation Council for Continuing Medical Education. Nurse practitioners can also apply for credit through their state boards.

      CPE Credit (Pharmacists):
      ACPECME Outfitters, LLC, is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. 1.25 contact hours (0.125 CEUs) Universal Activity Number:
      Live: 0376-0000-18-015-L01-P
      Enduring: 0376-0000-18-015-H01-P

      Type: Knowledge-based

      ABIM/MOC Credit:
      Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.25 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

      Learning Formats
      Live activity
      Enduring material

      MIPS Improvement Activity: This activity counts towards MIPS Improvement Activity requirements under the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.

      Note to Physician Assistants: AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 CreditTM from organizations accredited by the Accreditation Council for Continuing Medical Education.

      Post-tests, credit request forms, and activity evaluations must be completed online at www.cmeoutfitters.com/TST27381 (requires free account activation), and participants can print their certificate or statement of credit immediately (75% pass rate required). This website supports all browsers except Internet Explorer for Mac. For complete technical requirements and privacy policy, visit www.neurosciencecme.com/technical.asp.

      Disclosure Declaration

      It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

      Dr. Segev reports that he receives speaker honoraria for sanofi-aventis U.S. LLC, and Novartis Pharmaceuticals Corporation for lectures unrelated to their products.

      Dr. Vincenti reports that he receives research support from Angion Biomedica Corp.; Astellas Pharma US, Inc.; Bristol-Myers Squibb Company; Genentech, Inc.; Novartis Pharmaceuticals Corporation; Pfizer Inc.

      Jeffrey Helfand, DO, MS (peer reviewer) has no disclosures to report.

      Mae Ochoa, RPh (peer reviewer) has no disclosures to report.

      Sharon Tordoff(planning committee) has no disclosures to report.

      Jan Perez (planning committee) has no disclosures to report.

      Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report.

      Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.

      Questions about this activity? Call us at 877.CME.PROS(877.263.7767).

      This document was last modified on: 08/01/2018 09:31:32

      MM-083-060418-45

      ]]> CMEO Medical Meeting

      Symposium Date: Monday, June 4, 2018
      On June 4, 2018, Sheraton Hotel, Seattle, WA

      This activity offers CE credit for:

      1. Physicians (CME)
      2. Nurses (CNE)
      3. Pharmacists (ACPE)
      4. ABIM (ABIM)
      5. Other

      All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™

      Credit Expiration Date: Tuesday, June 4, 2019

      Begin Activity Now

      Faculty

       

      Flavio Vincenti, MD Flavio Vincenti, MD
      Professor of Clinical Medicine and Surgery
      Medical Director, Kidney-Pancreas Program
      University of California San Francisco
      San Francisco, CA

       

      Dorry  Segev, MD, PhD Dorry  Segev, MD, PhD
      Marjory K. and Thomas Pozefsky Professor of Surgery and Epidemiology
      Associate Vice Chair, Department of Surgery
      Director, Epidemiology Research Group in Organ Transplantation
      Johns Hopkins University
      Baltimore, MD

       

      Statement of Need

      The optimization of immunosuppression is an important modifiable risk factor that can have a positive impact on long-term outcomes in transplantation. Breakthroughs in transplant procedures and the development of more effective immunosuppressive therapies have improved patient outcomes, with short-term survival rates over 80%. However, by five years post-transplant, up to 25% of patients have returned to dialysis, and 50% of all grafts fail within 10 years. Emerging literature that supports minimization or elimination of CNI therapy while maintaining optimal levels of immunosuppression, may offer new strategies for post-transplant immunosuppression.

      Transplant medicine is moving toward a future of precision medicine that will improve long-term patient outcomes. How success in transplant is defined in 2018 may look much different from what will define success in 2025. Join experts Dr. Vincenti and Dr. Segev as they translate the dynamics of immunosuppression optimization, precision medicine, and the impact of big data on the future of transplant medicine.

      Learning Objectives

      At the end of this CE activity, participants should be able to:

      • Identify modifiable and non-modifiable risk factors for allograft loss in patients receiving a kidney transplant.
      • Integrate strategies to optimize immunosuppression and minimize adverse events in transplant recipients.
      • Explore the impact of big data on precision medicine and the future of transplant medicine.

      The following learning objectives pertain only to those requesting CNE or CPE credit:

      • Differentiate between modifiable and non-modifiable risk factors for allograft loss in patients receiving a kidney transplant.
      • Assess strategies to optimize immunosuppression and minimize adverse events in transplant recipients.
      • Analyze the impact of big data on precision medicine and the future of transplant medicine.

      Financial Support

      Suppo]]> CMEO Medical Meeting

      Symposium Date: Monday, June 4, 2018
      On June 4, 2018, Sheraton Hotel, Seattle, WA

      This activity offers CE credit for:

      1. Physicians (CME)
      2. Nurses (CNE)
      3. Pharmacists (ACPE)
      4. ABIM (ABIM)
      5. Other

      All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™

      Credit Expiration Date: Tuesday, June 4, 2019

      Begin Activity Now

      Faculty

       

      Flavio Vincenti, MD Flavio Vincenti, MD
      Professor of Clinical Medicine and Surgery
      Medical Director, Kidney-Pancreas Program
      University of California San Francisco
      San Francisco, CA

       

      Dorry  Segev, MD, PhD Dorry  Segev, MD, PhD
      Marjory K. and Thomas Pozefsky Professor of Surgery and Epidemiology
      Associate Vice Chair, Department of Surgery
      Director, Epidemiology Research Group in Organ Transplantation
      Johns Hopkins University
      Baltimore, MD

       

      Statement of Need

      The optimization of immunosuppression is an important modifiable risk factor that can have a positive impact on long-term outcomes in transplantation. Breakthroughs in transplant procedures and the development of more effective immunosuppressive therapies have improved patient outcomes, with short-term survival rates over 80%. However, by five years post-transplant, up to 25% of patients have returned to dialysis, and 50% of all grafts fail within 10 years. Emerging literature that supports minimization or elimination of CNI therapy while maintaining optimal levels of immunosuppression, may offer new strategies for post-transplant immunosuppression.

      Transplant medicine is moving toward a future of precision medicine that will improve long-term patient outcomes. How success in transplant is defined in 2018 may look much different from what will define success in 2025. Join experts Dr. Vincenti and Dr. Segev as they translate the dynamics of immunosuppression optimization, precision medicine, and the impact of big data on the future of transplant medicine.

      Learning Objectives

      At the end of this CE activity, participants should be able to:

      • Identify modifiable and non-modifiable risk factors for allograft loss in patients receiving a kidney transplant.
      • Integrate strategies to optimize immunosuppression and minimize adverse events in transplant recipients.
      • Explore the impact of big data on precision medicine and the future of transplant medicine.

      The following learning objectives pertain only to those requesting CNE or CPE credit:

      • Differentiate between modifiable and non-modifiable risk factors for allograft loss in patients receiving a kidney transplant.
      • Assess strategies to optimize immunosuppression and minimize adverse events in transplant recipients.
      • Analyze the impact of big data on precision medicine and the future of transplant medicine.

      Financial Support

      Suppo]]> clean No no no 1:10:56 Ben Scarborough Stopping Ulcerative Colitis Progression in its Tract: Combining the Latest Evidence and Engaging Teaching Tools to Improve Patient Outcomes https://www.cmeoutfitters.com/stopping-ulcerative-colitis-progression-in-its-tract-combining-the-latest-evidence-and-engaging-teaching-tools-to-improve-patient-outcomes/ Wed, 01 Aug 2018 13:26:36 +0000 Ben Scarborough https://www.cmeoutfitters.com/?p=9869 full CMEO Medical Meeting

      Symposium Date: Sunday, June 3, 2018
      On June 3, 2018, Marriott Marquis, Washington, DC

      This activity offers CE credit for:

      1. Physicians (CME)
      2. Nurses (CNE)
      3. Pharmacists (ACPE)
      4. ABIM (ABIM)
      5. Other

      All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™

      Credit Expiration Date: Monday, June 3, 2019

      Begin Activity Now

      Faculty

       

      David T. Rubin, MD, FACG, AGAF, FACP, FASGE David T. Rubin, MD, FACG, AGAF, FACP, FASGE
      Joseph B. Kirsner Professor of Medicine
      Section Chief, Gastroenterology, Hepatology and Nutrition
      Co-Director, Digestive Diseases Center
      University of Chicago Medicine
      Chicago, IL

       

      Miguel Regueiro, MD, AGAF, FACG, FACP Miguel Regueiro, MD, AGAF, FACG, FACP
      Chair, Department of Gastroenterology and Hepatology
      Vice Chair, Digestive Disease and Surgery Institute
      Professor of Medicine, Lerner College of Medicine
      Cleveland Clinic
      Cleveland, OH

       

      Statement of Need

      Managing patients with ulcerative colitis (UC) is as complex as the disease itself. As science progresses the understanding of UC, strategies for its management have also progressed. Treatment goals have now shifted from resolution of symptoms to full control of the disease (clinical remission and mucosal healing), with a final aim of halting or preventing disease progression, surgery, and disability; and restoration of quality of life.

      This symposium, featuring interactive infographics and live webstream, will provide clinicians with evidence-based direction to achieve sustained remission in UC through implementation of early intervention of treat-to-target approaches as recommended by the AGA UC Care Pathway. Dr. Rubin and Dr. Regueiro will integrate interactive infographics to provide a targeted review of the MOA of biologics and explain the impact of these biologics on histological and endoscopic disease progression for learners to explore. After the symposium these infographics can serve as an educational resource for use in practice to enhance patient health literacy about UC and to facilitate shared decision-making with patients.

      Learning Objectives

      At the end of this CE activity, participants should be able to:

      • Examine the rationale for the use of early, effective treatment in altering the progression course of ulcerative colitis (UC).
      • Utilize the AGA Clinical Care Pathway to guide personalized biologic therapy to halt disease progression in UC.
      • Incorporate disease activity monitoring strategies, including objective measures of disease improvement, to facilitate optimal management of UC.

      The following learning objectives pertain only to those requesting CNE or CPE credit:

      • Examine the rationale for the use of early, effective treatment in altering the progressive course of ulcerative colitis (UC).
      • Explain the AGA UC Care Pathway to guide personalized biologic therapy to halt disease progression in UC.
      • Describe disease activity monitoring strategies, including objective measures of disease improvement, to facilitate optimal management of UC.

      Financial Support

      Supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc.

      Target Audience

      Gastroenterologists, primary care physicians, physician assistants, nurse practitioners, nurses, and pharmacists who treat patients with ulcerative colitis.

      Credit Information

      CME Credit (Physicians):
      CME Outfitters, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

      CME Outfitters, LLC designates this live activity for a maximum of 1.25 AMA PRA Category 1 Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

      CNE Credit (Nurses):
      Provider approved by the California Board of Registered Nursing, Provider Number CEP 15510, for 1.25 contact hours

      Note to Nurse Practitioners and Clinical Nurse Specialists: the content of this activity pertains to pharmacology. Earn up to 1.25 contact hours of pharmacotherapeutic contact hours.

      Note to Nurse Practitioners: Nurse practitioners can apply for AMA PRA Category 1 CreditTMthrough the American Academy of Nurse Practitioners (AANP). AANP will accept AMA PRA Category 1 CreditTM from organizations accredited by the Accreditation Council for Continuing Medical Education. Nurse practitioners can also apply for credit through their state boards.

      CPE Credit (Pharmacists):
      ACPECME Outfitters, LLC, is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. 1.25 contact hours (0.125 CEUs) Universal Activity Number:
      Live: 0376-0000-18-014-L01-P
      Enduring: 0376-0000-18-014-H01-P

      Type: Knowledge-based

      ABIM/MOC Credit:
      Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.25 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

      Learning Formats
      Live activity
      Enduring material

      MIPS Improvement Activity: This activity counts towards MIPS Improvement Activity requirements under the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.

      Note to Physician Assistants: AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 CreditTM from organizations accredited by the Accreditation Council for Continuing Medical Education.

      Post-tests, credit request forms, and activity evaluations must be completed online at www.cmeoutfitters.com/TST27380 (requires free account activation), and participants can print their certificate or statement of credit immediately (75% pass rate required). This website supports all browsers except Internet Explorer for Mac. For complete technical requirements and privacy policy, visit www.neurosciencecme.com/technical.asp.

      Disclosure Declaration

      It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

      Dr. Regueiro reports that he conducts research support for Abbvie Inc.; Janssen Pharmaceuticals, Inc.; Takeda Pharmaceuticals U.S.A., Inc. He receives unrestricted educational grants from Abbvie Inc.; Janssen Pharmaceuticals, Inc.; Pfizer Inc.; Salix Pharmaceuticals; Shire; Takeda Pharmaceuticals U.S.A., Inc.; UCB, Inc.

      Dr. Rubin reports that he receives grants from AbbVie Inc.; Genentech, Inc./Roche; Janssen Pharmaceuticals, Inc.’ Prometheus Laboratories Inc.; Shire; Takeda Pharmaceuticals U.S.A., Inc.; UCB, Inc. He is a consultant for AbbVie Inc.; AbGenomics; Allergan; Amgen Inc.; Celgene Corporation; Forward Pharma; Genentech, Inc./Roche; Janssen Pharmaceuticals, Inc.; Pfizer Inc.; Salix Pharmaceuticals; Samsung Bioepis; Sandoz; Shire; Takeda Pharmaceuticals U.S.A., Inc.; TARGET PharmaSolutions, Inc. He is on the Board of Trustees for the American College of Gastroenterology; is Co-Founder and CFO of Cornerstones Health, Inc. (non-profit); and is Co-Founder of GoDuRn, LLC.

      Jeffrey Helfand, DO, MS (peer reviewer) has no disclosures to report.

      Mae Ochoa, RPh (peer reviewer) has no disclosures to report.

      Sharon Tordoff(planning committee) has no disclosures to report.

      Jan Perez (planning committee) has no disclosures to report.

      Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report.

      Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.

      Questions about this activity? Call us at 877.CME.PROS(877.263.7767).

      This document was last modified on: 08/01/2018 09:24:49

      MM-082-060318-20

      ]]> CMEO Medical Meeting

      Symposium Date: Sunday, June 3, 2018
      On June 3, 2018, Marriott Marquis, Washington, DC

      This activity offers CE credit for:

      1. Physicians (CME)
      2. Nurses (CNE)
      3. Pharmacists (ACPE)
      4. ABIM (ABIM)
      5. Other

      All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™

      Credit Expiration Date: Monday, June 3, 2019

      Begin Activity Now

      Faculty

       

      David T. Rubin, MD, FACG, AGAF, FACP, FASGE David T. Rubin, MD, FACG, AGAF, FACP, FASGE
      Joseph B. Kirsner Professor of Medicine
      Section Chief, Gastroenterology, Hepatology and Nutrition
      Co-Director, Digestive Diseases Center
      University of Chicago Medicine
      Chicago, IL

       

      Miguel Regueiro, MD, AGAF, FACG, FACP Miguel Regueiro, MD, AGAF, FACG, FACP
      Chair, Department of Gastroenterology and Hepatology
      Vice Chair, Digestive Disease and Surgery Institute
      Professor of Medicine, Lerner College of Medicine
      Cleveland Clinic
      Cleveland, OH

       

      Statement of Need

      Managing patients with ulcerative colitis (UC) is as complex as the disease itself. As science progresses the understanding of UC, strategies for its management have also progressed. Treatment goals have now shifted from resolution of symptoms to full control of the disease (clinical remission and mucosal healing), with a final aim of halting or preventing disease progression, surgery, and disability; and restoration of quality of life.

      This symposium, featuring interactive infographics and live webstream, will provide clinicians with evidence-based direction to achieve sustained remission in UC through implementation of early intervention of treat-to-target approaches as recommended by the AGA UC Care Pathway. Dr. Rubin and Dr. Regueiro will integrate interactive infographics to provide a targeted review of the MOA of biologics and explain the impact of these biologics on histological and endoscopic disease progression for learners to explore. After the symposium these infographics can serve as an educational resource for use in practice to enhance patient health literacy about UC and to facilitate shared decision-making with patients.

      Learning Objectives

      At the end of this CE activity, participants should be able to:

      • Examine the rationale for the use of early, effective treatment in altering the progression course of ulcerative colitis (UC).
      • Utilize the AGA Clinical Care Pathway to guide personalized biologic therapy to halt disease progression in UC.
      • Incorporate disease activity monitoring strategies, including objective measures of disease improvement, to facilitate optimal management of UC.

      The following learning objectives pertain only to those requesting CNE or CPE credit:

      • Examine the rationale for the use of early, effective treatment in altering the progressive course of ulcerative colitis (UC).
      • Explain t]]> CMEO Medical Meeting

        Symposium Date: Sunday, June 3, 2018
        On June 3, 2018, Marriott Marquis, Washington, DC

        This activity offers CE credit for:

        1. Physicians (CME)
        2. Nurses (CNE)
        3. Pharmacists (ACPE)
        4. ABIM (ABIM)
        5. Other

        All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™

        Credit Expiration Date: Monday, June 3, 2019

        Begin Activity Now

        Faculty

         

        David T. Rubin, MD, FACG, AGAF, FACP, FASGE David T. Rubin, MD, FACG, AGAF, FACP, FASGE
        Joseph B. Kirsner Professor of Medicine
        Section Chief, Gastroenterology, Hepatology and Nutrition
        Co-Director, Digestive Diseases Center
        University of Chicago Medicine
        Chicago, IL

         

        Miguel Regueiro, MD, AGAF, FACG, FACP Miguel Regueiro, MD, AGAF, FACG, FACP
        Chair, Department of Gastroenterology and Hepatology
        Vice Chair, Digestive Disease and Surgery Institute
        Professor of Medicine, Lerner College of Medicine
        Cleveland Clinic
        Cleveland, OH

         

        Statement of Need

        Managing patients with ulcerative colitis (UC) is as complex as the disease itself. As science progresses the understanding of UC, strategies for its management have also progressed. Treatment goals have now shifted from resolution of symptoms to full control of the disease (clinical remission and mucosal healing), with a final aim of halting or preventing disease progression, surgery, and disability; and restoration of quality of life.

        This symposium, featuring interactive infographics and live webstream, will provide clinicians with evidence-based direction to achieve sustained remission in UC through implementation of early intervention of treat-to-target approaches as recommended by the AGA UC Care Pathway. Dr. Rubin and Dr. Regueiro will integrate interactive infographics to provide a targeted review of the MOA of biologics and explain the impact of these biologics on histological and endoscopic disease progression for learners to explore. After the symposium these infographics can serve as an educational resource for use in practice to enhance patient health literacy about UC and to facilitate shared decision-making with patients.

        Learning Objectives

        At the end of this CE activity, participants should be able to:

        • Examine the rationale for the use of early, effective treatment in altering the progression course of ulcerative colitis (UC).
        • Utilize the AGA Clinical Care Pathway to guide personalized biologic therapy to halt disease progression in UC.
        • Incorporate disease activity monitoring strategies, including objective measures of disease improvement, to facilitate optimal management of UC.

        The following learning objectives pertain only to those requesting CNE or CPE credit:

        • Examine the rationale for the use of early, effective treatment in altering the progressive course of ulcerative colitis (UC).
        • Explain t]]> clean No no no 1:10:15 Ben Scarborough Getting to the Gut of the Matter: Closing the Gaps in Diagnosis, Effective Treatment, and Comprehensive Care in IBS and CIC https://www.cmeoutfitters.com/getting-to-the-gut-of-the-matter-closing-the-gaps-in-diagnosis-effective-treatment-and-comprehensive-care-in-ibs-and-cic/ Wed, 01 Aug 2018 12:59:34 +0000 Ben Scarborough https://www.cmeoutfitters.com/?p=9862 full CMEO Medical Meeting

          Symposium Date: Saturday, June 2, 2018
          On June 2, 2018, Marriott Marquis, Washington, DC

          This activity offers CE credit for:

          1. Physicians (CME)
          2. Nurses (CNE)
          3. Pharmacists (ACPE)
          4. ABIM (ABIM)
          5. Other

          All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™

          Credit Expiration Date: Sunday, June 2, 2019

          Begin Activity Now

          Faculty

           

          Brooks D. Cash, MD, AGAF, FACG, FACP, FASGE
          Chief, Division of Gastroenterology, Hepatology, and Nutrition
          University of Texas Health Science Center at Houston
          Visiting Professor of Medicine
          University of Texas McGovern Medical School
          Houston, TX

           

          William D. Chey, MD, AGAF, FACG, FACP
          Timothy T. Nostrant Collegiate Professor of Gastroenterology
          Director, GI Physiology Laboratory
          Director, Digestive Disorders Nutrition & Behavioral Health Program
          Medical Director, Michigan Bowel Control Program
          Departments of Internal Medicine and Nutritional Sciences
          University of Michigan Health System
          Ann Arbor, MI

           

          Kareen Turner, MPH, RD
          Healthcare Leader | Speaker | Writer
          Murrieta, CA

           

          Statement of Need

          Irritable bowel syndrome (IBS) is the most common diagnosis in clinical gastroenterology, affecting approximately ten to fifteen percent of the general adult population. IBS and chronic idiopathic constipation (CIC) are disorders of gut-brain interaction; they are debilitating, often misunderstood, and a challenge to diagnose and manage.

          Shame and embarrassment are often core components affecting patients seeking treatment for their bowel symptoms. Therefore, the symposium and live webstream will integrate a patient into the faculty panel to provide clinicians with strategies to enhance patient-provider communication to engage patients in discussions about their bowel health and patient-centric treatment strategies that promote symptomatic relief. The use of video vignettes of realistic patient-provider interactions will reflect the variability in symptom presentation, patient preferences or reluctance to move beyond OTC treatments, and treatment selection encountered in routine practice. Following each video vignette, learners will be asked to make decisions regarding the case scenario followed by a discussion among the clinical faculty and patient faculty to address variabilities in patient vs. clinician perspectives to enhance optimal management approaches with the goal of providing strategies to enhance communication and improve patient outcomes.

          Learning Objectives

          At the end of this CE activity, participants should be able to:

          • Improve the diagnostic accuracy of IBS and CIC through patient queries, patient-centered communication, and use of diagnostic tools.
          • Apply evidence-based treatment strategies for symptomatic relief of IBS and CIC in patients experiencing residual symptoms after initial dietary and OTC approaches fail.
          • Promote collaborative care strategies that facilitate comprehensive management of IBS and CIC, including early initiation of care and optimal long-term management.

          The following learning objectives pertain only to those requesting CNE or CPE credit:

          • Explain the diagnostic accuracy of IBS and CIC through patient queries, patient-centered communication, and use of diagnostic tools.
          • Describe evidence-based treatment strategies for symptomatic relief of IBS and CIC in patients experiencing residual symptoms after initial dietary and OTC approaches fail.
          • Explain collaborative care strategies that facilitate comprehensive management of IBS and CIC, including early initiation of care and optimal long-term management.

          Financial Support

          Supported by an educational grant from Allergan and Ironwood Pharmaceuticals.

          Target Audience

          Gastroenterologists, physicians, physician assistants, nurse practitioners, nurses, and pharmacists who treat patients with IBS.

          Credit Information

          CME Credit (Physicians):
          CME Outfitters, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

          CME Outfitters, LLC designates this live activity for a maximum of 1.25 AMA PRA Category 1 Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

          CNE Credit (Nurses):
          Provider approved by the California Board of Registered Nursing, Provider Number CEP 15510, for 1.25 contact hours

          Note to Nurse Practitioners and Clinical Nurse Specialists: the content of this activity pertains to pharmacology. Earn up to 1.25 contact hours of pharmacotherapeutic contact hours.

          Note to Nurse Practitioners: Nurse practitioners can apply for AMA PRA Category 1 CreditTMthrough the American Academy of Nurse Practitioners (AANP). AANP will accept AMA PRA Category 1 CreditTM from organizations accredited by the Accreditation Council for Continuing Medical Education. Nurse practitioners can also apply for credit through their state boards.

          CPE Credit (Pharmacists):
          ACPECME Outfitters, LLC, is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. 1.25 contact hours (0.125 CEUs) Universal Activity Number:
          Live: 0376-0000-18-013-L01-P
          Enduring: 0376-0000-18-013-H01-P

          Type: Knowledge-based

          ABIM/MOC Credit:
          Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.25 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

          Learning Formats
          Live activity
          Enduring material

          Note to Physician Assistants: AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 CreditTM from organizations accredited by the Accreditation Council for Continuing Medical Education.

          MIPS Improvement Activity: This activity counts towards MIPS Improvement Activity requirements under the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.

          Post-tests, credit request forms, and activity evaluations must be completed online at www.cmeoutfitters.com/TST27379 (requires free account activation), and participants can print their certificate or statement of credit immediately (75% pass rate required). This website supports all browsers except Internet Explorer for Mac. For complete technical requirements and privacy policy, visit www.neurosciencecme.com/technical.asp.

          Disclosure Declaration

          It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

          Dr. Brooks D. Cash disclosed that he is on the speakers bureau for Allergan; Salix Pharmaceuticals; and Synergy Pharmaceuticals Inc. He is a consultant for Allergan; IM HealthScience; Shire; and Synergy Pharmaceuticals Inc.

          Dr. William D. Chey disclosed that he receives grants from Biomerica, Inc.; Ironwood Pharmaceuticals, Inc.; Nestle; and Vibrant Pharma Inc. He is a consultant for Allergan; Biomerica, Inc.; IM HealthScience; Nestle; Outpost Medicine; Prometheus Laboratories Inc.; QOL Medical; Ritter Pharmaceuticals; Salix Pharmaceuticals; and Valeant.

          Kareen Turner, MPH, RD (patient panelist) has no disclosures to report.

          Jeffrey Helfand, DO, MS (peer reviewer) has no disclosures to report.

          Mae Ochoa, RPh (peer reviewer) has no disclosures to report.

          Sharon Tordoff(planning committee) has no disclosures to report.

          Jan Perez (planning committee) has no disclosures to report.

          Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report.

          Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.

          Questions about this activity? Call us at 877.CME.PROS(877.263.7767).

          This document was last modified on: 08/01/2018 08:41:11

          MM-081-060218-03

          ]]>
          CMEO Medical Meeting

          Symposium Date: Saturday, June 2, 2018
          On June 2, 2018, Marriott Marquis, Washington, DC

          This activity offers CE credit for:

          1. Physicians (CME)
          2. Nurses (CNE)
          3. Pharmacists (ACPE)
          4. ABIM (ABIM)
          5. Other

          All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™

          Credit Expiration Date: Sunday, June 2, 2019

          Begin Activity Now

          Faculty

           

          Brooks D. Cash, MD, AGAF, FACG, FACP, FASGE
          Chief, Division of Gastroenterology, Hepatology, and Nutrition
          University of Texas Health Science Center at Houston
          Visiting Professor of Medicine
          University of Texas McGovern Medical School
          Houston, TX

           

          William D. Chey, MD, AGAF, FACG, FACP
          Timothy T. Nostrant Collegiate Professor of Gastroenterology
          Director, GI Physiology Laboratory
          Director, Digestive Disorders Nutrition & Behavioral Health Program
          Medical Director, Michigan Bowel Control Program
          Departments of Internal Medicine and Nutritional Sciences
          University of Michigan Health System
          Ann Arbor, MI

           

          Kareen Turner, MPH, RD
          Healthcare Leader | Speaker | Writer
          Murrieta, CA

           

          Statement of Need

          Irritable bowel syndrome (IBS) is the most common diagnosis in clinical gastroenterology, affecting approximately ten to fifteen percent of the general adult population. IBS and chronic idiopathic constipation (CIC) are disorders of gut-brain interaction; they are debilitating, often misunderstood, and a challenge to diagnose and manage.

          Shame and embarrassment are often core components affecting patients seeking treatment for their bowel symptoms. Therefore, the symposium and live webstream will integrate a patient into the faculty panel to provide clinicians with strategies to enhance patient-provider communication to engage patients in discussions about their bowel health and patient-centric treatment strategies that promote symptomatic relief. The use of video vignettes of realistic patient-provider interactions will reflect the variability in symptom presentation, patient preferences or reluctance to move beyond OTC treatments, and treatment selection encountered in routine practice. Following each video vignette, learners will be asked to make decisions regarding the case scenario followed by a discussion among the clinical faculty and patient faculty to address variabilities in patient vs. clinician perspectives to enhance optimal management approaches with the goal of providing strategies]]> CMEO Medical Meeting

          Symposium Date: Saturday, June 2, 2018
          On June 2, 2018, Marriott Marquis, Washington, DC

          This activity offers CE credit for:

          1. Physicians (CME)
          2. Nurses (CNE)
          3. Pharmacists (ACPE)
          4. ABIM (ABIM)
          5. Other

          All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™

          Credit Expiration Date: Sunday, June 2, 2019

          Begin Activity Now

          Faculty

           

          Brooks D. Cash, MD, AGAF, FACG, FACP, FASGE
          Chief, Division of Gastroenterology, Hepatology, and Nutrition
          University of Texas Health Science Center at Houston
          Visiting Professor of Medicine
          University of Texas McGovern Medical School
          Houston, TX

           

          William D. Chey, MD, AGAF, FACG, FACP
          Timothy T. Nostrant Collegiate Professor of Gastroenterology
          Director, GI Physiology Laboratory
          Director, Digestive Disorders Nutrition & Behavioral Health Program
          Medical Director, Michigan Bowel Control Program
          Departments of Internal Medicine and Nutritional Sciences
          University of Michigan Health System
          Ann Arbor, MI

           

          Kareen Turner, MPH, RD
          Healthcare Leader | Speaker | Writer
          Murrieta, CA

           

          Statement of Need

          Irritable bowel syndrome (IBS) is the most common diagnosis in clinical gastroenterology, affecting approximately ten to fifteen percent of the general adult population. IBS and chronic idiopathic constipation (CIC) are disorders of gut-brain interaction; they are debilitating, often misunderstood, and a challenge to diagnose and manage.

          Shame and embarrassment are often core components affecting patients seeking treatment for their bowel symptoms. Therefore, the symposium and live webstream will integrate a patient into the faculty panel to provide clinicians with strategies to enhance patient-provider communication to engage patients in discussions about their bowel health and patient-centric treatment strategies that promote symptomatic relief. The use of video vignettes of realistic patient-provider interactions will reflect the variability in symptom presentation, patient preferences or reluctance to move beyond OTC treatments, and treatment selection encountered in routine practice. Following each video vignette, learners will be asked to make decisions regarding the case scenario followed by a discussion among the clinical faculty and patient faculty to address variabilities in patient vs. clinician perspectives to enhance optimal management approaches with the goal of providing strategies]]> clean No no no 1:27:29 Ben Scarborough Uncovering the Secret Sauce: Strategies for Increasing Prior Authorization Success Rates for Patients with IBD https://www.cmeoutfitters.com/podcast/uncovering-the-secret-sauce-strategies-for-increasing-prior-authorization-success-rates-for-patients-with-ibd/ Thu, 19 Jul 2018 14:16:05 +0000 Alex Perez https://www.cmeoutfitters.com/?post_type=podcast&p=9760 full clean No no no 0:00 Alex Perez A Team Approach to Improving Outcomes in Rheumatoid Arthritis: Clinicians, Patients, and Digital Health Coaches https://www.cmeoutfitters.com/a-team-approach-to-improving-outcomes-in-rheumatoid-arthritis-clinicians-patients-and-digital-health-coaches/ Thu, 07 Jun 2018 16:25:33 +0000 Alex Perez https://www.cmeoutfitters.com/?p=9356 full CMEO Live and On Demand

          Premiere Date: Tuesday, May 15, 2018

          This activity offers CE credit for:

          1. Physicians (CME)
          2. Nurses (CNE)
          3. Pharmacists (ACPE)
          4. ABIM (ABIM)
          5. Other

          All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™

          Credit Expiration Date: Wednesday, May 15, 2019

          Begin Activity Now

          Faculty

           

          Leonard H. Calabrese, DO Leonard H. Calabrese, DO (Moderator)
          Professor of Medicine
          Vice Chair, Department of Rheumatic & Immunologic Disease
          Cleveland Clinic Lerner College of Medicine
          of Case Western Reserve University
          R.J. Fasenmyer Chair of Clinical Immunology
          Cleveland Clinic Foundation
          Cleveland, OH

           

          Stanley B. Cohen, MD Stanley B. Cohen, MD
          Clinical Professor, Department of Internal Medicine
          University of Texas Southwestern Medical School
          Co-Director, Division of Rheumatology
          Presbyterian Hospital, Dallas
          Co-Medical Director
          Metroplex Clinical Research Center
          Dallas, TX
          Past President of the American College of Rheumatology
          Atlanta, GA

           

          Eileen J. Lydon, ANP-BC Eileen J. Lydon, ANP-BC
          Adult Nurse Practitioner
          Department of Rheumatology
          NYU Langone Orthopedic Hospital
          New York, NY

           

          Rochelle Rosian, MD Rochelle Rosian, MD
          Staff member
          Department of Rheumatic and Immunologic Diseases
          Director of Regional Rheumatology
          Cleveland Clinic
          Solon, OH

           

          Statement of Need

          Rheumatoid arthritis (RA) is a chronic inflammatory disease affecting over 1.3 million Americans and approximately 1% of the global population.1 Many treatment options are available to treat RA, and these agents may be used as monotherapy, as sequential treatment strategies, or as combination treatment. To successfully treat patients with RA, clinicians must be aware of the various treatment strategies outlined in the ACR guidelines and clinical evidence that supports these treat-to-target approaches. The management of RA is complex and requires the involvement of the entire treatment team—that includes the patient—in order to maximize the benefits of existing treatment approaches, incorporate new treatments when appropriate, and ensure the health care needs of all patients with RA are met.

          This live, interactive webcast features a panel discussion moderated by Leonard Calabrese, DO with audio input from patients with RA, video interviews from RA team care members at the Cleveland Clinic, and a live Q&A.

          Reference:
          Rheumatoid Arthritis Support Network. Rheumatoid arthritis facts and figures. Rheumatoid Arthritis Support Network Website. https://www.rheumatoidarthritis.org/ra/facts-and-statistics/.

          Learning Objectives

          At the end of this CE activity, participants should be able to:

          • Align treatment decisions with ACR recommendations which support a treat-to-target approach in the care of patients with RA.
          • Critically appraise DMARD monotherapy treatment options, including JAK-inhibitors in the care of patients with moderate-to-severe RA.
          • Integrate one best practice that can be utilized by the multidisciplinary care team to monitor for signs and symptoms of methotrexate intolerance and medication nonadherence.

          The following learning objectives pertain only to those requesting CNE or CPE credit:

          • Describe treatment decisions that align with ACR recommendations which support a treat-to-target approach in the care of patients with RA.
          • Critically appraise DMARD monotherapy treatment options, including JAK-inhibitors in the care of patients with moderate-to-severe RA.
          • Identify best practices that can be utilized by the multidisciplinary care team to monitor for signs and symptoms of methotrexate intolerance and medication nonadherence.

          Financial Support

          Supported by an educational grant from Pfizer Inc.

          Target Audience

          Rheumatologists, PAs, NPs, nurses, pharmacists, and other healthcare providers who treat patients with rheumatoid arthritis.

          Credit Information

          CME Credit (Physicians):
          CME Outfitters, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

          CME Outfitters, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

          CNE Credit (Nurses):
          Provider approved by the California Board of Registered Nursing, Provider Number CEP 15510, for 1.5 contact hours

          Note to Nurse Practitioners and Clinical Nurse Specialists: the content of this activity pertains to pharmacology.  Earn up to 1.5 contact hours of pharmacotherapeutic contact hours.

          Note to Nurse Practitioners: Nurse practitioners can apply for AMA PRA Category 1 CreditTMthrough the American Academy of Nurse Practitioners (AANP). AANP will accept AMA PRA Category 1 Credit(s)TM from organizations accredited by the Accreditation Council for Continuing Medical Education. Nurse practitioners can also apply for credit through their state boards.

          CPE Credit (Pharmacists):
          ACPECME Outfitters, LLC, is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. 1.5 contact hours (0.15 CEUs) Universal Activity Number:
          Live: 0376-0000-18-003-L01-P
          Enduring: 0376-0000-18-003-H01-P

          Type: Knowledge-based

          ABIM/MOC Credit:
          Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

          Learning Formats
          Live activity
          Enduring material

          Note to Physician Assistants: AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 CreditTM from organizations accredited by the Accreditation Council for Continuing Medical Education.

          Post-tests, credit request forms, and activity evaluations must be completed online at www.cmeoutfitters.com/TST26326 (requires free account activation), and participants can print their certificate or statement of credit immediately (75% pass rate required). This website supports all browsers except Internet Explorer for Mac. For complete technical requirements and privacy policy, visit www.neurosciencecme.com/technical.asp.

          Disclosure Declaration

          It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

          Dr. Calabrese reports that he is a consultant for AbbVie Inc.; Centecor Biopharmaceutical; Crescendo Bioscience, Inc.; GlaxoSmithKline; Horizon Pharma; Janssen Pharmaceuticals, Inc.; Pfizer Inc.; Regeneron Pharmaceuticals, Inc.; and UCB, Inc.

          Dr. Stanley B. Cohen has no disclosures to report.

          Ms. Eileen J. Lydon has no disclosures to report.

          Dr. Rochelle Rosian has no disclosures to report.

          Sharon Tordoff (planning committee) has no disclosures to report.

          Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report.

          Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.

          Questions about this activity? Call us at 877.CME.PROS(877.263.7767).

          This document was last modified on: 06/07/2018 12:16:34

          TV-095-051518-02

          ]]> CMEO Live and On Demand

          Premiere Date: Tuesday, May 15, 2018

          This activity offers CE credit for:

          1. Physicians (CME)
          2. Nurses (CNE)
          3. Pharmacists (ACPE)
          4. ABIM (ABIM)
          5. Other

          All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™

          Credit Expiration Date: Wednesday, May 15, 2019

          Begin Activity Now

          Faculty

           

          Leonard H. Calabrese, DO Leonard H. Calabrese, DO (Moderator)
          Professor of Medicine
          Vice Chair, Department of Rheumatic & Immunologic Disease
          Cleveland Clinic Lerner College of Medicine
          of Case Western Reserve University
          R.J. Fasenmyer Chair of Clinical Immunology
          Cleveland Clinic Foundation
          Cleveland, OH

           

          Stanley B. Cohen, MD Stanley B. Cohen, MD
          Clinical Professor, Department of Internal Medicine
          University of Texas Southwestern Medical School
          Co-Director, Division of Rheumatology
          Presbyterian Hospital, Dallas
          Co-Medical Director
          Metroplex Clinical Research Center
          Dallas, TX
          Past President of the American College of Rheumatology
          Atlanta, GA

           

          Eileen J. Lydon, ANP-BC Eileen J. Lydon, ANP-BC
          Adult Nurse Practitioner
          Department of Rheumatology
          NYU Langone Orthopedic Hospital
          New York, NY

           

          Rochelle Rosian, MD Rochelle Rosian, MD
          Staff member
          Department of Rheumatic and Immunologic Diseases
          Director of Regional Rheumatology
          Cleveland Clinic
          Solon, OH

           

          Statement of Need

          Rheumatoid arthritis (RA) is a chronic inflammatory disease affecting over 1.3 million Americans and approximately 1% of the global population.1 Many treatment options are available to treat RA, and these agents may]]> CMEO Live and On Demand

          Premiere Date: Tuesday, May 15, 2018

          This activity offers CE credit for:

          1. Physicians (CME)
          2. Nurses (CNE)
          3. Pharmacists (ACPE)
          4. ABIM (ABIM)
          5. Other

          All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™

          Credit Expiration Date: Wednesday, May 15, 2019

          Begin Activity Now

          Faculty

           

          Leonard H. Calabrese, DO Leonard H. Calabrese, DO (Moderator)
          Professor of Medicine
          Vice Chair, Department of Rheumatic & Immunologic Disease
          Cleveland Clinic Lerner College of Medicine
          of Case Western Reserve University
          R.J. Fasenmyer Chair of Clinical Immunology
          Cleveland Clinic Foundation
          Cleveland, OH

           

          Stanley B. Cohen, MD Stanley B. Cohen, MD
          Clinical Professor, Department of Internal Medicine
          University of Texas Southwestern Medical School
          Co-Director, Division of Rheumatology
          Presbyterian Hospital, Dallas
          Co-Medical Director
          Metroplex Clinical Research Center
          Dallas, TX
          Past President of the American College of Rheumatology
          Atlanta, GA

           

          Eileen J. Lydon, ANP-BC Eileen J. Lydon, ANP-BC
          Adult Nurse Practitioner
          Department of Rheumatology
          NYU Langone Orthopedic Hospital
          New York, NY

           

          Rochelle Rosian, MD Rochelle Rosian, MD
          Staff member
          Department of Rheumatic and Immunologic Diseases
          Director of Regional Rheumatology
          Cleveland Clinic
          Solon, OH

           

          Statement of Need

          Rheumatoid arthritis (RA) is a chronic inflammatory disease affecting over 1.3 million Americans and approximately 1% of the global population.1 Many treatment options are available to treat RA, and these agents may]]> clean No no no 0:00 Alex Perez Precision Medicine in Ankylosing Spondylitis: Fine-tuning Diagnosis and Treatment https://www.cmeoutfitters.com/precision-medicine-in-ankylosing-spondylitis-fine-tuning-diagnosis-and-treatment/ Sat, 02 Jun 2018 16:48:13 +0000 Alex Perez https://www.cmeoutfitters.com/?p=10366 full

          Premiere Date: Sunday, May 20, 2018

          This activity offers CE credit for:

          1. Physicians (CME)
          2. Nurses (CNE)
          3. Pharmacists (ACPE)
          4. ABIM (ABIM)
          5. Other

          All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™

          Credit Expiration Date: Monday, May 20, 2019

          Faculty

          Allan Gibofsky, MD, JD, MACR, FACP, FCLM Allan Gibofsky, MD, JD, MACR, FACP, FCLM
          Professor of Medicine, Healthcare Policy and Research
          Weill Medical College of Cornell University
          Attending Rheumatologist
          Hospital for Special Surgery
          New York, NY
          Joerg Ermann, MD Joerg Ermann, MD
          Instructor in Medicine
          Brigham and Women’s Hospital
          Harvard Medical School
          Boston, MA

          Statement of Need

          Ankylosing spondylitis (AS) is a chronic, inflammatory arthritis that affects the axial skeleton. Due to an aging population, declining number of rheumatologists, and limited access to care, care for patients with AS is suboptimal and it is critically important that primary care can optimally recognize and manage these patients. AS is challenging to diagnose and has a 5-10 year delay in diagnosis, the longest diagnostic delay among rheumatic diseases. Studies have shown that patients with shorter disease duration have better response to treatment. A diagnostic delay may cause patients to miss the chance of early appropriate treatment and consequently have poorer prognosis, increased disability, limitation of spinal and hip movements, pain, poor quality of life, and poor functional status.

          This CME Outfitters recorded symposium features expert faculty and aims to improve confidence in practitioners that will lead to improved screening, evaluation, and early treatment of individuals with AS.

          Learning Objectives

          At the end of this CE activity, participants should be able to:

          • Recognize key clinical features of ankylosing spondylitis (AS) to aid in timely diagnosis.
          • Incorporate classification criteria and diagnostic tests into clinical practice to support early detection of AS.
          • Implement biologic treatments for AS into clinical practice when appropriate.

          The following learning objectives pertain only to those requesting CNE or CPE credit:

          • Describe key clinical features of ankylosing spondylitis (AS) that aid in timely diagnosis.
          • Identify classification criteria and diagnostic tests that support early detection of AS.
          • Explain appropriate implementation of biologic treatments for AS.

          Financial Support

          Supported by an educational grant from Novartis Pharmaceuticals Corporation.

          Target Audience

          Primary care physicians, internists, physician assistants, nurse practitioners, nurses, and pharmacists who treat patients with ankylosing spondylitis.

          Credit Information

          CME Credit (Physicians):
          CME Outfitters, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

          CME Outfitters, LLC designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

          CNE Credit (Nurses):
          Provider approved by the California Board of Registered Nursing, Provider Number CEP 15510, for 1.5 contact hours

          Note to Nurse Practitioners and Clinical Nurse Specialists: the content of this activity pertains to pharmacology. Earn up to 1.5 contact hours of pharmacotherapeutic contact hours.

          Note to Nurse Practitioners: Nurse practitioners can apply for AMA PRA Category 1 CreditTMthrough the American Academy of Nurse Practitioners (AANP). AANP will accept AMA PRA Category 1 CreditTM from organizations accredited by the Accreditation Council for Continuing Medical Education. Nurse practitioners can also apply for credit through their state boards.

          CPE Credit (Pharmacists):
          ACPECME Outfitters, LLC, is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. 1.5 contact hours (0.15 CEUs) Universal Activity Number:
          Enduring: 0376-0000-18-010-H01-P

          Type: Knowledge-based

          ABIM/MOC Credit:
          Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

          Learning Formats
          Enduring material

          Note to Physician Assistants: AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 CreditTM from organizations accredited by the Accreditation Council for Continuing Medical Education.

          Post-tests, credit request forms, and activity evaluations must be completed online at www.cmeoutfitters.com/TST27393 (requires free account activation), and participants can print their certificate or statement of credit immediately (75% pass rate required). This website supports all browsers except Internet Explorer for Mac. For complete technical requirements and privacy policy, visit www.neurosciencecme.com/technical.asp.

          Disclosure Declaration

          It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

          Dr. Allan Gibofsky disclosed that he is on the Speakers Bureau for AbbVie Inc.; Celgene Corporation; Merck & Co., Inc.; Pfizer Inc. He is a consultant for AbbVie Inc., Celgene Corporation; Merck & Co., Inc.; Pfizer Inc.; Regeneron Pharmaceuticals, Inc.; Samumed, LLC; Sandoz. He is a stock shareholder of AbbVie Inc.; Bristol-Myers Squibb Company; Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Pfizer Inc.; Regeneron Pharmaceuticals, Inc.

          Dr. Joerg Ermann disclosed that he receives grants from Boehringer Ingelheim and Pfizer Inc.

          Sharon Tordoff(planning committee) has no disclosures to report.

          Jan Perez (planning committee) has no disclosures to report.

          Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report.

          Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.

          Questions about this activity? Call us at 877.CME.PROS(877.263.7767).

      ]]>

      Premiere Date: Sunday, May 20, 2018

      This activity offers CE credit for:

      1. Physicians (CME)
      2. Nurses (CNE)
      3. Pharmacists (ACPE)
      4. ABIM (ABIM)
      5. Other

      All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™

      Credit Expiration Date: Monday, May 20, 2019

      Faculty

      Allan Gibofsky, MD, JD, MACR, FACP, FCLM Allan Gibofsky, MD, JD, MACR, FACP, FCLM
      Professor of Medicine, Healthcare Policy and Research
      Weill Medical College of Cornell University
      Attending Rheumatologist
      Hospital for Special Surgery
      New York, NY
      Joerg Ermann, MD Joerg Ermann, MD
      Instructor in Medicine
      Brigham and Women’s Hospital
      Harvard Medical School
      Boston, MA

      Statement of Need

      Ankylosing spondylitis (AS) is a chronic, inflammatory arthritis that affects the axial skeleton. Due to an aging population, declining number of rheumatologists, and limited access to care, care for patients with AS is suboptimal and it is critically important that primary care can optimally recognize and manage these patients. AS is challenging to diagnose and has a 5-10 year delay in diagnosis, the longest diagnostic delay among rheumatic diseases. Studies have shown that patients with shorter disease duration have better response to treatment. A diagnostic delay may cause patients to miss the chance of early appropriate treatment and consequently have poorer prognosis, increased disability, limitation of spinal and hip movements, pain, poor quality of life, and poor functional status.

      This CME Outfitters recorded symposium features expert faculty and aims to improve confidence in practitioners that will lead to improved screening, evaluation, and early treatment of individuals with AS.

      Learning Objectives

      At the end of this CE activity, participants should be able to:

      • Recognize key clinical features of ankylosing spondylitis (AS) to aid in timely diagnosis.
      • Incorporate classification criteria and diagnostic tests into clinical practice to support early detection of AS.
      • Implement biologic treatments for AS into clinical practice when appropriate.

      The following learning objectives pertain only to those requesting CNE or CPE credit:

      • Describe key clinical features of ankylosing spondylitis (AS) that aid in timely diagnosis.
      • Identify classification criteria and diagnostic tests that support early detection of AS.
      • Explain appropriate implementation of biologic treatments for AS.

      Financial Support

      Supported by an educational grant from Novartis Pharmaceuticals Corporation.

      Target Audience

      Primary car]]>

      Premiere Date: Sunday, May 20, 2018

      This activity offers CE credit for:

      1. Physicians (CME)
      2. Nurses (CNE)
      3. Pharmacists (ACPE)
      4. ABIM (ABIM)
      5. Other

      All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™

      Credit Expiration Date: Monday, May 20, 2019

      Faculty

      Allan Gibofsky, MD, JD, MACR, FACP, FCLM Allan Gibofsky, MD, JD, MACR, FACP, FCLM
      Professor of Medicine, Healthcare Policy and Research
      Weill Medical College of Cornell University
      Attending Rheumatologist
      Hospital for Special Surgery
      New York, NY
      Joerg Ermann, MD Joerg Ermann, MD
      Instructor in Medicine
      Brigham and Women’s Hospital
      Harvard Medical School
      Boston, MA

      Statement of Need

      Ankylosing spondylitis (AS) is a chronic, inflammatory arthritis that affects the axial skeleton. Due to an aging population, declining number of rheumatologists, and limited access to care, care for patients with AS is suboptimal and it is critically important that primary care can optimally recognize and manage these patients. AS is challenging to diagnose and has a 5-10 year delay in diagnosis, the longest diagnostic delay among rheumatic diseases. Studies have shown that patients with shorter disease duration have better response to treatment. A diagnostic delay may cause patients to miss the chance of early appropriate treatment and consequently have poorer prognosis, increased disability, limitation of spinal and hip movements, pain, poor quality of life, and poor functional status.

      This CME Outfitters recorded symposium features expert faculty and aims to improve confidence in practitioners that will lead to improved screening, evaluation, and early treatment of individuals with AS.

      Learning Objectives

      At the end of this CE activity, participants should be able to:

      • Recognize key clinical features of ankylosing spondylitis (AS) to aid in timely diagnosis.
      • Incorporate classification criteria and diagnostic tests into clinical practice to support early detection of AS.
      • Implement biologic treatments for AS into clinical practice when appropriate.

      The following learning objectives pertain only to those requesting CNE or CPE credit:

      • Describe key clinical features of ankylosing spondylitis (AS) that aid in timely diagnosis.
      • Identify classification criteria and diagnostic tests that support early detection of AS.
      • Explain appropriate implementation of biologic treatments for AS.

      Financial Support

      Supported by an educational grant from Novartis Pharmaceuticals Corporation.

      Target Audience

      Primary car]]> clean No no no 1:30:28 Alex Perez Uncovering the Secret Sauce: Strategies for Increasing Prior Authorization Success Rates for Patients with IBD https://www.cmeoutfitters.com/uncovering-the-secret-sauce-strategies-for-increasing-prior-authorization-success-rates-for-patients-with-ibd/ Fri, 01 Jun 2018 20:09:45 +0000 Alex Perez https://www.cmeoutfitters.com/?p=9290 full CMEO Multimedia Snack

      Premiere Date: Monday, April 30, 2018

      This activity offers CE credit for:

      1. Physicians (CME)
      2. Pharmacists (ACPE)
      3. Nurse Practitioners (AANP)
      4. Physician Assistants (AAPA)
      5. Other

      All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™

      Credit Expiration Date: Tuesday, April 30, 2019

      Begin Activity Now

      Faculty

       

      Francis A. Farraye, MD, MSc Francis A. Farraye, MD, MSc
      Clinical Director, Section of Gastroenterology
      Director, Inflammatory Bowel Disease Center
      Boston Medical Center
      Professor of Medicine
      Boston University School of Medicine
      Boston, MA

       

      Michele A. Rubin, APN, CNS, CGRN Michele A. Rubin, APN, CNS, CGRN 
      Associate Director, Inflammatory Bowel Disease Center
      Director, Advanced Practice Nursing
      University of Chicago Medicine
      Chicago, IL

       

      Toni M. Zahorian, PharmD, BCACP Toni M. Zahorian, PharmD, BCACP
      Clinical Pharmacy Specialist – Ambulatory Care
      Center for Digestive Disorders
      Boston Medical Center
      Boston, MA

       

      Statement of Need

      Much of the national healthcare debate is centered around gaining insurance coverage for more Americans. But individuals with chronic disease know that their issue is not always about having coverage. It is about gaining access to treatment within their insurance coverage. Forty percent (40%) of prescriptions requiring PA are abandoned or delayed due to current processes. Inefficient PA processes put patients with IBD at risk for poor outcomes from denied access to needed care. Having a plan with proven strategies and resources that meet the needs of the practice can help reduce practice headaches, increase timely patient access to needed medication, and ultimately, improve outcomes and satisfaction in patients with IBD.

      The first module of this CME Outfitters 3-part series is designed to provide you with best practice strategies that you can use to improve your success rates for PA and to minimize the impact of prior authorization on staff administrative time, clinical workflow, and patient care. Have questions for our faculty? Use the comment box below the presentation. The faculty will be checking in to respond to learners!

      We encourage learners to complete all 3 CME Snacks in this series to receive a Certificate of Excellence in Prior Authorization.

      Learning Objectives

      At the end of this CE activity, participants should be able to:

      • Evaluate prior authorization (PA) methods that best fit clinical workflow to reduce disruption, establish clear communication with the payer, and minimize delays.

      The following learning objectives pertain only to those requesting CNE or CPE credit:

      • Evaluate prior authorization (PA) methods that best fit clinical workflow to reduce disruption, establish clear communication with the payer, and minimize delays.

      Financial Support

      Supported by an educational grant from Takeda Pharmaceuticals USA, Inc.

      Target Audience

      Gastroenterologists, physicians, nurses, nurse practitioners, physician assistants, medical assistants, and other healthcare professionals responsible for the prior authorization process.

      Credit Information

      CME Credit (Physicians):
      CME Outfitters, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

      CME Outfitters designates this enduring material for a maximum of .25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

      AANP Credit (American Association of Nurse Practitioners):
      This activity is approved for 0.25 contact hour(s) of continuing education by the American Association of Nurse Practitioners. Activity ID 18033122. This activity was planned in accordance with AANP CE Standards and Policies.

      AAPA Credit (American Academy of PA’s):
      This activity has been reviewed by the AAPA Review Panel and is compliant with AAPA CME Criteria. This activity is designated for 0.25 AAPA Category 1 CME credits. Approval is valid for one year from 04/30/2018. PAs should only claim credit commensurate with the extent of their participation.

      CNE Credit (Nurses):
      Provider approved by the California Board of Registered Nursing, Provider Number CEP 15510, for .25 contact hours

      Note to Nurse Practitioners and Clinical Nurse Specialists: the content of this activity pertains to pharmacology. Earn up to 1.5 contact hours of pharmacotherapeutic contact hours.

      Note to Nurse Practitioners: Nurse practitioners can apply for AMA PRA Category 1 CreditTMthrough the American Academy of Nurse Practitioners (AANP). AANP will accept AMA PRA Category 1 CreditTM from organizations accredited by the Accreditation Council for Continuing Medical Education. Nurse practitioners can also apply for credit through their state boards.

      CPE Credit (Pharmacists):
      ACPECME Outfitters, LLC, is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. .25 contact hours (0.025 CEUs) Universal Activity Number:
      Enduring: 0376-0000-18-005-H01-P

      Type: Knowledge-based

      Post-tests, credit request forms, and activity evaluation must be completed online at www.cmeoutfitters.com/TST27363 (requires free account activation), and participants can print their certificate or statement of credit immediately (75% pass rate required). this website supports all browsers except Internet Explorer for Mac. For complete technical requirements and privacy policy, visit www.neurosciencecme.com/technical.asp.

      Disclosure Declaration

      It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, sue of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentation.

      Dr. Farraye reports that he is a consultant for Braintree Laboratories Inc.; Celgene Corporation; Ferring Pharmaceuticals; Janssen Pharmaceuticals, Inc.; Merck & Co., Inc; Pfizer Inc.; Protagonist Therapeutics Inc. (DSMB); Takeda Pharmaceuticals U.S.A., Inc. He is a stock shareholder (directly purchased) of Innovation Pharmaceuticals Inc.

      Dr. Rubin reports that she is on the advisory board for Pfizer Inc as spokesperson for results of patient and GI survey only.

      Dr. Zahorian has no disclosures to report.

      Tony Graham, MD (peer reviewer) has no disclosures to report.

      Michelle H. Lavigne, PA-C (peer reviewer) has no disclosures to report.

      Mae Ochoa, Rph (peer reviewer) has no disclosures to report.

      Jan Perez (planning committee) has no disclosures to report.

      Sharon Tordoff (planning committee) has no disclosures to report.

      Disclosures were obtained from the CME Outfitters, LLC staff. No disclosures to report.

      Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.

      Questions about this activity? Call us at 877.CME.PROS(877.263.7767).

      This document was last modified on: 06/01/2018 16:01:56

      SN-088-043018-20

      ]]> CMEO Multimedia Snack

      Premiere Date: Monday, April 30, 2018

      This activity offers CE credit for:

      1. Physicians (CME)
      2. Pharmacists (ACPE)
      3. Nurse Practitioners (AANP)
      4. Physician Assistants (AAPA)
      5. Other

      All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™

      Credit Expiration Date: Tuesday, April 30, 2019

      Begin Activity Now

      Faculty

       

      Francis A. Farraye, MD, MSc Francis A. Farraye, MD, MSc
      Clinical Director, Section of Gastroenterology
      Director, Inflammatory Bowel Disease Center
      Boston Medical Center
      Professor of Medicine
      Boston University School of Medicine
      Boston, MA

       

      Michele A. Rubin, APN, CNS, CGRN Michele A. Rubin, APN, CNS, CGRN 
      Associate Director, Inflammatory Bowel Disease Center
      Director, Advanced Practice Nursing
      University of Chicago Medicine
      Chicago, IL

       

      Toni M. Zahorian, PharmD, BCACP Toni M. Zahorian, PharmD, BCACP
      Clinical Pharmacy Specialist – Ambulatory Care
      Center for Digestive Disorders
      Boston Medical Center
      Boston, MA

       

      Statement of Need

      Much of the national healthcare debate is centered around gaining insurance coverage for more Americans. But individuals with chronic disease know that their issue is not always about having coverage. It is about gaining access to treatment within their insurance coverage. Forty percent (40%) of prescriptions requiring PA are abandoned or delayed due to current processes. Inefficient PA processes put patients with IBD at risk for poor outcomes from denied access to needed care. Having a plan with proven strategies and resources that meet the needs of the practice can help reduce practice headaches, increase timely patient access to needed medication, and ultimately, improve outcomes and satisfaction in patients with IBD.

      The first module of this CME Outfitters 3-part series is designed to provide you with best practice strategies that you can use to improve your success rates for PA and to minimize the impact of prior authorization on staff administrative time, clinical workflow, and patient care. Have questions for our faculty? Use the ]]> CMEO Multimedia Snack

      Premiere Date: Monday, April 30, 2018

      This activity offers CE credit for:

      1. Physicians (CME)
      2. Pharmacists (ACPE)
      3. Nurse Practitioners (AANP)
      4. Physician Assistants (AAPA)
      5. Other

      All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™

      Credit Expiration Date: Tuesday, April 30, 2019

      Begin Activity Now

      Faculty

       

      Francis A. Farraye, MD, MSc Francis A. Farraye, MD, MSc
      Clinical Director, Section of Gastroenterology
      Director, Inflammatory Bowel Disease Center
      Boston Medical Center
      Professor of Medicine
      Boston University School of Medicine
      Boston, MA

       

      Michele A. Rubin, APN, CNS, CGRN Michele A. Rubin, APN, CNS, CGRN 
      Associate Director, Inflammatory Bowel Disease Center
      Director, Advanced Practice Nursing
      University of Chicago Medicine
      Chicago, IL

       

      Toni M. Zahorian, PharmD, BCACP Toni M. Zahorian, PharmD, BCACP
      Clinical Pharmacy Specialist – Ambulatory Care
      Center for Digestive Disorders
      Boston Medical Center
      Boston, MA

       

      Statement of Need

      Much of the national healthcare debate is centered around gaining insurance coverage for more Americans. But individuals with chronic disease know that their issue is not always about having coverage. It is about gaining access to treatment within their insurance coverage. Forty percent (40%) of prescriptions requiring PA are abandoned or delayed due to current processes. Inefficient PA processes put patients with IBD at risk for poor outcomes from denied access to needed care. Having a plan with proven strategies and resources that meet the needs of the practice can help reduce practice headaches, increase timely patient access to needed medication, and ultimately, improve outcomes and satisfaction in patients with IBD.

      The first module of this CME Outfitters 3-part series is designed to provide you with best practice strategies that you can use to improve your success rates for PA and to minimize the impact of prior authorization on staff administrative time, clinical workflow, and patient care. Have questions for our faculty? Use the ]]> clean No no no 0:00 Alex Perez Best Practices for EHR Documentation to Overcome Barriers to Prior Authorization for Patients with IBD https://www.cmeoutfitters.com/best-practices-for-ehr-documentation-to-overcome-barriers-to-prior-authorization-for-patients-with-ibd/ Fri, 01 Jun 2018 20:08:39 +0000 Alex Perez https://www.cmeoutfitters.com/?p=9299 full CMEO Multimedia Snack

      Premiere Date: Monday, April 30, 2018

      This activity offers CE credit for:

      1. Physicians (CME)
      2. Pharmacists (ACPE)
      3. Nurse Practitioners (AANP)
      4. Physician Assistants (AAPA)
      5. Other

      All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™

      Credit Expiration Date: Tuesday, April 30, 2019

      Begin Activity Now

      Faculty

       

      Francis A. Farraye, MD, MSc Francis A. Farraye, MD, MSc
      Clinical Director, Section of Gastroenterology
      Director, Inflammatory Bowel Disease Center
      Boston Medical Center
      Professor of Medicine
      Boston University School of Medicine
      Boston, MA

       

      Michele A. Rubin, APN, CNS, CGRN Michele A. Rubin, APN, CNS, CGRN 
      Associate Director, Inflammatory Bowel Disease Center
      Director, Advanced Practice Nursing
      University of Chicago Medicine
      Chicago, IL

       

      Toni M. Zahorian, PharmD, BCACP Toni M. Zahorian, PharmD, BCACP
      Clinical Pharmacy Specialist – Ambulatory Care
      Center for Digestive Disorders
      Boston Medical Center
      Boston, MA

       

      Statement of Need

      To increase prior authorization (PA) success rates, a detailed protocol for recording and retrieving information about the patient’s disease course within the EHR can minimize barriers and increase the chances that the biologic agent will be deemed medically necessary. It is important to have detailed documentation of IBD diagnosis (including diagnosis codes), colonoscopy results, laboratory results, and detailed disease course information in the EHR progress notes that identify aggressive disease. The non adherence of payer policies to the established, evidence-based AGA Clinical Pathways presents significant barriers to patients in need of appropriate biologic treatment to manage their moderate to severe IBD.

      For clinicians, managing the PA process, it underscores the necessity of preparation, documentation, and retrieval of key information from the EHR for the PA submission.

      In the second module of this CME Outfitters 3-part series, expert faculty will share best practices for creating processes that ensure important clinical information needed for PA is routinely gathered and documented in the patient’s EHR to minimize barriers to biologic approval. Have questions for our faculty? Use the comment box below the presentation. The faculty will be checking in to respond to learners!

      We encourage learners to complete all 3 CME Snacks in this series to receive a Certificate of Excellence in Prior Authorization.

      Learning Objectives

      At the end of this CE activity, participants should be able to:

      • Implement a PA protocol to improve documentation in the EHR and minimize barriers to medication approval.

      The following learning objectives pertain only to those requesting CNE or CPE credit:

      • Describe a PA protocol to improve documentation in the EHR and minimize barriers to medication approval.

      Financial Support

      Supported by an educational grant from Takeda Pharmaceuticals, Inc.

      Target Audience

      Gastroenterologists, physicians, nurses, nurse practitioners, physician assistants, medical assistants, and other healthcare professionals responsible for the prior authorization process.

      Credit Information

      CME Credit (Physicians):
      CME Outfitters, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

      CME Outfitters designates this enduring material for a maximum of .25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

      AANP Credit (American Association of Nurse Practitioners):
      This activity is approved for 0.25 contact hour(s) of continuing education by the American Association of Nurse Practitioners. Activity ID 18033121. This activity was planned in accordance with AANP CE Standards and Policies.

      AAPA Credit (American Academy of PA’s):
      This activity has been reviewed by the AAPA Review Panel and is compliant with AAPA CME Criteria. This activity is designated for 0.25 AAPA Category 1 CME credits. Approval is valid for one year from 04/30/2018. PAs should only claim credit commensurate with the extent of their participation.

      CPE Credit (Pharmacists):
      ACPECME Outfitters, LLC, is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. .25 contact hours (0.025 CEUs) Universal Activity Number:
      Enduring: 0376-0000-18-006-H01-P

      Type: Knowledge-based

      Post-tests, credit request forms, and activity evaluation must be completed online at www.cmeoutfitters.com/TST27364 (requires free account activation), and participants can print their certificate or statement of credit immediately (75% pass rate required). this website supports all browsers except Internet Explorer for Mac. For complete technical requirements and privacy policy, visit www.neurosciencecme.com/technical.asp.

      Disclosure Declaration

      It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, sue of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentation.

      Dr. Farraye reports that he is a consultant for Braintree Laboratories Inc.; Celgene Corporation; Ferring Pharmaceuticals; Janssen Pharmaceuticals, Inc.; Merck & Co., Inc; Pfizer Inc.; Protagonist Therapeutics Inc. (DSMB); Takeda Pharmaceuticals U.S.A., Inc. He is a stock shareholder (directly purchased) of Innovation Pharmaceuticals Inc.

      Dr. Rubin reports that she is on the advisory board for Pfizer Inc as spokesperson for results of patient and GI survey only.

      Dr. Zahorian has no disclosures to report.

      Tony Graham, MD (peer reviewer) has no disclosures to report.

      Michelle H. Lavigne, PA-C (peer reviewer) has no disclosures to report.

      Mae Ochoa, Rph (peer reviewer) has no disclosures to report.

      Jan Perez (planning committee) has no disclosures to report.

      Sharon Tordoff (planning committee) has no disclosures to report.

      Disclosures were obtained from the CME Outfitters, LLC staff. No disclosures to report.

      Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.

      Questions about this activity? Call us at 877.CME.PROS(877.263.7767).

      This document was last modified on: 06/01/2018 16:10:57

      SN-089-043018-20

      ]]> CMEO Multimedia Snack

      Premiere Date: Monday, April 30, 2018

      This activity offers CE credit for:

      1. Physicians (CME)
      2. Pharmacists (ACPE)
      3. Nurse Practitioners (AANP)
      4. Physician Assistants (AAPA)
      5. Other

      All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™

      Credit Expiration Date: Tuesday, April 30, 2019

      Begin Activity Now

      Faculty

       

      Francis A. Farraye, MD, MSc Francis A. Farraye, MD, MSc
      Clinical Director, Section of Gastroenterology
      Director, Inflammatory Bowel Disease Center
      Boston Medical Center
      Professor of Medicine
      Boston University School of Medicine
      Boston, MA

       

      Michele A. Rubin, APN, CNS, CGRN Michele A. Rubin, APN, CNS, CGRN 
      Associate Director, Inflammatory Bowel Disease Center
      Director, Advanced Practice Nursing
      University of Chicago Medicine
      Chicago, IL

       

      Toni M. Zahorian, PharmD, BCACP Toni M. Zahorian, PharmD, BCACP
      Clinical Pharmacy Specialist – Ambulatory Care
      Center for Digestive Disorders
      Boston Medical Center
      Boston, MA

       

      Statement of Need

      To increase prior authorization (PA) success rates, a detailed protocol for recording and retrieving information about the patient’s disease course within the EHR can minimize barriers and increase the chances that the biologic agent will be deemed medically necessary. It is important to have detailed documentation of IBD diagnosis (including diagnosis codes), colonoscopy results, laboratory results, and detailed disease course information in the EHR progress notes that identify aggressive disease. The non adherence of payer policies to the established, evidence-based AGA Clinical Pathways presents significant barriers to patients in need of appropriate biologic treatment to manage their moderate to severe IBD.

      For clinicians, managing the PA process, it underscores the necessity of preparation, documentation, and retrieval of key information from the EHR for the PA submission.

      In the second module of this CME Outfitters 3-part series, expert faculty will share best practices for creating processes that ensure importan]]> CMEO Multimedia Snack

      Premiere Date: Monday, April 30, 2018

      This activity offers CE credit for:

      1. Physicians (CME)
      2. Pharmacists (ACPE)
      3. Nurse Practitioners (AANP)
      4. Physician Assistants (AAPA)
      5. Other

      All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™

      Credit Expiration Date: Tuesday, April 30, 2019

      Begin Activity Now

      Faculty

       

      Francis A. Farraye, MD, MSc Francis A. Farraye, MD, MSc
      Clinical Director, Section of Gastroenterology
      Director, Inflammatory Bowel Disease Center
      Boston Medical Center
      Professor of Medicine
      Boston University School of Medicine
      Boston, MA

       

      Michele A. Rubin, APN, CNS, CGRN Michele A. Rubin, APN, CNS, CGRN 
      Associate Director, Inflammatory Bowel Disease Center
      Director, Advanced Practice Nursing
      University of Chicago Medicine
      Chicago, IL

       

      Toni M. Zahorian, PharmD, BCACP Toni M. Zahorian, PharmD, BCACP
      Clinical Pharmacy Specialist – Ambulatory Care
      Center for Digestive Disorders
      Boston Medical Center
      Boston, MA

       

      Statement of Need

      To increase prior authorization (PA) success rates, a detailed protocol for recording and retrieving information about the patient’s disease course within the EHR can minimize barriers and increase the chances that the biologic agent will be deemed medically necessary. It is important to have detailed documentation of IBD diagnosis (including diagnosis codes), colonoscopy results, laboratory results, and detailed disease course information in the EHR progress notes that identify aggressive disease. The non adherence of payer policies to the established, evidence-based AGA Clinical Pathways presents significant barriers to patients in need of appropriate biologic treatment to manage their moderate to severe IBD.

      For clinicians, managing the PA process, it underscores the necessity of preparation, documentation, and retrieval of key information from the EHR for the PA submission.

      In the second module of this CME Outfitters 3-part series, expert faculty will share best practices for creating processes that ensure importan]]> clean No no no 0:00 Alex Perez No Doesn’t Necessarily Mean No: Strategies for Successful Prior Authorization Appeals for Patients with IBD https://www.cmeoutfitters.com/no-doesnt-necessarily-mean-no-strategies-for-successful-prior-authorization-appeals-for-patients-with-ibd/ Fri, 01 Jun 2018 19:49:58 +0000 Alex Perez https://www.cmeoutfitters.com/?p=9318 full CMEO Multimedia Snack

      Premiere Date: Monday, April 30, 2018

      This activity offers CE credit for:

      1. Physicians (CME)
      2. Pharmacists (ACPE)
      3. Nurse Practitioners (AANP)
      4. Physician Assistants (AAPA)
      5. Other

      All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™

      Credit Expiration Date: Tuesday, April 30, 2019

      Begin Activity Now

      Faculty

       

      Francis A. Farraye, MD, MSc Francis A. Farraye, MD, MSc
      Clinical Director, Section of Gastroenterology
      Director, Inflammatory Bowel Disease Center
      Boston Medical Center
      Professor of Medicine
      Boston University School of Medicine
      Boston, MA

       

      Michele A. Rubin, APN, CNS, CGRN Michele A. Rubin, APN, CNS, CGRN 
      Associate Director, Inflammatory Bowel Disease Center
      Director, Advanced Practice Nursing
      University of Chicago Medicine
      Chicago, IL

       

      Toni M. Zahorian, PharmD, BCACP Toni M. Zahorian, PharmD, BCACP
      Clinical Pharmacy Specialist – Ambulatory Care
      Center for Digestive Disorders
      Boston Medical Center
      Boston, MA

       

      Statement of Need

      Payers block treatments for more than one-third of patients for their chronic disease. Practices without a sound appeals process can further increase treatment delays for individuals with moderate to severe IBD that need biologic therapy; therefore, it is important to develop an organized appeals process for prior authorizations that are inappropriately declined. A successful appeal is an exercise in organization. Often, denials are a result of clerical error, but other times, a broader appeal is needed to persuade the payer that the physician’s recommendations are warranted. As with the PA process, the appeals process varies by payer, adding to the complexity and the need for a sound process and effective appeal templates.

      In the third module of this CME Outfitters 3-part series on prior authorization strategies, expert faculty will focus on creating a structured appeals process for when their prior authorization request is declined. Have questions for our faculty? Use the comment box below the presentation. The faculty will be checking in to respond to learners!

      We encourage learners to complete all 3 CME Snacks in this series to receive a Certificate of Excellence in Prior Authorization.

      Learning Objectives

      At the end of this CE activity, participants should be able to:

      • Develop a process for an organized and clinically supported appeal for PAs that are inappropriately declined.

      The following learning objectives pertain only to those requesting CNE or CPE credit:

      • Describe a process for an organized and clinically supported appeal for PAs that are inappropriately declined.

      Financial Support

      Supported by an educational grant from Takeda Pharmaceuticals USA, Inc.

      Target Audience

      Gastroenterologists, physicians, nurses, nurse practitioners, physician assistants, medical assistants, and other healthcare professionals responsible for the prior authorization process.

      Credit Information

      CME Credit (Physicians):
      CME Outfitters, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

      CME Outfitters designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

      AANP Credit (American Association of Nurse Practitioners):
      This activity is approved for 0.25 contact hour(s) of continuing education by the American Association of Nurse Practitioners. Activity ID 18033120. This activity was planned in accordance with AANP CE Standards and Policies.

      AAPA Credit (American Academy of PA’s):
      This activity has been reviewed by the AAPA Review Panel and is compliant with AAPA CME Criteria. This activity is designated for 0.25 AAPA Category 1 CME credits. Approval is valid for one year from 04/30/2018. PAs should only claim credit commensurate with the extent of their participation.

      CNE Credit (Nurses):
      Provider approved by the California Board of Registered Nursing, Provider Number CEP 15510, for .25 contact hours

      Note to Nurse Practitioners and Clinical Nurse Specialists: the content of this activity pertains to pharmacology. Earn up to 1.5 contact hours of pharmacotherapeutic contact hours.

      Note to Nurse Practitioners: Nurse practitioners can apply for AMA PRA Category 1 CreditTMthrough the American Academy of Nurse Practitioners (AANP). AANP will accept AMA PRA Category 1 CreditTM from organizations accredited by the Accreditation Council for Continuing Medical Education. Nurse practitioners can also apply for credit through their state boards.

      CPE Credit (Pharmacists):
      ACPECME Outfitters, LLC, is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. 0.5 contact hours (0.05 CEUs) Universal Activity Number:
      Enduring: 0376-0000-18-007-H01-P

      Type: Knowledge-based

      Post-tests, credit request forms, and activity evaluation must be completed online at www.cmeoutfitters.com/TST27365 (requires free account activation), and participants can print their certificate or statement of credit immediately (75% pass rate required). this website supports all browsers except Internet Explorer for Mac. For complete technical requirements and privacy policy, visit www.neurosciencecme.com/technical.asp.

      Disclosure Declaration

      It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, sue of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentation.

      Dr. Farraye reports that he is a consultant for Braintree Laboratories Inc.; Celgene Corporation; Ferring Pharmaceuticals; Janssen Pharmaceuticals, Inc.; Merck & Co., Inc; Pfizer Inc.; Protagonist Therapeutics Inc. (DSMB); Takeda Pharmaceuticals U.S.A., Inc. He is a stock shareholder (directly purchased) of Innovation Pharmaceuticals Inc.

      Dr. Rubin reports that she is on the advisory board for Pfizer Inc as spokesperson for results of patient and GI survey only.

      Dr. Zahorian has no disclosures to report.

      Tony Graham, MD (peer reviewer) has no disclosures to report.

      Michelle H. Lavigne, PA-C (peer reviewer) has no disclosures to report.

      Mae Ochoa, Rph (peer reviewer) has no disclosures to report.

      Jan Perez (planning committee) has no disclosures to report.

      Sharon Tordoff (planning committee) has no disclosures to report.

      Disclosures were obtained from the CME Outfitters, LLC staff. No disclosures to report.

      Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.

      Questions about this activity? Call us at 877.CME.PROS(877.263.7767).

      This document was last modified on: 06/01/2018 16:22:43

      SN-090-043018-20

      ]]> CMEO Multimedia Snack

      Premiere Date: Monday, April 30, 2018

      This activity offers CE credit for:

      1. Physicians (CME)
      2. Pharmacists (ACPE)
      3. Nurse Practitioners (AANP)
      4. Physician Assistants (AAPA)
      5. Other

      All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™

      Credit Expiration Date: Tuesday, April 30, 2019

      Begin Activity Now

      Faculty

       

      Francis A. Farraye, MD, MSc Francis A. Farraye, MD, MSc
      Clinical Director, Section of Gastroenterology
      Director, Inflammatory Bowel Disease Center
      Boston Medical Center
      Professor of Medicine
      Boston University School of Medicine
      Boston, MA

       

      Michele A. Rubin, APN, CNS, CGRN Michele A. Rubin, APN, CNS, CGRN 
      Associate Director, Inflammatory Bowel Disease Center
      Director, Advanced Practice Nursing
      University of Chicago Medicine
      Chicago, IL

       

      Toni M. Zahorian, PharmD, BCACP Toni M. Zahorian, PharmD, BCACP
      Clinical Pharmacy Specialist – Ambulatory Care
      Center for Digestive Disorders
      Boston Medical Center
      Boston, MA

       

      Statement of Need

      Payers block treatments for more than one-third of patients for their chronic disease. Practices without a sound appeals process can further increase treatment delays for individuals with moderate to severe IBD that need biologic therapy; therefore, it is important to develop an organized appeals process for prior authorizations that are inappropriately declined. A successful appeal is an exercise in organization. Often, denials are a result of clerical error, but other times, a broader appeal is needed to persuade the payer that the physician’s recommendations are warranted. As with the PA process, the appeals process varies by payer, adding to the complexity and the need for a sound process and effective appeal templates.

      In the third module of this CME Outfitters 3-part series on prior authorization strategies, expert faculty will focus on creating a structured appeals process for when their prior authorization request is declined. Have questions for our faculty? Use the comment box below the presentation. The faculty will]]> CMEO Multimedia Snack

      Premiere Date: Monday, April 30, 2018

      This activity offers CE credit for:

      1. Physicians (CME)
      2. Pharmacists (ACPE)
      3. Nurse Practitioners (AANP)
      4. Physician Assistants (AAPA)
      5. Other

      All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™

      Credit Expiration Date: Tuesday, April 30, 2019

      Begin Activity Now

      Faculty

       

      Francis A. Farraye, MD, MSc Francis A. Farraye, MD, MSc
      Clinical Director, Section of Gastroenterology
      Director, Inflammatory Bowel Disease Center
      Boston Medical Center
      Professor of Medicine
      Boston University School of Medicine
      Boston, MA

       

      Michele A. Rubin, APN, CNS, CGRN Michele A. Rubin, APN, CNS, CGRN 
      Associate Director, Inflammatory Bowel Disease Center
      Director, Advanced Practice Nursing
      University of Chicago Medicine
      Chicago, IL

       

      Toni M. Zahorian, PharmD, BCACP Toni M. Zahorian, PharmD, BCACP
      Clinical Pharmacy Specialist – Ambulatory Care
      Center for Digestive Disorders
      Boston Medical Center
      Boston, MA

       

      Statement of Need

      Payers block treatments for more than one-third of patients for their chronic disease. Practices without a sound appeals process can further increase treatment delays for individuals with moderate to severe IBD that need biologic therapy; therefore, it is important to develop an organized appeals process for prior authorizations that are inappropriately declined. A successful appeal is an exercise in organization. Often, denials are a result of clerical error, but other times, a broader appeal is needed to persuade the payer that the physician’s recommendations are warranted. As with the PA process, the appeals process varies by payer, adding to the complexity and the need for a sound process and effective appeal templates.

      In the third module of this CME Outfitters 3-part series on prior authorization strategies, expert faculty will focus on creating a structured appeals process for when their prior authorization request is declined. Have questions for our faculty? Use the comment box below the presentation. The faculty will]]> clean No no no 0:00 Alex Perez Getting Ahead of Migraine: Integrating Preventive Strategies Into Migraine Care https://www.cmeoutfitters.com/getting-ahead-of-migraine-integrating-preventive-strategies-into-migraine-care/ Fri, 01 Jun 2018 19:48:38 +0000 Alex Perez https://www.cmeoutfitters.com/?p=9280 full

      CMEO Webcast

      Premiere Date: Friday, May 18, 2018

      This activity offers CE credit for:

      1. Physicians (CME)
      2. Nurses (CNE)
      3. Pharmacists (ACPE)
      4. ABIM (ABIM)
      5. Other

      All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™

      Credit Expiration Date: Saturday, May 18, 2019

      Faculty

      Andrew C. Charles, MD Andrew C. Charles, MD
      Professor of Neurology
      Meyer and Renee Luskin Chair in Migraine and Headache Studies
      Director, Goldberg Migraine Program
      David Geffen School of Medicine, University of California, Los Angeles
      Los Angeles, CA
      Grace Forde, MD Grace Forde, MD
      Director of Neurological Services
      North American Partners in Pain Management, LLP
      Lake Success, NY

      Statement of Need

      Migraine is a debilitating condition with profound effects on individuals’ quality of life, accounting for five to nine million primary care visits each year. It is estimated that 38% of sufferers could benefit from preventative treatment, but few are currently using them nor are their healthcare providers discussing these options with them. Consequently, there is great interest in emerging data about calcitonin gene-related peptide (CGRP) agents as novel options for migraine prevention and the benefits they may provide to patients.

      In this CME Outfitters recorded symposium, expert faculty discuss the evidence for new agents, share strategies to address migraine prophylaxis, and translate evidence to real-world clinical practice utilizing case-based learning, which will optimize changes in practice for healthcare providers.

      Learning Objectives

      At the end of this CE activity, participants should be able to:

      • Apply knowledge of clinical features, symptoms, and key diagnostic criteria in the differential diagnosis of migraine.
      • Assess safety and efficacy data supporting the role of agents that target CGRP in the prevention and management of migraine.
      • Employ a patient-centered approach to the care of patients with migraine in order to improve outcomes, patient satisfaction, and treatment adherence.

      The following learning objectives pertain only to those requesting CNE or CPE credit:

      • Identify clinical features, symptoms, and key diagnostic criteria in the differential diagnosis of migraine.
      • Explain safety and efficacy data supporting the role of agents that target CGRP in the prevention and management of migraine.
      • Describe a patient-centered approach to the care of patients with migraine in order to improve outcomes, patient satisfaction, and treatment adherence.

      Financial Support

      This activity is supported by an educational grant from Lilly. For further information concerning Lilly grant funding visit www.lillygrantoffice.com.

      This activity is supported by an educational grant from Teva Pharmaceuticals.

      Target Audience

      Primary care physicians, internists, physician assistants, nurse practitioners, nurses, and pharmacists who treat patients with migraine.

      Credit Information

      CME Credit (Physicians):
      CME Outfitters, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

      CME Outfitters, LLC designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

      CNE Credit (Nurses):
      Provider approved by the California Board of Registered Nursing, Provider Number CEP 15510, for 1.5 contact hours

      Note to Nurse Practitioners and Clinical Nurse Specialists: the content of this activity pertains to pharmacology. Earn up to 1.5 contact hours of pharmacotherapeutic contact hours.

      Note to Nurse Practitioners: Nurse practitioners can apply for AMA PRA Category 1 CreditTMthrough the American Academy of Nurse Practitioners (AANP). AANP will accept AMA PRA Category 1 CreditTM from organizations accredited by the Accreditation Council for Continuing Medical Education. Nurse practitioners can also apply for credit through their state boards.

      CPE Credit (Pharmacists):
      ACPECME Outfitters, LLC, is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. 1.5 contact hours (0.15 CEUs) Universal Activity Number:
      Enduring: 0376-0000-18-009-H01-P

      Type: Knowledge-based

      ABIM/MOC Credit:
      Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

      Learning Formats
      Enduring material

      Note to Physician Assistants: AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 CreditTM from organizations accredited by the Accreditation Council for Continuing Medical Education.

      Post-tests, credit request forms, and activity evaluations must be completed online at www.cmeoutfitters.com/TST27392 (requires free account activation), and participants can print their certificate or statement of credit immediately (75% pass rate required). This website supports all browsers except Internet Explorer for Mac. For complete technical requirements and privacy policy, visit www.neurosciencecme.com/technical.asp.

      Disclosure Declaration

      It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

      Dr. Andrew Charles disclosed he serves as consultant for Alder BioPharmaceuticals Inc.; Amgen Inc.; Biohaven Pharmaceuticals; Eli Lilly and Company and eNeura, Inc.

      Dr. Grace Forde disclosed she is on the Speakers Bureau for Allergan and Supernus Pharmaceuticals, Inc.

      Jeffrey Helfand, DO, MS (peer reviewer) has no disclosures to report.

      Mae Ochoa, RPh (peer reviewer) has no disclosures to report.

      Jan Perez (planning committee) has no disclosures to report.

      Sharon Tordoff (planning committee) has no disclosures to report.

      Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report.

      Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.

      Questions about this activity? Call us at 877.CME.PROS(877.263.7767).

      This document was last modified on: 06/01/2018 15:46:09

      MMV-078-051818-11

    ]]>

    CMEO Webcast

    Premiere Date: Friday, May 18, 2018

    This activity offers CE credit for:

    1. Physicians (CME)
    2. Nurses (CNE)
    3. Pharmacists (ACPE)
    4. ABIM (ABIM)
    5. Other

    All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™

    Credit Expiration Date: Saturday, May 18, 2019

    Faculty

    Andrew C. Charles, MD Andrew C. Charles, MD
    Professor of Neurology
    Meyer and Renee Luskin Chair in Migraine and Headache Studies
    Director, Goldberg Migraine Program
    David Geffen School of Medicine, University of California, Los Angeles
    Los Angeles, CA
    Grace Forde, MD Grace Forde, MD
    Director of Neurological Services
    North American Partners in Pain Management, LLP
    Lake Success, NY

    Statement of Need

    Migraine is a debilitating condition with profound effects on individuals’ quality of life, accounting for five to nine million primary care visits each year. It is estimated that 38% of sufferers could benefit from preventative treatment, but few are currently using them nor are their healthcare providers discussing these options with them. Consequently, there is great interest in emerging data about calcitonin gene-related peptide (CGRP) agents as novel options for migraine prevention and the benefits they may provide to patients.

    In this CME Outfitters recorded symposium, expert faculty discuss the evidence for new agents, share strategies to address migraine prophylaxis, and translate evidence to real-world clinical practice utilizing case-based learning, which will optimize changes in practice for healthcare providers.

    Learning Objectives

    At the end of this CE activity, participants should be able to:

    • Apply knowledge of clinical features, symptoms, and key diagnostic criteria in the differential diagnosis of migraine.
    • Assess safety and efficacy data supporting the role of agents that target CGRP in the prevention and management of migraine.
    • Employ a patient-centered approach to the care of patients with migraine in order to improve outcomes, patient satisfaction, and treatment adherence.

    The following learning objectives pertain only to those requesting CNE or CPE credit:

    • Identify clinical features, symptoms, and key diagnostic criteria in the differential diagnosis of migraine.
    • Explain safety and efficacy data supporting the role of agents that target CGRP in the prevention and management of migraine.
    • Describe a patient-centered approach to the care of patients with migraine in order to improve outcomes, patient satisfaction, and treatment adherence.

    Financial Support

    This activity is supported by an edu]]>

    CMEO Webcast

    Premiere Date: Friday, May 18, 2018

    This activity offers CE credit for:

    1. Physicians (CME)
    2. Nurses (CNE)
    3. Pharmacists (ACPE)
    4. ABIM (ABIM)
    5. Other

    All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™

    Credit Expiration Date: Saturday, May 18, 2019

    Faculty

    Andrew C. Charles, MD Andrew C. Charles, MD
    Professor of Neurology
    Meyer and Renee Luskin Chair in Migraine and Headache Studies
    Director, Goldberg Migraine Program
    David Geffen School of Medicine, University of California, Los Angeles
    Los Angeles, CA
    Grace Forde, MD Grace Forde, MD
    Director of Neurological Services
    North American Partners in Pain Management, LLP
    Lake Success, NY

    Statement of Need

    Migraine is a debilitating condition with profound effects on individuals’ quality of life, accounting for five to nine million primary care visits each year. It is estimated that 38% of sufferers could benefit from preventative treatment, but few are currently using them nor are their healthcare providers discussing these options with them. Consequently, there is great interest in emerging data about calcitonin gene-related peptide (CGRP) agents as novel options for migraine prevention and the benefits they may provide to patients.

    In this CME Outfitters recorded symposium, expert faculty discuss the evidence for new agents, share strategies to address migraine prophylaxis, and translate evidence to real-world clinical practice utilizing case-based learning, which will optimize changes in practice for healthcare providers.

    Learning Objectives

    At the end of this CE activity, participants should be able to:

    • Apply knowledge of clinical features, symptoms, and key diagnostic criteria in the differential diagnosis of migraine.
    • Assess safety and efficacy data supporting the role of agents that target CGRP in the prevention and management of migraine.
    • Employ a patient-centered approach to the care of patients with migraine in order to improve outcomes, patient satisfaction, and treatment adherence.

    The following learning objectives pertain only to those requesting CNE or CPE credit:

    • Identify clinical features, symptoms, and key diagnostic criteria in the differential diagnosis of migraine.
    • Explain safety and efficacy data supporting the role of agents that target CGRP in the prevention and management of migraine.
    • Describe a patient-centered approach to the care of patients with migraine in order to improve outcomes, patient satisfaction, and treatment adherence.

    Financial Support

    This activity is supported by an edu]]> clean No no no 1:18:59 Alex Perez HBV Is Not a Game: Or Is It? Optimizing Your Approach to HBV Management https://www.cmeoutfitters.com/hbv-is-not-a-game-or-is-it-optimizing-your-approach-to-hbv-management/ Fri, 01 Jun 2018 19:43:42 +0000 Alex Perez https://www.cmeoutfitters.com/?p=9274 full CMEO Webcast

    Premiere Date: Friday, May 18, 2018

    This activity offers CE credit for:

    1. Physicians (CME)
    2. Nurses (CNE)
    3. Pharmacists (ACPE)
    4. ABIM (ABIM)
    5. Other

    All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™

    Credit Expiration Date: Saturday, May 18, 2019

    Faculty

     

    Joseph Ahn, MD, MS, FAASLD, FACG, AGAF Joseph Ahn, MD, MS, FAASLD, FACG, AGAF
    Associate Professor of Medicine
    Director of Clinical Hepatology
    Oregon Health & Science University
    Portland, OR

     

    Amy Shen Tang, MD Amy Shen Tang, MD
    Hepatitis B Program Director
    Charles B. Wang Community Health Center
    New York, NY

     

    Statement of Need

    Missed opportunities, new challenges, a growing threat. Compared to 2014, cases of acute HBV infection increased 20.7% in 2015, fueled by the opioid epidemic which accounted for 59.4% of cases. 1,000 babies are infected each year through mother to child transmission. Barriers to vaccination, screening, and treatment – from providers and patients – can be broken down by best practice strategies driven by data. Is HBV a game? No, but that doesn’t mean learning best practices strategies can’t be.

    Join our expert faculty for this interactive CME Outfitters recorded symposium with its goal of improving confidence to make practice changes that will result in improved screening, evaluation, treatment, and monitoring of individuals infected with chronic HBV. Test your knowledge of HBV along the way and see how you answer compared to the live audience from this symposium.

    Learning Objectives

    At the end of this CE activity, participants should be able to:

    • In at-risk populations, document that appropriate patients have been screened for HBV in alignment with the best practice advice of the new ACP clinical guidelines.
    • Initiate antiviral therapy in patients with immune-active chronic hepatitis B (CHB) aligned to AASLD and EASL recommendations.
    • Establish regular monitoring protocols for patients with CHB infection to prevent reactivation and surveil for HCC.

    The following learning objectives pertain only to those requesting CNE or CPE credit:

    • Describe ACP clinical guidelines for screening appropriate at-risk patient populations for HBV and how to properly document.
    • Summarize antiviral therapy for patients with immune-active chronic hepatitis B (CHB) aligned to AASLD and EASL recommendations.
    • Explain regular monitoring protocols for patients with CHB infection to prevent reactivation and surveil for HCC.

    Financial Support

    Supported by an educational grant from Gilead Sciences, Inc.

    Target Audience

    Primary care physicians, internists, gastroenterologists, physician assistants, nurse practitioners, nurses, and pharmacists who treat patients with HBV.

    Credit Information

    CME Credit (Physicians):
    CME Outfitters, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    CME Outfitters, LLC designates this enduring material for a maximum of 1 AMA PRA Category 1 Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    CNE Credit (Nurses):
    Provider approved by the California Board of Registered Nursing, Provider Number CEP 15510, for 1.0 contact hours

    Note to Nurse Practitioners and Clinical Nurse Specialists: the content of this activity pertains to pharmacology. Earn up to 1 contact hours of pharmacotherapeutic contact hours.

    Note to Nurse Practitioners: Nurse practitioners can apply for AMA PRA Category 1 CreditTMthrough the American Academy of Nurse Practitioners (AANP). AANP will accept AMA PRA Category 1 CreditTM from organizations accredited by the Accreditation Council for Continuing Medical Education. Nurse practitioners can also apply for credit through their state boards.

    CPE Credit (Pharmacists):
    ACPECME Outfitters, LLC, is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. 1 contact hours (0.10 CEUs) Universal Activity Number:
    Enduring: 0376-0000-18-008-H01-P

    Type: Knowledge-based

    ABIM/MOC Credit:
    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    Learning Formats
    Enduring material

    Note to Physician Assistants: AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 CreditTM from organizations accredited by the Accreditation Council for Continuing Medical Education.

    Post-tests, credit request forms, and activity evaluations must be completed online at www.cmeoutfitters.com/TST27391 (requires free account activation), and participants can print their certificate or statement of credit immediately (75% pass rate required). This website supports all browsers except Internet Explorer for Mac. For complete technical requirements and privacy policy, visit www.neurosciencecme.com/technical.asp.

    Disclosure Declaration

    It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

    Dr. Ahn reports that he is an advisory board member of Gilead.

    Dr. Tang has no disclosures to report.

    Jeffrey Helfand, DO, MS (peer reviewer) has no disclosures to report.

    Mae Ochoa, RPh (peer reviewer) has no disclosures to report.

    Kashemi D. Rorie, PhD (planning committee) has no disclosures to report.

    Sharon Tordoff (planning committee) has no disclosures to report.

    Disclosures were obtained fro the CME Outfitters, LLC staff: No disclosures to report.

    Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.

    Questions about this activity? Call us at 877.CME.PROS(877.263.7767).

    This document was last modified on: 06/01/2018 15:36:27

    MMV-077-051818-47

    ]]> CMEO Webcast

    Premiere Date: Friday, May 18, 2018

    This activity offers CE credit for:

    1. Physicians (CME)
    2. Nurses (CNE)
    3. Pharmacists (ACPE)
    4. ABIM (ABIM)
    5. Other

    All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™

    Credit Expiration Date: Saturday, May 18, 2019

    Faculty

     

    Joseph Ahn, MD, MS, FAASLD, FACG, AGAF Joseph Ahn, MD, MS, FAASLD, FACG, AGAF
    Associate Professor of Medicine
    Director of Clinical Hepatology
    Oregon Health & Science University
    Portland, OR

     

    Amy Shen Tang, MD Amy Shen Tang, MD
    Hepatitis B Program Director
    Charles B. Wang Community Health Center
    New York, NY

     

    Statement of Need

    Missed opportunities, new challenges, a growing threat. Compared to 2014, cases of acute HBV infection increased 20.7% in 2015, fueled by the opioid epidemic which accounted for 59.4% of cases. 1,000 babies are infected each year through mother to child transmission. Barriers to vaccination, screening, and treatment – from providers and patients – can be broken down by best practice strategies driven by data. Is HBV a game? No, but that doesn’t mean learning best practices strategies can’t be.

    Join our expert faculty for this interactive CME Outfitters recorded symposium with its goal of improving confidence to make practice changes that will result in improved screening, evaluation, treatment, and monitoring of individuals infected with chronic HBV. Test your knowledge of HBV along the way and see how you answer compared to the live audience from this symposium.

    Learning Objectives

    At the end of this CE activity, participants should be able to:

    • In at-risk populations, document that appropriate patients have been screened for HBV in alignment with the best practice advice of the new ACP clinical guidelines.
    • Initiate antiviral therapy in patients with immune-active chronic hepatitis B (CHB) aligned to AASLD and EASL recommendations.
    • Establish regular monitoring protocols for patients with CHB infection to prevent reactivation and surveil for HCC.

    The following learning objectives pertain only to those requesting CNE or CPE credit:

    • Describe ACP clinical guidelines for screening appropriate at-risk patient populations for HBV and how to properly document.
    • Summarize antiviral therapy for patients with immune-active chronic hepatitis B (CHB) aligned to AASLD and EASL recommendations.
    • Explain regular monitoring protocols for patients with CHB infection to prevent reactivation and surveil for HCC.

    Financial Support

    Supported by an educational grant from Gilead Sciences, Inc.

    CMEO Webcast

    Premiere Date: Friday, May 18, 2018

    This activity offers CE credit for:

    1. Physicians (CME)
    2. Nurses (CNE)
    3. Pharmacists (ACPE)
    4. ABIM (ABIM)
    5. Other

    All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™

    Credit Expiration Date: Saturday, May 18, 2019

    Faculty

     

    Joseph Ahn, MD, MS, FAASLD, FACG, AGAF Joseph Ahn, MD, MS, FAASLD, FACG, AGAF
    Associate Professor of Medicine
    Director of Clinical Hepatology
    Oregon Health & Science University
    Portland, OR

     

    Amy Shen Tang, MD Amy Shen Tang, MD
    Hepatitis B Program Director
    Charles B. Wang Community Health Center
    New York, NY

     

    Statement of Need

    Missed opportunities, new challenges, a growing threat. Compared to 2014, cases of acute HBV infection increased 20.7% in 2015, fueled by the opioid epidemic which accounted for 59.4% of cases. 1,000 babies are infected each year through mother to child transmission. Barriers to vaccination, screening, and treatment – from providers and patients – can be broken down by best practice strategies driven by data. Is HBV a game? No, but that doesn’t mean learning best practices strategies can’t be.

    Join our expert faculty for this interactive CME Outfitters recorded symposium with its goal of improving confidence to make practice changes that will result in improved screening, evaluation, treatment, and monitoring of individuals infected with chronic HBV. Test your knowledge of HBV along the way and see how you answer compared to the live audience from this symposium.

    Learning Objectives

    At the end of this CE activity, participants should be able to:

    • In at-risk populations, document that appropriate patients have been screened for HBV in alignment with the best practice advice of the new ACP clinical guidelines.
    • Initiate antiviral therapy in patients with immune-active chronic hepatitis B (CHB) aligned to AASLD and EASL recommendations.
    • Establish regular monitoring protocols for patients with CHB infection to prevent reactivation and surveil for HCC.

    The following learning objectives pertain only to those requesting CNE or CPE credit:

    • Describe ACP clinical guidelines for screening appropriate at-risk patient populations for HBV and how to properly document.
    • Summarize antiviral therapy for patients with immune-active chronic hepatitis B (CHB) aligned to AASLD and EASL recommendations.
    • Explain regular monitoring protocols for patients with CHB infection to prevent reactivation and surveil for HCC.

    Financial Support

    Supported by an educational grant from Gilead Sciences, Inc.

    clean No no no 0:00 Alex Perez Fact or Fiction? Sorting Out Common Misconceptions About Ulcerative Colitis to Improve Patient Care https://www.cmeoutfitters.com/fact-or-fiction-sorting-out-common-misconceptions-about-ulcerative-colitis-to-improve-patient-care/ Mon, 26 Feb 2018 10:06:46 +0000 CME Outfitters, LLC https://www.cmeoutfitters.com/?p=8397 full .content-image {display: none;} .single-content-title {display: none;}

    Click here for activity details, credit information, and faculty bios!

    Click Here to Collect Credit

    ]]> .content-image {display: none;} .single-content-title {display: none;}

    Click here for activity details, credit information, and faculty bios!

    Click Here to Collect Credit

    ]]>
    .content-image {display: none;} .single-content-title {display: none;}

    Click here for activity details, credit information, and faculty bios!

    Click Here to Collect Credit

    ]]>
    clean No no no 1:06:30 CME Outfitters, LLC Managing Patients with Psoriasis and Comorbidities: Cases, Evidence and Action Plans https://www.cmeoutfitters.com/managing-patients-with-psoriasis-and-comorbidities-cases-evidence-and-action-plans/ Sat, 03 Feb 2018 05:47:31 +0000 CME Outfitters, LLC http://www.cmeoutfitters.com/?p=8062 Click here for activity details, credit information, and faculty bios!

    Click Here to Collect Credit

    ]]>
    Click here for activity details, credit information, and faculty bios!

    Click Here to Collect Credit

    ]]>
    Click here for activity details, credit information, and faculty bios!

    Click Here to Collect Credit

    ]]>
    clean No no no 51:56 CME Outfitters, LLC
    An Evolving Treatment Landscape for Inflammatory Disease: Debating Interchangeability, Efficacy, and Safety of Biosimilars https://www.cmeoutfitters.com/an-evolving-treatment-landscape-for-inflammatory-disease-debating-interchangeability-efficacy-and-safety-of-biosimilars-2/ Sun, 27 Aug 2017 12:52:31 +0000 CME Outfitters, LLC http://www.cmeoutfitters.com/?p=8006 full Click here for activity details, credit information, and faculty bios!

    Click Here to Collect Credit

    ]]>
    Click here for activity details, credit information, and faculty bios!

    Click Here to Collect Credit

    ]]>
    Click here for activity details, credit information, and faculty bios!

    Click Here to Collect Credit

    ]]>
    clean No no no 1:25:18 CME Outfitters, LLC
    Best Practices for Managing Cognitive Dysfunction in Schizophrenia: A Patient Case Consult https://www.cmeoutfitters.com/best-practices-for-managing-cognitive-dysfunction-in-schizophrenia-a-patient-case-consult/ Fri, 25 Aug 2017 12:36:31 +0000 CME Outfitters, LLC http://www.cmeoutfitters.com/?p=7999 Click here for activity details, credit information, and faculty bios!

    Click Here to Collect Credit

    ]]>
    Click here for activity details, credit information, and faculty bios!

    Click Here to Collect Credit

    ]]>
    Click here for activity details, credit information, and faculty bios!

    Click Here to Collect Credit

    ]]>
    clean No no no 22:36 CME Outfitters, LLC
    Clinical Pearls for Achieving Functional Recovery in Schizophrenia: A Patient Case Consult https://www.cmeoutfitters.com/clinical-pearls-for-achieving-functional-recovery-in-schizophrenia-a-patient-case-consult/ Thu, 24 Aug 2017 12:32:53 +0000 CME Outfitters, LLC http://www.cmeoutfitters.com/?p=7996 Click here for activity details, credit information, and faculty bios!

    Click Here to Collect Credit

    ]]>
    Click here for activity details, credit information, and faculty bios!

    Click Here to Collect Credit

    ]]>
    Click here for activity details, credit information, and faculty bios!

    Click Here to Collect Credit

    ]]>
    clean No no no 26:44 CME Outfitters, LLC
    Managing Residual Symptoms in Bipolar Disorder: A Patient Case Consult https://www.cmeoutfitters.com/managing-residual-symptoms-in-bipolar-disorder-a-patient-case-consult/ Fri, 18 Aug 2017 12:50:55 +0000 CME Outfitters, LLC http://www.cmeoutfitters.com/?p=6861 Evidence suggests that the symptoms of bipolar disorder are recurrent and can worsen over repeated relapses. Even patients who follow treatment advice are still at a high relapse risk. Repeated relapses and rehospitalizations are main distresses, indicating a “downward spiral” of declined functioning and greater dependency on support and care by others.The goal is to effectively manage symptoms and prevent relapse. In this CME Outfitters patient case and expert consult Q & A session, Dr. Roger McIntyre goes in-depth with the case study answering questions while offering evidence, guidelines, and quality measures to manage residual symptoms and avoid relapse in patients with bipolar disorder.

    ]]>
    Evidence suggests that the symptoms of bipolar disorder are recurrent and can worsen over repeated relapses. Even patients who follow treatment advice are still at a high relapse risk. Repeated relapses and rehospitalizations are main distresses, indicating a “downward spiral” of declined functioning and greater dependency on support and care by others.The goal is to effectively manage symptoms and prevent relapse. In this CME Outfitters patient case and expert consult Q & A session, Dr. Roger McIntyre goes in-depth with the case study answering questions while offering evidence, guidelines, and quality measures to manage residual symptoms and avoid relapse in patients with bipolar disorder.

    ]]>
    Evidence suggests that the symptoms of bipolar disorder are recurrent and can worsen over repeated relapses. Even patients who follow treatment advice are still at a high relapse risk. Repeated relapses and rehospitalizations are main distresses, indicating a “downward spiral” of declined functioning and greater dependency on support and care by others.The goal is to effectively manage symptoms and prevent relapse. In this CME Outfitters patient case and expert consult Q & A session, Dr. Roger McIntyre goes in-depth with the case study answering questions while offering evidence, guidelines, and quality measures to manage residual symptoms and avoid relapse in patients with bipolar disorder.

    ]]>
    clean No no no 34:54 CME Outfitters, LLC
    Clinical Updates on Mixed Features in Bipolar Disorder: A Patient Case Consult https://www.cmeoutfitters.com/clinical-updates-on-mixed-features-in-bipolar-disorder-a-patient-case-consult/ Fri, 18 Aug 2017 12:49:38 +0000 CME Outfitters, LLC http://www.cmeoutfitters.com/?p=6859 Click here for activity details, credit information, and faculty bios!

    Click Here to Collect Credit

    ]]>
    Click here for activity details, credit information, and faculty bios!

    Click Here to Collect Credit

    ]]>
    Click here for activity details, credit information, and faculty bios!

    Click Here to Collect Credit

    ]]>
    clean No no no 35:26 CME Outfitters, LLC
    Debating Interchangeability, Efficacy, and Safety of Biosimilars in the Management of Inflammatory Diseases https://www.cmeoutfitters.com/debating-interchangeability-efficacy-and-safety-of-biosimilars-in-the-management-of-inflammatory-diseases/ Tue, 25 Jul 2017 12:39:54 +0000 CME Outfitters, LLC http://www.cmeoutfitters.com/?p=8002 Click here for activity details, credit information, and faculty bios!

    Click Here to Collect Credit

    ]]>
    Click here for activity details, credit information, and faculty bios!

    Click Here to Collect Credit

    ]]>
    Click here for activity details, credit information, and faculty bios!

    Click Here to Collect Credit

    ]]>
    clean No no no 22:34 CME Outfitters, LLC
    Advancing the Treatment of Focal Seizures in the Intensive Care Setting: A Multidisciplinary Team Approach https://www.cmeoutfitters.com/advancing-the-treatment-of-focal-seizures-in-the-intensive-care-setting-a-multidisciplinary-team-approach/ Wed, 28 Jun 2017 12:45:34 +0000 CME Outfitters, LLC http://www.cmeoutfitters.com/?p=6857 Click here for activity details, credit information, and faculty bios!

    Click Here to Collect Credit

    ]]>
    Click here for activity details, credit information, and faculty bios!

    Click Here to Collect Credit

    ]]>
    Click here for activity details, credit information, and faculty bios!

    Click Here to Collect Credit

    ]]>
    clean No no no 1:27:22 CME Outfitters, LLC
    Integrated Care Strategies to Address the Impact of Residual Symptoms on Functional Outcomes in MDD https://www.cmeoutfitters.com/mmv073pc/ Fri, 16 Jun 2017 21:45:46 +0000 CME Outfitters, LLC http://www.cmeoutfitters.com/?p=6358 MMV-073-061617-20 Click here for activity details, credit information, and faculty bios!

    Click Here to Collect Credit

    ]]>
    Click here for activity details, credit information, and faculty bios!

    Click Here to Collect Credit

    ]]>
    Click here for activity details, credit information, and faculty bios!

    Click Here to Collect Credit

    ]]>
    clean No no no 1:52:06 CME Outfitters, LLC
    The Immunosuppression Balancing Act: Preserving Long-Term Allograft Function for Optimal Patient Outcomes https://www.cmeoutfitters.com/podcast/mmv074pc/ Thu, 08 Jun 2017 14:55:21 +0000 CME Outfitters, LLC http://www.cmeoutfitters.com/?post_type=podcast&p=6112 MMV-074-060217-45 In this replay from a live CME Outfitters symposium, expert faculty guide learners through patient cases using an interactive infographic to explain the importance of initiating early targeted biologic therapy and provide evidence-based strategies to take action to achieve sustained remission and long-term clinical outcomes.

    This activity offers CE credit for:

    1. Physicians (CME)
    2. Nurses (CNE)
    3. Pharmacists (ACPE)
    4. Other

    All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™

    Credit Expiration Date: Friday, June 8, 2018

    Faculty

     

    Maria T. Abreu, MD Maria T. Abreu, MD (Moderator)
    Director, Crohn’s & Colitis Center
    Martin Kalser Chair in Gastroenterology
    Professor of Medicine
    Professor of Microbiology and Immunology
    University of Miami Miller School of Medicine
    Miami, FL

     

    Arthur A. Kornbluth, MD Arthur A. Kornbluth, MD
    Clinical Professor of Medicine
    Inflammatory Bowel Disease Center
    Henry D. Janowitz Division of Gastroenterology
    Mount Sinai School of Medicine
    New York, NY

     

    Miguel Regueiro, MD, FACP, FACG, AGAF Miguel Regueiro, MD, FACP, FACG, AGAF
    Professor of Medicine, Professor of Clinical and Translational Science
    University of Pittsburgh School of Medicine
    Associate Chief, Education
    Division of Gastroenterology, Hepatology, and Nutrition
    Clinical Medical Director of Inflmmatory Bowel Disease
    Senior Medical Lead of Specialty Medical Homes
    University of Pittsburgh Medical Center
    Pittsburgh, PA

     

    Statement of Need

    Ulcerative colitis (UC) is an inflammatory bowel disease with a progressive course characterized by exacerbations and remissions. Traditionally, the goals of therapy for UC have entailed resolution of clinical symptoms such as rectal bleeding, bloody diarrhea, abdominal cramps, pain, and fatigue. However, treatment goals for UC have evolved to a treat-to-target strategy with targets such as mucosal/endoscopic healing, histologic healing, or deep remission (i.e., clinical, biochemical, and endoscopic remission) with the objective of preventing structural damage and disability. Conventional therapies have not been uniformly effective in achieving these aims, necessitating augmentation with steroids and carrying adverse risk often requiring discontinuation.

    There has been an exponential growth in the pursuits of better targeted therapy to optimize IBD clinical outcomes. IBD therapies that explore new targets and inflammatory pathways are emerging to address the current treatment gaps observed with conventional and biologic therapies.

    In this CME Outfitters symposium, expert faculty will guide learners through patient cases using an interactive infographic to explain the importance of initiating early targeted biologic therapy and provide evidence-based strategies to take action to achieve sustained remission and long-term clinical outcomes.

    Learning Objectives

    At the end of this CE activity, participants should be able to:

    • Differentiate between disease activity and disease severity to drive treatment decisions in patients with UC.
    • Apply the unique risk/benefit profiles of different biologic therapies when making treatment decisions based on individual prognosis and severity of disease.
    • Utilize data from real-world studies on the use and effectiveness of biologic therapy for UC to initiate early, effective treatment for patients with UC.

    The following learning objectives pertain only to those requesting CNE credit:

    • Differentiate between disease activity and disease severity to drive treatment decisions in patients with UC.
    • Explain the unique risk/benefit profiles of different biologic therapies for making treatment decisions based on individual prognosis and severity of disease.
    • Describe data from real-world studies on the use and effectiveness of biologic therapy for UC to initiate early, effective treatment for patients with UC.

    Financial Support

    Supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc.

    Target Audience

    Physicians, physician assistants, nurse practitioners, pharmacists, and other healthcare providers treating patients with ulcerative colitis (UC).

    Credit Information

    CME Credit (Physicians):
    CME Outfitters, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    CME Outfitters, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    CNE Credit (Nurses):
    Provider approved by the California Board of Registered Nursing, Provider Number CEP 15510, for 1.5 contact hours

    Note to Nurse Practitioners and Clinical Nurse Specialists: the content of this activity pertains to pharmacology. Earn up to 1.5 contact hours of pharmacotherapeutic contact hours.

    Note to Nurse Practitioners: Nurse practitioners can apply for AMA PRA Category 1 CreditTMthrough the American Academy of Nurse Practitioners (AANP). AANP will accept AMA PRA Category 1 CreditTM from organizations accredited by the Accreditation Council for Continuing Medical Education

    CPE Credit (Pharmacists):
    ACPECME Outfitters, LLC, is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. 1.5 contact hours (0.15 CEUs) Universal Activity Number:

    Enduring: 0376-0000-17-011-H01-P

    Type: knowledge-based

    Note to Physician Assistants: AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 CreditTM from organizations accredited by the Accreditation Council for Continuing Medical Education.

    Post-tests, credit request forms, and activity evaluations must be completed online at www.cmeoutfitters.com/TST21246 (requires free account activation), and participants can print their certificate or statement of credit immediately (75% pass rate required). This website supports all browsers except Internet Explorer for Mac. For complete technical requirements and privacy policy, visit www.neurosciencecme.com/technical.asp.

    This program is not affiliated with Digestive Disease Week®.

    Disclosure Declaration

    It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

    Dr. Abreu reports she serves on the speaker’s bureau for AbbVie Inc.; and Imedex. She is a consultant for Eli Lilly and Company; Focus Medical Communications; Janssen Pharmaceuticals, Inc.; Pfizer Inc.; Prometheus Laboratories Inc.; Takeda Pharmaceuticals U.S.A., Inc.; Theravance Biopharma US, Inc.; and UCB, Inc. She serves on the scientific advisory board for AbbVie Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Celgene Corporation; Roche Pharmaceuticals; and Shire.

    Dr. Kornbluth reports that he receives research support from AbbVie Inc.; Bristol Myers Squibb Company; and Janssen Pharmaceuticals, Inc. He serves on the speakers bureau for AbbVie Inc.; Janssen Pharmaceuticals, Inc.; Millennium Pharmaceuticals, Inc./Takeda Pharmaceutical Company Limited; Prometheus Laboratories Inc.; and Santarus, Inc./Salix Pharmaceuticals. He serves on the advisory board for AbbVie Inc.; Janssen Pharmaceuticals, Inc.; Millennium Pharmaceuticals, Inc./Takeda Pharmaceutical Company Limited; and Prometheus Laboratories Inc.

    Dr. Reguiero reports that he is a consultant for AbbVie Inc.; Janssen Pharmaceuticals, Inc.; Pfizer Inc.; Takeda Pharmaceuticals U.S.A., Inc.; and UCB, Inc.

    Jeffrey Helfand, DO, MS (peer reviewer) has no disclosures to report.

    Kimberley Murray, RN, MS (peer reviewer) has no disclosures to report.

    Kashemi D. Rorie, PhD (planning committee) has no disclosures to report.

    Sharon Tordoff, CHCP (planning committee) has no disclosures to report.

    Jan Perez, CHCP (planning committee) has no disclosures to report.

    Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report.

    Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.

    Questions about this activity? Call us at 877.CME.PROS(877.263.7767).

    ]]>
    In this replay from a live CME Outfitters symposium, expert faculty guide learners through patient cases using an interactive infographic to explain the importance of initiating early targeted biologic therapy and provide evidence-based strategies to take action to achieve sustained remission and long-term clinical outcomes.

    This activity offers CE credit for:

    1. Physicians (CME)
    2. Nurses (CNE)
    3. Pharmacists (ACPE)
    4. Other

    All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™

    Credit Expiration Date: Friday, June 8, 2018

    Faculty

     

    Maria T. Abreu, MD Maria T. Abreu, MD (Moderator)
    Director, Crohn’s & Colitis Center
    Martin Kalser Chair in Gastroenterology
    Professor of Medicine
    Professor of Microbiology and Immunology
    University of Miami Miller School of Medicine
    Miami, FL

     

    Arthur A. Kornbluth, MD Arthur A. Kornbluth, MD
    Clinical Professor of Medicine
    Inflammatory Bowel Disease Center
    Henry D. Janowitz Division of Gastroenterology
    Mount Sinai School of Medicine
    New York, NY

     

    Miguel Regueiro, MD, FACP, FACG, AGAF Miguel Regueiro, MD, FACP, FACG, AGAF
    Professor of Medicine, Professor of Clinical and Translational Science
    University of Pittsburgh School of Medicine
    Associate Chief, Education
    Division of Gastroenterology, Hepatology, and Nutrition
    Clinical Medical Director of Inflmmatory Bowel Disease
    Senior Medical Lead of Specialty Medical Homes
    University of Pittsburgh Medical Center
    Pittsburgh, PA

     

    Statement of Need

    Ulcerative colitis (UC) is an inflammatory bowel disease with a progressive course characterized by exacerbations and remissions. Traditionally, the goals of therapy for UC have entailed resolution of clinical symptoms such as rectal bleeding, bloody diarrhea, abdominal cramps, pain, and fatigue. However, treatment goals for UC have evolved to a treat-to-target strategy with targets such as mucosal/endoscopic healing, histologic healing, or deep remission (i.e., clinical, biochemical, and endoscopic remission) with the objective of preventing structural damage and disability. Conventional therapies have not been uniformly effective in achieving these aims, necessitating augmentation with steroids and carrying adverse risk often requiring discontinuation.

    There has been an e]]> In this replay from a live CME Outfitters symposium, expert faculty guide learners through patient cases using an interactive infographic to explain the importance of initiating early targeted biologic therapy and provide evidence-based strategies to take action to achieve sustained remission and long-term clinical outcomes.

    This activity offers CE credit for:

    1. Physicians (CME)
    2. Nurses (CNE)
    3. Pharmacists (ACPE)
    4. Other

    All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™

    Credit Expiration Date: Friday, June 8, 2018

    Faculty

     

    Maria T. Abreu, MD Maria T. Abreu, MD (Moderator)
    Director, Crohn’s & Colitis Center
    Martin Kalser Chair in Gastroenterology
    Professor of Medicine
    Professor of Microbiology and Immunology
    University of Miami Miller School of Medicine
    Miami, FL

     

    Arthur A. Kornbluth, MD Arthur A. Kornbluth, MD
    Clinical Professor of Medicine
    Inflammatory Bowel Disease Center
    Henry D. Janowitz Division of Gastroenterology
    Mount Sinai School of Medicine
    New York, NY

     

    Miguel Regueiro, MD, FACP, FACG, AGAF Miguel Regueiro, MD, FACP, FACG, AGAF
    Professor of Medicine, Professor of Clinical and Translational Science
    University of Pittsburgh School of Medicine
    Associate Chief, Education
    Division of Gastroenterology, Hepatology, and Nutrition
    Clinical Medical Director of Inflmmatory Bowel Disease
    Senior Medical Lead of Specialty Medical Homes
    University of Pittsburgh Medical Center
    Pittsburgh, PA

     

    Statement of Need

    Ulcerative colitis (UC) is an inflammatory bowel disease with a progressive course characterized by exacerbations and remissions. Traditionally, the goals of therapy for UC have entailed resolution of clinical symptoms such as rectal bleeding, bloody diarrhea, abdominal cramps, pain, and fatigue. However, treatment goals for UC have evolved to a treat-to-target strategy with targets such as mucosal/endoscopic healing, histologic healing, or deep remission (i.e., clinical, biochemical, and endoscopic remission) with the objective of preventing structural damage and disability. Conventional therapies have not been uniformly effective in achieving these aims, necessitating augmentation with steroids and carrying adverse risk often requiring discontinuation.

    There has been an e]]> clean No no no 1:01:19 CME Outfitters, LLC Deep Remission, Top-Down Treatment Strategies and Real-World Data in Patients with UC: An Interactive and Innovative Case Series https://www.cmeoutfitters.com/mmv071pc/ Thu, 08 Jun 2017 14:41:11 +0000 CME Outfitters, LLC http://www.cmeoutfitters.com/?p=6107 MMV-071-060717-20 Click here for activity details, credit information, and faculty bios!

    Click Here to Collect Credit

    ]]> Click here for activity details, credit information, and faculty bios!

    Click Here to Collect Credit

    ]]>
    Click here for activity details, credit information, and faculty bios!

    Click Here to Collect Credit

    ]]>
    clean No no no 1:03:00 CME Outfitters, LLC
    New and Emerging Treatments and Treatment Guidelines in the Optimal Management of Moderate-to-Severe Psoriasis https://www.cmeoutfitters.com/sn081pc/ Tue, 16 May 2017 16:59:19 +0000 CME Outfitters, LLC http://www.cmeoutfitters.com/?p=6138 SN-081-042817-45 Click here for activity details, credit information, and faculty bios!

    Click Here to Collect Credit

    ]]>
    Click here for activity details, credit information, and faculty bios!

    Click Here to Collect Credit

    ]]>
    Click here for activity details, credit information, and faculty bios!

    Click Here to Collect Credit

    ]]>
    clean No no no 19:07 CME Outfitters, LLC
    Team-based Care, Patient Goals, and Engaging Patients to Improve Adherence and Satisfaction in Psoriasis https://www.cmeoutfitters.com/sn082pc/ Tue, 16 May 2017 16:39:58 +0000 CME Outfitters, LLC http://www.cmeoutfitters.com/?p=6130 SN-082-042817-45 Click here for activity details, credit information, and faculty bios!

    Click Here to Collect Credit

    ]]>
    Click here for activity details, credit information, and faculty bios!

    Click Here to Collect Credit

    ]]>
    Click here for activity details, credit information, and faculty bios!

    Click Here to Collect Credit

    ]]>
    clean No no no 16:40 CME Outfitters, LLC
    Developing Personalized Action Plans With Patients With Atopic Dermatitis https://www.cmeoutfitters.com/sn085pc/ Fri, 12 May 2017 17:05:35 +0000 CME Outfitters, LLC http://www.cmeoutfitters.com/?p=6142 SN-085-042817-53 Click here for activity details, credit information, and faculty bios!

    Click Here to Collect Credit

    ]]>
    Click here for activity details, credit information, and faculty bios!

    Click Here to Collect Credit

    ]]>
    Click here for activity details, credit information, and faculty bios!

    Click Here to Collect Credit

    ]]>
    clean No no no 9:40 CME Outfitters, LLC
    Evidence-Based Recommendations for Therapeutic Options and Newly Approved and Emerging Treatments in Atopic Dermatitis https://www.cmeoutfitters.com/sn084pc/ Fri, 12 May 2017 16:44:02 +0000 CME Outfitters, LLC http://www.cmeoutfitters.com/?p=6133 SN-084-0428-17-53 Click here for activity details, credit information, and faculty bios!

    Click Here to Collect Credit

    ]]>
    Click here for activity details, credit information, and faculty bios!

    Click Here to Collect Credit

    ]]>
    Click here for activity details, credit information, and faculty bios!

    Click Here to Collect Credit

    ]]>
    clean No no no 39:49 CME Outfitters, LLC
    A Framework for Successful Intrathecal Pain Management: New Insights from the 2017 Polyanalgesic Consensus Conference (PACC) Guidelines https://www.cmeoutfitters.com/mmv072pc/ Tue, 18 Apr 2017 21:00:32 +0000 CME Outfitters, LLC http://www.cmeoutfitters.com/?p=6180 MMV-072-041817 Click here for activity details, credit information, and faculty bios!

    Click Here to Collect Credit

    ]]>
    Click here for activity details, credit information, and faculty bios!

    Click Here to Collect Credit

    ]]>
    Click here for activity details, credit information, and faculty bios!

    Click Here to Collect Credit

    ]]>
    clean No no no 1:01:56 CME Outfitters, LLC
    The Latest on Key Nutrients, Dietary Supplementation, and Healthy Skin: A Virtual Reality Learning Experience https://www.cmeoutfitters.com/mmv070pc/ Fri, 07 Apr 2017 17:37:35 +0000 CME Outfitters, LLC http://www.cmeoutfitters.com/?p=6159 MMV-070-040717-02 Click here for activity details, credit information, and faculty bios!

    Click Here to Collect Credit

    ]]>
    Click here for activity details, credit information, and faculty bios!

    Click Here to Collect Credit

    ]]>
    Click here for activity details, credit information, and faculty bios!

    Click Here to Collect Credit

    ]]>
    clean No no no 1:20:09 CME Outfitters, LLC
    Mental Health 101: The Class No One Wants to Talk About https://www.cmeoutfitters.com/sn083pc/ Thu, 06 Apr 2017 20:49:27 +0000 CME Outfitters, LLC http://www.cmeoutfitters.com/?p=6177 SN-083-040617-55 Click here for activity details, credit information, and faculty bios!

    Click Here to Collect Credit

    ]]>
    Click here for activity details, credit information, and faculty bios!

    Click Here to Collect Credit

    ]]>
    Click here for activity details, credit information, and faculty bios!

    Click Here to Collect Credit

    ]]>
    clean No no no 19:39 CME Outfitters, LLC
    Collaborative Care Strategies for Reducing Hospital Readmissions in Patients with Heart Failure with Reduced Ejection Fraction https://www.cmeoutfitters.com/sn076pc/ Mon, 27 Mar 2017 18:17:13 +0000 CME Outfitters, LLC http://www.cmeoutfitters.com/?p=6163 SN-076-022417-90 Click here for activity details, credit information, and faculty bios!

    Click Here to Collect Credit

    ]]>
    Click here for activity details, credit information, and faculty bios!

    Click Here to Collect Credit

    ]]>
    Click here for activity details, credit information, and faculty bios!

    Click Here to Collect Credit

    ]]>
    clean No no no 25:17 CME Outfitters, LLC
    Selecting Appropriate Treatment for Patients With IPF: Applying Guidelines and Clinical Evidence https://www.cmeoutfitters.com/tv3092pc/ Thu, 02 Mar 2017 21:48:46 +0000 CME Outfitters, LLC http://www.cmeoutfitters.com/?p=6174 TV3-092-030217-90 Click here for activity details, credit information, and faculty bios!

    Click Here to Collect Credit

    ]]>
    Click here for activity details, credit information, and faculty bios!

    Click Here to Collect Credit

    ]]>
    Click here for activity details, credit information, and faculty bios!

    Click Here to Collect Credit

    ]]>
    clean No no no 19:01 CME Outfitters, LLC
    Working Together to Diagnose IPF: A Multidisciplinary Approach https://www.cmeoutfitters.com/tv2092pc/ Thu, 02 Mar 2017 21:36:15 +0000 CME Outfitters, LLC http://www.cmeoutfitters.com/?p=6170 TV2-092-030217-90 Click here for activity details, credit information, and faculty bios!

    Click Here to Collect Credit

    ]]>
    Click here for activity details, credit information, and faculty bios!

    Click Here to Collect Credit

    ]]>
    Click here for activity details, credit information, and faculty bios!

    Click Here to Collect Credit

    ]]>
    clean No no no 31:15 CME Outfitters, LLC
    Working Together to Diagnose IPF: Identifying the Signs and Symptoms https://www.cmeoutfitters.com/tv1092pc/ Thu, 02 Mar 2017 21:31:03 +0000 CME Outfitters, LLC http://www.cmeoutfitters.com/?p=6167 TV1-092-030217-90 Click here for activity details, credit information, and faculty bios!

    Click Here to Collect Credit

    ]]>
    Click here for activity details, credit information, and faculty bios!

    Click Here to Collect Credit

    ]]>
    Click here for activity details, credit information, and faculty bios!

    Click Here to Collect Credit

    ]]>
    clean No no no 19:50 CME Outfitters, LLC
    Integrating New Options Into Guideline-Directed Management of Heart Failure with Reduced Ejection Fraction https://www.cmeoutfitters.com/tv088pc/ Thu, 23 Feb 2017 22:03:58 +0000 CME Outfitters, LLC http://www.cmeoutfitters.com/?p=6184 TV-088-022317-90 Click here for activity details, credit information, and faculty bios!

    Click Here to Collect Credit

    ]]>
    Click here for activity details, credit information, and faculty bios!

    Click Here to Collect Credit

    ]]>
    Click here for activity details, credit information, and faculty bios!

    Click Here to Collect Credit

    ]]>
    clean No no no 1:26:03 CME Outfitters, LLC
    Coordinating Care to Improve Outcomes in Patients with Psoriatic Arthritis: Bridging Rheumatology and Dermatology https://www.cmeoutfitters.com/mmv068pc/ Fri, 17 Feb 2017 22:11:22 +0000 CME Outfitters, LLC http://www.cmeoutfitters.com/?p=6187 MMV-068-021717-45 Click here for activity details, credit information, and faculty bios!

    Click Here to Collect Credit

    ]]>
    Click here for activity details, credit information, and faculty bios!

    Click Here to Collect Credit

    ]]>
    Click here for activity details, credit information, and faculty bios!

    Click Here to Collect Credit

    ]]>
    clean No no no 59:04 CME Outfitters, LLC
    Bringing Health Care Providers Together to Diagnose and Treat Idiopathic Pulmonary Fibrosis https://www.cmeoutfitters.com/tv092pc/ Wed, 18 Jan 2017 22:21:22 +0000 CME Outfitters, LLC http://www.cmeoutfitters.com/?p=6190 TV-092-011817-90 Click here for activity details, credit information, and faculty bios!

    Click Here to Collect Credit

    ]]>
    Click here for activity details, credit information, and faculty bios!

    Click Here to Collect Credit

    ]]>
    Click here for activity details, credit information, and faculty bios!

    Click Here to Collect Credit

    ]]>
    clean No no no 1:23:03 CME Outfitters, LLC
    https://www.cmeoutfitters.com/sn071pc/ Fri, 30 Dec 2016 16:36:16 +0000 Tom Meyers http://www.cmeoutfitters.com/?p=6118 SN-071 Click here for activity details, credit information, and faculty bios!

    Click Here to Collect Credit

    This activity is supported by an educational grant from Lilly.

    ]]>
    Click here for activity details, credit information, and faculty bios!

    Click Here to Collect Credit

    This activity is supported by an educational grant from Lilly.

    ]]>
    Click here for activity details, credit information, and faculty bios!

    Click Here to Collect Credit

    This activity is supported by an educational grant from Lilly.

    ]]>
    clean No no no 4:34 Tom Meyers
    Treating the Full Spectrum of Narcolepsy: Improving Nighttime Symptoms to Enhance Daytime Quality of Life: A Moderated Discussion with the Experts and Q&A https://www.cmeoutfitters.com/treating-the-full-spectrum-of-narcolepsy-improving-nighttime-symptoms-to-enhance-daytime-quality-of-life-a-moderated-discussion-with-the-experts-and-qa/ Mon, 14 Nov 2016 11:28:47 +0000 CME Outfitters, LLC https://www.cmeoutfitters.com/?p=8422 SN-071 full Click here for activity details, credit information, and faculty bios!

    Click Here to Collect Credit

    ]]>
    Click here for activity details, credit information, and faculty bios!

    Click Here to Collect Credit

    ]]>
    Click here for activity details, credit information, and faculty bios!

    Click Here to Collect Credit

    ]]>
    clean No no no 26:02 CME Outfitters, LLC
    From Symptom Recognition to Narcolepsy Diagnosis: Shortening the Diagnostic Journey: A Moderated Discussion with the Experts and Q&A https://www.cmeoutfitters.com/from-symptom-recognition-to-narcolepsy-diagnosis-shortening-the-diagnostic-journey-a-moderated-discussion-with-the-experts-and-qa/ Mon, 14 Nov 2016 11:24:46 +0000 CME Outfitters, LLC https://www.cmeoutfitters.com/?p=8419 SN-071 full Click here for activity details, credit information, and faculty bios!

    Click Here to Collect Credit

    ]]>
    Click here for activity details, credit information, and faculty bios!

    Click Here to Collect Credit

    ]]>
    Click here for activity details, credit information, and faculty bios!

    Click Here to Collect Credit

    ]]>
    clean No no no 23:16 CME Outfitters, LLC
    Recognizing the Symptoms of Narcolepsy: Screening Your Sleepy Patient for Cataplexy: A Moderated Discussion with the Experts and Q&A https://www.cmeoutfitters.com/recognizing-the-symptoms-of-narcolepsy-screening-your-sleepy-patient-for-cataplexy-a-moderated-discussion-with-the-experts-and-qa/ Mon, 14 Nov 2016 11:20:24 +0000 CME Outfitters, LLC https://www.cmeoutfitters.com/?p=8416 SN-071 full Click here for activity details, credit information, and faculty bios!

    Click Here to Collect Credit

    ]]>
    Click here for activity details, credit information, and faculty bios!

    Click Here to Collect Credit

    ]]>
    Click here for activity details, credit information, and faculty bios!

    Click Here to Collect Credit

    ]]>
    clean No no no 26:43 CME Outfitters, LLC
    Treating to Target in Patients with Gout and Chronic Kidney Disease https://www.cmeoutfitters.com/tv090pc/ Tue, 01 Nov 2016 21:30:13 +0000 CME Outfitters, LLC http://www.cmeoutfitters.com/?p=6193 TV-090-110116-20 Audio responses from patient interviews will be at the center of the discussion in this CME Outfitters Live and On Demand podcast as expert faculty discuss best practices, effective patient communication, and treatment options for patients with hyperuricemia or gout and chronic kidney disease.

     

    This activity offers CE credit for:

    1. Physicians (CME)
    2. Nurses (CNE)
    3. Pharmacists (ACPE)
    4. Nurse Practitioners (AANP)
    5. Physician Assistants (AAPA)
    6. Other

    All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™

    Credit Expiration Date: Wednesday, November 1, 2017

    Faculty

     

    Allan Gibofsky, MD, JD, MACR, FACP, FCLM Allan Gibofsky, MD, JD, MACR, FACP, FCLM
    Professor of Medicine, Healthcare Policy and Research
    Weill Medical College of Cornell University
    Attending Rheumatologist
    Hospital for Special Surgery
    New York, NY

     

    Robin K. Dore, MD Robin K. Dore, MD
    Clinical Professor of Medicine
    David Geffen School of Medicine at UCLA
    Los Angeles, CA

     

    Eva Hardy, MS, RN, ANP-BC Eva Hardy, MS, RN, ANP-BC
    Department of General Orthopedic Surgery
    Presbyterian Health Services
    Presbyterian Rust Medical Center
    Rio Rancho, NM

     

    Statement of Need

    Gout is the most common form of inflammatory arthritis in the United States.1 Hyperuricemia/gout in patients with CKD constitutes a significant burden for patients and society. Patients who are not managed adequately experience painful gout attacks, loss of function and productivity, and may develop long-term complications. The economic burden is also increased from patient utilization of prescription medication use, emergency room visits, and hospitalizations from gout or its serious complications.

    Despite effective treatment for prevention, acute attacks, and tophi, and the availability of published treatment guidelines, there are significant gaps in treatment, patient communication, and clinical and economic outcomes for patients with hyperuricemia/gout and chronic kidney disease (CKD).

    Audio responses from patient interviews will be at the center of the discussion in this CME Outfitters Live and On Demand as expert faculty discuss best practices, effective patient communication, and treatment options for patients with hyperuricemia or gout and chronic kidney disease.

    Reference:
    Mandell B, Keenan R. So you think you know gout? Fresh perspectives on hyperuricemia for today’s complicated patients. Medscape Website. http://www.medscape.org/viewarticle/837667. Published January 30, 2015. Accessed October 16, 2016.

    Learning Objectives

    At the end of this CE activity, participants should be able to:

    • Execute strategies to enhance an understanding of the association among hyperuricemia, gout, and CKD.
    • Utilize educational resources in shared decision-making discussions with patients to promote medication adherence and optimize outcomes.
    • Implement strategies to achieve optimal clinical and economic outcomes in patients with hyperuricemia or gout and CKD.

    The following learning objectives pertain only to those requesting CNE credit:

    • Identify strategies to enhance an understanding of the association among hyperuricemia, gout, and CKD.
    • Describe ways to engage patients with gout and CKD in discussions of gout education and medication adherence.
    • Assess strategies to achieve optimal clinical and economic outcomes in patients with hyperuricemia or gout and CKD.

    Financial Support

    Supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc.

    Target Audience

    Physicians, physician assistants, nurse practitioners, pharmacists, and other healthcare professionals with an interest in gout and chronic kidney disease.

    Credit Information

    CME Credit (Physicians):
    CME Outfitters, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    CME Outfitters, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    AANP Credit (American Association of Nurse Practitioners):
    This program is approved for 1.5 contact hour(s) of continuing education by the American Association of Nurse Practitioners. Program ID 16102399. This program was planned in accordance with AANP CE Standards and Policies.(Effective 12/9/16)

    AAPA Credit (American Academy of PA’s):
     This program has been reviewed and is approved for a maximum of 1.5 hours of AAPA Category 1 CME credit by the Physician Assistant Review Panel. Approval is valid for one year from the issue date of 11/22/2016. Participants may submit the post-test at any time during that period.

    This program was planned in accordance with AAPA’s CME Standards for Enduring Material Programs and for Commercial Support of Enduring Material Programs.

    CNE Credit (Nurses):
    Provider approved by the California Board of Registered Nursing, Provider Number CEP 15510, for 1.5 contact hours.

    Note to Nurse Practitioners and Clinical Nurse Specialists: the content of this activity pertains to pharmacology. Earn up to 1.5 contact hours of pharmacotherapeutic contact hours.

    CPE Credit (Pharmacists):
    ACPECME Outfitters, LLC, is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. 1.5 contact hours (0.15 CEUs)

    Universal Activity Number:
    0376-0000-16-028-L01-P (live program)
    0376-0000-16-028-H01-P (enduring program)

    Type: knowledge-based

    Post-tests, credit request forms, and activity evaluations must be completed online at www.cmeoutfitters.com/TST20163 (requires free account activation), and participants can print their certificate or statement of credit immediately (75% pass rate required). This website supports all browsers except Internet Explorer for Mac. For complete technical requirements and privacy policy, visit www.neurosciencecme.com/technical.asp.

    Disclosure Declaration

    It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

    Robin K. Dore, MD has disclosed she received research support from AbbVie Inc.; Amgen Inc.; Eli Lilly and Company; Pfizer Inc. and UCB, Inc. She serves on speakers bureau for AbbVie Inc.; Amgen Inc.; Eli Lilly and Company; Pfizer Inc.; Sanofi-Genzyme; Takeda Pharmaceuticals U.S.A., Inc. and UCB, Inc. She serves as consultant for AbbVie Inc.; Amgen Inc.; Eli Lilly and Company and Sanofi-Genzyme.

    Allan Gibofsky, MD, JD, MACR, FACP, FCLM has disclosed he serves on speakers bureau for AbbVie Inc.; Amgen Inc.; Novartis Pharmaceuticals Corporation; Pfizer Inc. and UCB, Inc. He serves as consultant for AbbVie; Amgen Inc.; Eli Lilly and Company; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Regeneron Pharmaceuticals, Inc. and Takeda Pharmaceuticals U.S.A., Inc. He is a stock shareholder in AbbVie Inc.; Amgen Inc.; GlaxoSmithKline; Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Pfizer Inc. and Regeneron Pharmaceuticals, Inc.

    Eva Hardy, MS, RN, ANP-BC has no disclosures to report

    Jeffrey Helfand, DO, MD (peer reviewer) has no disclosures to report.

    Scott Richards, PhD, PA-C, DFAAPA (peer reviewer) has no disclosures to report.

    Sharon Tordoff, CHCP (planning committee) has no disclosures to report.

    Jan Perez, CHCP (planning committee) has no disclosures to report

    Daniela V. DiBiase, MS (planning committee) has no disclosures to report

    Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report.

    Unlabeled Use Disclosure

    Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.

    CME Outfitters, LLC, the faculty, and Takeda Pharmaceuticals U.S.A., Inc. do not endorse the use of any product outside of the FDA labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use.

    Questions about this activity? Call us at 877.CME.PROS(877.263.7767).

    ]]>
    Audio responses from patient interviews will be at the center of the discussion in this CME Outfitters Live and On Demand podcast as expert faculty discuss best practices, effective patient communication, and treatment options for patients with hyperuricemia or gout and chronic kidney disease.

     

    This activity offers CE credit for:

    1. Physicians (CME)
    2. Nurses (CNE)
    3. Pharmacists (ACPE)
    4. Nurse Practitioners (AANP)
    5. Physician Assistants (AAPA)
    6. Other

    All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™

    Credit Expiration Date: Wednesday, November 1, 2017

    Faculty

     

    Allan Gibofsky, MD, JD, MACR, FACP, FCLM Allan Gibofsky, MD, JD, MACR, FACP, FCLM
    Professor of Medicine, Healthcare Policy and Research
    Weill Medical College of Cornell University
    Attending Rheumatologist
    Hospital for Special Surgery
    New York, NY

     

    Robin K. Dore, MD Robin K. Dore, MD
    Clinical Professor of Medicine
    David Geffen School of Medicine at UCLA
    Los Angeles, CA

     

    Eva Hardy, MS, RN, ANP-BC Eva Hardy, MS, RN, ANP-BC
    Department of General Orthopedic Surgery
    Presbyterian Health Services
    Presbyterian Rust Medical Center
    Rio Rancho, NM

     

    Statement of Need

    Gout is the most common form of inflammatory arthritis in the United States.1 Hyperuricemia/gout in patients with CKD constitutes a significant burden for patients and society. Patients who are not managed adequately experience painful gout attacks, loss of function and productivity, and may develop long-term complications. The economic burden is also increased from patient utilization of prescription medication use, emergency room visits, and hospitalizations from gout or its serious complications.

    Despite effective treatment for prevention, acute attacks, and tophi, and the availability of published treatment guidelines, there are significant gaps in treatment, patient communication, and clinical and economic outcomes for patients with hyperuricemia/gout and chronic kidney disease (CKD).

    Audio responses from patient interviews will be at the center of the discussion in this CME Outfitters Live and On Demand as expert faculty discuss best practices, effective patient communication, and treatment options for patients with hyperuricemia or gout and chronic kidney disease.

    <]]>
    Audio responses from patient interviews will be at the center of the discussion in this CME Outfitters Live and On Demand podcast as expert faculty discuss best practices, effective patient communication, and treatment options for patients with hyperuricemia or gout and chronic kidney disease.

     

    This activity offers CE credit for:

    1. Physicians (CME)
    2. Nurses (CNE)
    3. Pharmacists (ACPE)
    4. Nurse Practitioners (AANP)
    5. Physician Assistants (AAPA)
    6. Other

    All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™

    Credit Expiration Date: Wednesday, November 1, 2017

    Faculty

     

    Allan Gibofsky, MD, JD, MACR, FACP, FCLM Allan Gibofsky, MD, JD, MACR, FACP, FCLM
    Professor of Medicine, Healthcare Policy and Research
    Weill Medical College of Cornell University
    Attending Rheumatologist
    Hospital for Special Surgery
    New York, NY

     

    Robin K. Dore, MD Robin K. Dore, MD
    Clinical Professor of Medicine
    David Geffen School of Medicine at UCLA
    Los Angeles, CA

     

    Eva Hardy, MS, RN, ANP-BC Eva Hardy, MS, RN, ANP-BC
    Department of General Orthopedic Surgery
    Presbyterian Health Services
    Presbyterian Rust Medical Center
    Rio Rancho, NM

     

    Statement of Need

    Gout is the most common form of inflammatory arthritis in the United States.1 Hyperuricemia/gout in patients with CKD constitutes a significant burden for patients and society. Patients who are not managed adequately experience painful gout attacks, loss of function and productivity, and may develop long-term complications. The economic burden is also increased from patient utilization of prescription medication use, emergency room visits, and hospitalizations from gout or its serious complications.

    Despite effective treatment for prevention, acute attacks, and tophi, and the availability of published treatment guidelines, there are significant gaps in treatment, patient communication, and clinical and economic outcomes for patients with hyperuricemia/gout and chronic kidney disease (CKD).

    Audio responses from patient interviews will be at the center of the discussion in this CME Outfitters Live and On Demand as expert faculty discuss best practices, effective patient communication, and treatment options for patients with hyperuricemia or gout and chronic kidney disease.

    <]]>
    clean No no no 1:26:31 CME Outfitters, LLC
    Optimizing Care in IBD: Evidence, Cost, and Patient Goals https://www.cmeoutfitters.com/podcast/tv089pc/ Thu, 08 Sep 2016 13:10:16 +0000 CME Outfitters, LLC http://www.cmeoutfitters.com/?post_type=podcast&p=5402 TV-090-110116-20 Tune into this CME Outfitters On Demand activity as expert faculty will highlight the clinical progression of IBD and its impact on patient outcomes and treatment choices. The panel will address risk/benefit of treatment options, direct and indirect cost, and clinical considerations critical to informed decisions about treatment plans for individuals with IBD.

     

    This activity offers CE credit for:

    1. Physicians (CME)
    2. Nurses (CNE)
    3. Pharmacists (ACPE)
    4. Other

    All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™

    Credit Expiration Date: Friday, September 8, 2017

    Faculty

     

    Russell D. Cohen, MD, FACG, AGAF Russell D. Cohen, MD, FACG, AGAF
    Professor of Medicine, Pritzker School of Medicine
    Director, Inflammatory Bowel Disease Center
    Co-Director, Advanced IBD Fellowship Program
    University of Chicago Medicine
    Chicago, IL

     

    Huda-Marie Kandah, PharmD, BCPS Huda-Marie Kandah, PharmD, BCPS
    Clinical Coordinator, Specialty Pharmacy
    University of Chicago Medicine
    Chicago, IL

     

    Thomas A. Ullman, MD Thomas A. Ullman, MD
    Chief Medical Officer
    Mount Sinai Doctors Faculty Practice
    Senior Associate Dean for Clinical Affairs
    Icahn School of Medicine at Mount Sinai
    New York, NY

     

    Statement of Need

    Inflammatory bowel diseases (IBD)–Crohn’s disease (CD), and ulcerative colitis (UC) –have low remission rates, indicating that conventional treatment approaches are suboptimal for patients. Treatment goals in IBD have evolving beyond symptomatic relief to sustained remission and mucosal healing to prevent continued damage, disability, and surgical intervention.

    It is critical to identify patients at high risk for colectomy and plan their treatment appropriately with earlier, more aggressive utilization of immunomodulators and biologic agents; a step-down approach, in order to optimize mucosal healing and remission before permanent structural damage has occurred. Rising costs of specialty drugs are on the mind of specialty and managed care pharmacy directors, patients, and practicing physicians. When reviewing annual cost of care associated with IBD treatment, it is important to evaluate both direct costs (e.g. medication, surgery, hospitalization, lab tests) and indirect costs (e.g. quality of life, work/school productivity, absenteeism, disability).

    In this CME Outfitters Live and On Demand, expert faculty will highlight the clinical progression of IBD and its impact on patient outcomes and treatment choices. The panel will address risk/benefit of treatment options, direct and indirect cost, and clinical considerations critical to informed decisions about treatment plans for individuals with IBD.

    Learning Objectives

    At the end of this CE activity, participants should be able to:

    • Recognize the medical and financial cost of inadequately treated IBD.
    • Evaluate a step-down versus step-up treatment approach in appropriate patients with IBD to achieve remission and decrease health care utilization.

    The following learning objectives pertain only to those requesting CNE credit:

    • Identify the medical and financial cost if inadequately treated IBD.
    • Describe a step-down versus step-up treatment approach in appropriate patients with IBD to achieve remission and decrease health care utilization.

    Financial Support

    Supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc.

    Credit Information

    CME Credit (Physicians):
    CME Outfitters, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    CME Outfitters, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    CNE Credit (Nurses):
    Provider approved by the California Board of Registered Nursing, Provider Number CEP 15510, for 1.5 contact hours.

    CPE Credit (Pharmacists):
    ACPECME Outfitters, LLC, is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. 1.5 contact hours (0.15 CEUs)
    Universal Activity Number: 0376-0000-16-020-L01-P (live programs)
    0376-0000-16-020-H01-P (recorded programs)
    Activity Type: knowledge-based

    Post-tests, credit request forms, and activity evaluations must be completed online at www.cmeoutfitters.com/TST20151 (requires free account activation), and participants can print their certificate or statement of credit immediately (75% pass rate required). This website supports all browsers except Internet Explorer for Mac. For complete technical requirements and privacy policy, visit www.neurosciencecme.com/technical.asp.

    Disclosure Declaration

    It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CME/CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CME/CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

    Russell D. Cohen, MD, FACG, AGAF has disclosed he serves as consultant to AbbVie, Inc.; Celgene Corporation; Entera Health, Inc.; Hospira, Inc.; Janssen Research & Development, LLC (Johnson & Johnson / Centocor); Pfizer Inc.; Sandoz Biopharmaceuticals; Takeda Pharmaceuticals U.S.A., Inc.; and UCB, Inc. He is the principal investigator in clinical trials for AstraZeneca; Celgene Corporation; Gilead Sciences, Inc.; Medimmune; Mesoblast Ltd.; Osiris Therapeutics, Inc.; Pfizer Inc.; Receptos, Inc.; RedHill Biopharma; Sanofi-aventis; and UCB, Inc. He serves on speakers bureau for AbbVie Inc. and Takeda Pharmaceuticals U.S.A., Inc.

    Huda-Marie Kandah, PharmD, BCPS has no disclosures to report.

    Dr. Thomas Ullman has disclosed he serves as consultant to American Regent, Inc. and Janssen Pharmaceuticals, Inc.

    Jeffrey Helfand, DO, MS (peer reviewer) has no disclosures to report.

    Kimberley Murray, RN, MS (peer reviewer) has no disclosures to report.

    Jan Perez, CHCP (Planning Committee) has no disclosures to report.

    Sharon Tordoff, CHCP (planning committee) has no disclosures to report.

    Disclosures have been obtained from CME Outfitters staff: No disclosures to report.

    Unlabeled Use Disclosure

    Faculty of this CME/CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.

    CME Outfitters, LLC, the faculty and Takeda Pharmaceuticals U.S.A., Inc. do not endorse the use of any product outside of the FDA labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use.

    Questions about this activity? Call us at 877.CME.PROS(877.263.7767).

    ]]>
    Tune into this CME Outfitters On Demand activity as expert faculty will highlight the clinical progression of IBD and its impact on patient outcomes and treatment choices. The panel will address risk/benefit of treatment options, direct and indirect cost, and clinical considerations critical to informed decisions about treatment plans for individuals with IBD.

     

    This activity offers CE credit for:

    1. Physicians (CME)
    2. Nurses (CNE)
    3. Pharmacists (ACPE)
    4. Other

    All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™

    Credit Expiration Date: Friday, September 8, 2017

    Faculty

     

    Russell D. Cohen, MD, FACG, AGAF Russell D. Cohen, MD, FACG, AGAF
    Professor of Medicine, Pritzker School of Medicine
    Director, Inflammatory Bowel Disease Center
    Co-Director, Advanced IBD Fellowship Program
    University of Chicago Medicine
    Chicago, IL

     

    Huda-Marie Kandah, PharmD, BCPS Huda-Marie Kandah, PharmD, BCPS
    Clinical Coordinator, Specialty Pharmacy
    University of Chicago Medicine
    Chicago, IL

     

    Thomas A. Ullman, MD Thomas A. Ullman, MD
    Chief Medical Officer
    Mount Sinai Doctors Faculty Practice
    Senior Associate Dean for Clinical Affairs
    Icahn School of Medicine at Mount Sinai
    New York, NY

     

    Statement of Need

    Inflammatory bowel diseases (IBD)–Crohn’s disease (CD), and ulcerative colitis (UC) –have low remission rates, indicating that conventional treatment approaches are suboptimal for patients. Treatment goals in IBD have evolving beyond symptomatic relief to sustained remission and mucosal healing to prevent continued damage, disability, and surgical intervention.

    It is critical to identify patients at high risk for colectomy and plan their treatment appropriately with earlier, more aggressive utilization of immunomodulators and biologic agents; a step-down approach, in order to optimize mucosal healing and remission before permanent structural damage has occurred. Rising costs of specialty drugs are on the mind of specialty and managed care pharmacy directors, patients, and practicing physicians. When reviewing annual cost of care associated with IBD treatment, it is important to evaluate both direct costs (e.g. medication, surgery, hospitalization, lab tests) and indirect costs (e.g. quality of life, work/school productivity, absenteeism, dis]]> Tune into this CME Outfitters On Demand activity as expert faculty will highlight the clinical progression of IBD and its impact on patient outcomes and treatment choices. The panel will address risk/benefit of treatment options, direct and indirect cost, and clinical considerations critical to informed decisions about treatment plans for individuals with IBD.

     

    This activity offers CE credit for:

    1. Physicians (CME)
    2. Nurses (CNE)
    3. Pharmacists (ACPE)
    4. Other

    All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™

    Credit Expiration Date: Friday, September 8, 2017

    Faculty

     

    Russell D. Cohen, MD, FACG, AGAF Russell D. Cohen, MD, FACG, AGAF
    Professor of Medicine, Pritzker School of Medicine
    Director, Inflammatory Bowel Disease Center
    Co-Director, Advanced IBD Fellowship Program
    University of Chicago Medicine
    Chicago, IL

     

    Huda-Marie Kandah, PharmD, BCPS Huda-Marie Kandah, PharmD, BCPS
    Clinical Coordinator, Specialty Pharmacy
    University of Chicago Medicine
    Chicago, IL

     

    Thomas A. Ullman, MD Thomas A. Ullman, MD
    Chief Medical Officer
    Mount Sinai Doctors Faculty Practice
    Senior Associate Dean for Clinical Affairs
    Icahn School of Medicine at Mount Sinai
    New York, NY

     

    Statement of Need

    Inflammatory bowel diseases (IBD)–Crohn’s disease (CD), and ulcerative colitis (UC) –have low remission rates, indicating that conventional treatment approaches are suboptimal for patients. Treatment goals in IBD have evolving beyond symptomatic relief to sustained remission and mucosal healing to prevent continued damage, disability, and surgical intervention.

    It is critical to identify patients at high risk for colectomy and plan their treatment appropriately with earlier, more aggressive utilization of immunomodulators and biologic agents; a step-down approach, in order to optimize mucosal healing and remission before permanent structural damage has occurred. Rising costs of specialty drugs are on the mind of specialty and managed care pharmacy directors, patients, and practicing physicians. When reviewing annual cost of care associated with IBD treatment, it is important to evaluate both direct costs (e.g. medication, surgery, hospitalization, lab tests) and indirect costs (e.g. quality of life, work/school productivity, absenteeism, dis]]> clean No no no 1:24:02 CME Outfitters, LLC